Research activity information

• Optimal combination of heart and lung dose parameters in radiotherapy for locally advanced non-small cell lung carcinoma: a multicenter retrospective study
  Tomohiko Miyazaki; Koichi Yasuda; Hiroshi Taguchi; Hideki Minatogawa; Tetsuya Inoue; Rikiya Takashina; Manami Otsuka; Keiji Nakazato; Noriaki Nishiyama; Keiji Kobashi; Izuru Otake; Jun Sakakibara-Konishi; Satoshi Oizumi; Hajime Kikuchi; Takayuki Hashimoto; Hidefumi Aoyama
  Journal of Radiation Research, Oxford University Press (OUP), 14 May 2026
  Scientific journal, Abstract
  
  This study aimed to identify the optimal combination of heart and lung dose parameters associated with overall survival (OS) in patients with locally advanced non-small cell lung carcinoma (LA-NSCLC) receiving radiotherapy. Data from 278 patients treated definitively for LA-NSCLC at three institutions between 1 April 2013 and 31 October 2021 were retrospectively analyzed. Lung and heart dose parameters were categorized into high- or low-dose groups based on predefined thresholds for subsequent analysis. Univariable analysis of OS was conducted for all dose group combinations. The combination with the lowest P-value was identified as the most promising and included in the multivariable analysis along with other clinical factors. The combinations of mean heart dose (MHD)/lung V40 (LV40) (‘Vxx’ denotes the percentage of organ volume receiving ≥xx Gy) and heart V5 (HV5)/LV40 yielded the lowest P-values (P = 0.021). The thresholds for these dose parameters were MHD ≤24.4 Gy, HV5 ≤63% and LV40 ≤7.7%, respectively. Multivariable analysis incorporating clinical factors identified age ≥65 years (HR: 2.06, P = 0.002), performance status ≥1 (Hazard ratio [HR]: 1.68, P = 0.024), chemoradiotherapy (HR: 0.28, P < 0.001), current smoking history (HR: 2.21, P < 0.001), gross tumor volume (HR: 1.43, P = 0.007) and the MHD/LV40 combination (HR: 2.35, P = 0.003) as independent prognostic factors. While exploratory, this study highlights the clinical significance of the MHD/LV40 combination as a prognostic factor; integrating these parameters radiotherapy for LA-NSCLC may improve patient outcomes.
• Limited-Stage Small-Cell Lung Cancer With Severe Paraneoplastic Limbic Encephalitis Successfully Treated With Chemoradiotherapy Followed by Immune Checkpoint Inhibitor Maintenance Therapy: A Case Report.
  Daisuke Morinaga; Hidenori Kitai; Hanko Sato; Doppo Fukui; Wataru Harabayashi; Yukiko Yoshida; Shotaro Ito; Yuta Takashima; Megumi Furuta; Akihiko Kudo; Shintaro Fujii; Hisashi Uwatoko; Hiroaki Yaguchi; Keiko Tanaka; Ichiro Yabe; Jun Sakakibara-Konishi; Satoshi Konno
  Clinical lung cancer, 27, 2, 121, 125, Mar. 2026, [International Magazine]
  English, Scientific journal
• Impact of baseline regular magnesium oxide administration on chemotherapy-induced constipation during cisplatin-containing treatment.
  Yoshitaka Saito; Yoh Takekuma; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara
  International journal of clinical oncology, 31, 2, 336, 346, Feb. 2026, [Domestic magazines]
  English, Scientific journal, PURPOSE: Chemotherapy-induced constipation frequently occurs with cisplatin-containing treatments, partly because of concomitant neurokinin 1 and serotonin 3 receptor antagonists. We have clinically observed that patients with baseline regular laxative administration, most of whom were on magnesium oxide, exhibited less chemotherapy-induced constipation than those without, and assessed its impact on symptom development in real-world cisplatin-containing treatment. METHODS: Patients with lung cancer receiving cisplatin-containing treatment (n = 240) were divided into a control group without baseline laxative administration and a magnesium group with baseline regular magnesium oxide administration and retrospectively evaluated. The primary endpoint was evaluation of the incidence of grade ≥ 2 constipation during the first 7 days following treatment initiation. RESULTS: Incidence of grade ≥ 2 constipation was 82.5% in the control group and 50.0% in the magnesium group, which was significantly less in the magnesium group (P < 0.0001). The incidence of all-grade symptoms was also significantly lower in the magnesium group than in the control group (67.5% vs. 84.5%, P = 0.02). Additionally, the administration of new laxatives was less common in the magnesium group (P = 0.007). Multivariable logistic regression analysis suggested that baseline administration of magnesium oxide is a preventive factor for grade ≥ 2 constipation. Furthermore, patients receiving 2 g daily magnesium oxide at baseline developed significantly less grade ≥ 2 constipation than those with < 2 g (19.1% and 84.2%, respectively, P < 0.0001). CONCLUSION: The present study suggests that patients with baseline regular magnesium oxide administration exhibit less chemotherapy-induced constipation than those without the administration in cisplatin-containing treatments.
• Evaluating the potential to predict chemotherapy-induced nausea and vomiting in carboplatin-containing treatment based on symptoms induced by prior cisplatin-containing treatment.
  Yoshitaka Saito; Takuya Watanabe; Yoh Takekuma; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara
  Scientific reports, 16, 1, 5817, 5817, 20 Jan. 2026, [International Magazine]
  English, Scientific journal, Chemotherapy-induced nausea and vomiting (CINV) is a serious adverse effect of cisplatin (CDDP)- and carboplatin (CBDCA)-containing treatments. In this study, we aimed to assess the potential to predict CINV in subsequent CBDCA-containing chemotherapy based on symptoms induced by prior CDDP-containing treatments. Patients with thoracic cancer who received CDDP followed by CBDCA treatments (n = 52) were divided into a control group, including patients with total control (TC) of CINV during prior CDDP-containing treatment period, and a CINV-experience group, including patients who did not achieve TC of CINV during the CDDP-containing treatment period. Patients were retrospectively evaluated. The TC rates during all evaluation periods (0-120 h) were significantly lower in the CINV-experience group than in the control group (45.5% and 86.7%, respectively, P = 0.002), which met the primary endpoint. The incidence rates of all-grade nausea and anorexia were also significantly higher in the CINV-experience group. In conclusion, our study suggests that CINV prediction in subsequent CBDCA-containing treatment based on the symptoms induced by prior CDDP-containing treatment is achievable.
• A case of synchronous multiple primary lung cancers each harboring an EGFR mutation or an ALK fusion gene alone that responded to osimertinib with chemotherapy.
  Doppo Fukui; Daisuke Morinaga; Jun Sakakibara-Konishi; Yukiko Yoshida; Masahiro Kashima; Shotaro Ito; Megumi Furuta; Yuta Takashima; Zenichi Tanei; Satoshi Konno
  Respiratory investigation, 64, 2, 101375, 101375, 20 Jan. 2026, [International Magazine]
  English, Scientific journal, A comprehensive pathological evaluation is useful for diagnosing synchronous multiple primary lung cancer (sMPLC). However, a consensus regarding treatment for sMPLC with different driver mutations is lacking. We present a case of sMPLC harboring an epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) fusion gene. For the advanced EGFR-positive tumor, osimertinib plus chemotherapy was initiated, the latter also covering ALK-positive tumor. A marked response and slight reduction occurred in the EGFR-positive and ALK-positive tumors, respectively. Surgical resection of the ALK-positive tumor achieved negative margins. Targeted therapy with chemotherapy may effectively treat sMPLC with different driver mutations.
• Preventive effect of hot compress on phlebitis during cisplatin and Vinorelbine treatment for non-small cell lung cancer.
  Osamu Taniguchi; Yoshitaka Saito; Tatsuhiko Sakamoto; Jun Sakakibara-Konishi; Yoh Takekuma; Mitsuru Sugawara
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 34, 2, 107, 107, 19 Jan. 2026, [International Magazine]
  English, Scientific journal, BACKGROUND: Vinorelbine (VNR) is a key chemotherapeutic agent for treating non-small cell lung cancer (NSCLC). However, peripheral venous administration frequently induces phlebitis in 20-50% of patients. A previous study showed that applying a hot compress during VNR was effective in patients who had already developed symptoms. Therefore, this method was applied to all patients receiving VNR via peripheral venous administration at Hokkaido University Hospital. Herein, we aimed to evaluate the prophylactic efficacy of hot compresses for VNR-induced phlebitis in real-world settings. METHODS: Patients with NSCLC who received cisplatin (CDDP) + VNR (n = 92) were retrospectively evaluated. Patients were divided into a hot compress group, which included patients who received hot compresses during VNR administration, and a control group that did not receive hot compresses. The primary endpoint was the frequency of phlebitis during the first cycle between the groups. RESULTS: Hot compress significantly reduced the frequency of phlebitis during the first cycle (47.3% and 18.9% in the control and hot compress groups, respectively; P = 0.008) and on day 8 of the first cycle (38.2% and 10.8%; P = 0.004), with primary endpoint accomplishment. Furthermore, symptom reduction using hot compresses was confirmed among patients who received VNR on day 8 via a different arm from that administered on day 1 (31.6% vs. 3.0%, P = 0.002). Additionally, the onset of the first occurrence of VNR-induced phlebitis was significantly delayed (P = 0.008). CONCLUSION: Hot compresses significantly reduced the frequency of VNR-induced phlebitis in patients with NSCLC receiving CDDP + VNR.
• Phase 1/2 trial of brigatinib plus panitumumab in patients with osimertinib-resistant EGFR-mutated non-small cell lung cancer harboring EGFR C797S mutation.
  Hiroki Izumi; Tomohiro Sakamoto; Ken Uchibori; Kazumi Nishino; Jun Sakakibara-Konishi; Ryohei Katayama; Shogo Nomura; Shingo Matsumoto; Hibiki Udagawa; Yuji Shibata; Tetsuya Sakai; Kaname Nosaki; Yoshitaka Zenke; Kiyotaka Yoh; Seiji Niho; Koichi Goto
  Cancer treatment and research communications, 46, 101105, 101105, 2026, [International Magazine]
  English, Scientific journal, BACKGROUND: Osimertinib is a standard treatment for advanced EGFR-mutated non-small cell lung cancer (NSCLC). The EGFR C797S mutation is one of the most common resistant mechanisms to osimertinib. Based on our preclinical data, the safety and efficacy of brigatinib combined with panitumumab was evaluated in phase 1/2 study. METHOD: This open-label phase 1/2 study enrolled patients with osimertinib-resistant EGFR-mutated NSCLC, with phase 1 dose escalation part, followed by phase 2 dose expansion part. The primary endpoint was the incidence of dose-limiting toxicities for phase 1 part, and objective response rate for phase 2 part. RESULT: A total of 5 patients were enrolled between Dec 2020 and Jun 2021. Patients had received a median of 4 (range, 1-7) prior lines of treatment, no patient received prior immune checkpoint inhibitors. Median washout period from last dose of osimertinib was 10 days (range, 2-393). Three (60%) patients experienced early onset pulmonary event (EOPE) (grade [Gr] 2, n = 1; Gr 3, n = 2), all of which occurred during brigatinib monotherapy period. All cases with EOPE improved with brigatinib interruption for Gr 2, and systemic corticosteroid treatment for Gr 3. The efficacy to study treatment were PD in all 5 patients, with median progression-free survival of 1.7 months (95% CI, 1.2 to 3.4). Exploratory ctDNA analysis showed the decrease in relative allele frequency (C797S/exon19 deletion) between pre- and post-treatment (n = 3). CONCLUSION: The clinical development of this combination strategy was discontinued, as brigatinib treatment was not feasible in patients with advanced EGFR-mutated NSCLC resistant to osimertinib.
• Association between FDG accumulation in interstitial lesions and acute exacerbation risk in lung cancer: multicenter analysis.
  Yuriko Ishida; Shiro Watanabe; Jun Sakakibara-Konishi; Yasuyuki Ikezawa; Hajime Kikuchi; Yasutaka Kawai; Hirokazu Kimura; Sho Nakakubo; Kenji Hirata; Kohsuke Kudo; Satoshi Konno
  Japanese journal of radiology, 44, 1, 147, 155, Jan. 2026, [Domestic magazines]
  English, Scientific journal, PURPOSE: Interstitial pneumonia (IP) is associated with poor prognosis in lung cancer and increases the risk of acute exacerbation (AE). Few studies analyzed the relationship between fluorodeoxyglucose (FDG) accumulation in IP with lung cancer complicated with IP and the incidence of AE. This study investigates the association between FDG accumulation in the interstitial lesions and the AE incidence in patients with lung cancer complicated with IP. MATERIALS AND METHODS: This multicenter, retrospective study included patients with lung cancer complicated with IP who received chemotherapy. All CTs at baseline and the onset of AE were centrally adjudicated. The SUVpeak and FDGscore for interstitial lesions were calculated from FDG positron emission tomography images before chemotherapy, and these values were corrected using reference uptake. To determine the association with AE risk, clinical characteristics and imaging findings were compared between patients who developed AE and those who did not. Subsequently, logistic regression analysis was performed to identify risk factors for the development of AE. RESULTS: One hundred and thirteen patients who met the eligibility criteria were enrolled from three centers. However, 9 patients with a clinical diagnosis of collagen-related interstitial pneumonia were excluded due to predominant FDG accumulation in the interstitial lesions, and 104 patients were analyzed. Of those patients, 31.7% (33/104) developed all grade AE and 18.3% (19/104) developed grade 3 or higher. There were no significant differences in patient characteristics and imaging patterns between those with and without AE. SUVpeak in the ipsilateral and contralateral interstitial lesions to the tumor and the FDGscore did not differ between those with or without AE. CONCLUSIONS: No association was observed between FDG accumulation in interstitial lesions and AE in patients with lung cancer complicated with IP. We may have to remain cautious about the risk of AE in lung cancer complicated with IP, even when FDG accumulation in interstitial lesions is high or low.
• Atezolizumab長期投与中に免疫関連有害事象による乾癬を呈した肺大細胞神経内分泌癌の1例
  村山 千咲; 池澤 靖元; 池澤 将文; 福井 独歩; 吉田 有貴子; 松永 章宏; 森永 大亮; 辻 康介; 伊藤 祥太郎; 庄司 哲明; 古田 恵; 高島 雄太; 北井 英典; 榊原 純; 今野 哲; 椎谷 千尋; 小田 義崇
  肺癌, 65, 7, 1093, 1094, (NPO)日本肺癌学会, Dec. 2025
  Japanese
• Evaluation of factors associated with clinically problematic hiccups in cisplatin-containing treatment with dexamethasone and neurokinin 1 receptor antagonists.
  Yoshitaka Saito; Yoh Takekuma; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara
  International journal of clinical oncology, 30, 12, 2504, 2511, Dec. 2025, [Domestic magazines]
  English, Scientific journal, BACKGROUND: Chemotherapy-induced hiccups are one of the frequently appearing adverse events. Previous reports have suggested that cisplatin (CDDP) combined with dexamethasone and neurokinin 1 (NK1) receptor antagonists is particularly associated with these symptoms. Consequently, we aimed to identify additional factors involved in the development of problematic hiccups during the real-world treatment. METHODS: Patients with thoracic cancer first receiving CDDP-containing treatment (≥ 75 mg/m2) with dexamethasone, palonosetron, and aprepitant were retrospectively assessed (n = 286). The primary endpoint was the evaluation of risk factors for grade ≥ 2 hiccups during the first cycle. Secondary endpoints were the evaluation of factors for all-grade symptoms and the efficacy of rescue medication. RESULTS: The incidence of grade ≥ 2 hiccups was 32.9%, with all-grade symptoms of 44.8%. Grade 3 severe hiccups were observed in 5.2% of the patients. Most patients (96.8%) received metoclopramide as first-line treatment, and the efficacy of the first medication was confirmed in 59.6% of patients. Multivariate logistic regression analyses identified male sex, baseline hypoalbuminemia, and concomitant bevacizumab as significant risk factors for grade ≥ 2 problematic hiccups (adjusted odds ratio with 95% confidence interval 10.32 [4.38-24.32], P < 0.0001 for males; 2.41 [1.06-5.50], P = 0.04 for hypoalbuminemia; and 3.42 [1.25-9.36], P = 0.02 for concomitant bevacizumab). Moreover, male sex was identified as a singular risk factor for all-grade symptoms (7.94 [4.14-15.22], P < 0.0001). CONCLUSION: Our study revealed that male sex, hypoalbuminemia, and concomitant bevacizumab use were significant risk factors for clinically problematic hiccups in patients receiving CDDP-containing treatment along with dexamethasone and NK1 receptor inhibitors for thoracic cancer.
• Atezolizumab長期投与中に免疫関連有害事象による乾癬を呈した肺大細胞神経内分泌癌の1例
  村山 千咲; 池澤 靖元; 椎谷 千尋; 小田 義崇; 池澤 将文; 福井 独歩; 吉田 有貴子; 松永 章宏; 森永 大亮; 辻 康介; 伊藤 祥太郎; 庄司 哲明; 古田 恵; 高島 雄太; 北井 秀典; 榊原 純; 今野 哲
  肺癌, 65, 5, 671, 671, (NPO)日本肺癌学会, Nov. 2025
  Japanese
• 気管支鏡による検体採取と治療の最前線 マルチ遺伝子検査に最適な検体とは
  畑中 豊; 四宮 義貴; 横内 浩; 佐々木 高明; 榊原 純; 品川 尚文; 畑中 佳奈子; 大泉 聡史
  肺癌, 65, 5, 346, 346, (NPO)日本肺癌学会, Nov. 2025
  Japanese
• Younger age as a risk factor for rash development in pemetrexed and carboplatin treatment with dexamethasone prophylaxis.
  Yoshitaka Saito; Osamu Taniguchi; Yoh Takekuma; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 33, 11, 932, 932, 11 Oct. 2025, [International Magazine]
  English, Scientific journal, PURPOSE: Carboplatin (CBDCA) plus pemetrexed (PEM) is one of the most effective regimens for treating thoracic cancer. Rash, which is mainly caused by PEM, occurs in 15-30% of patients. Dexamethasone administration for 3 days is recommended to manage rash, chemotherapy-induced nausea, and vomiting in this regimen. However, the nature of the PEM-induced rashes is not fully understood. Consequently, we aimed to identify the risk factors associated with rash development under dexamethasone prophylaxis in CBDCA + PEM treatment. METHODS: Patients with thoracic cancer who underwent CBDCA + PEM treatment (n = 133) were retrospectively assessed. The primary endpoint of the present study was to identify the risk factor(s) for the incidence of all-grade rash in the first cycle. Factors affecting the incidence during all treatment cycles were also evaluated. RESULTS: The incidence of all-grade rash in the first cycle was 24.1%, including 16.5% for grade 1, 5.3% for grade 2, and 2.3% for grade 3, respectively. Moreover, that in all cycles, it was 27.1%, with 18.8% for grade 1, 6.0% for grade 2, and 2.3% for grade 3. Multivariate logistic regression analyses identified that age < 65 years was the singular independent risk factor for rash development in the first and all cycles (adjusted odds ratio, 2.79; 95% confidence interval, 1.17-6.67; p = 0.02 for the first cycle, 3.03, 1.29-7.09; p = 0.01 for all cycles). CONCLUSION: Our study revealed that patients aged < 65 years were at a significantly higher risk of rash development during CBDCA + PEM chemotherapy with dexamethasone prophylaxis than patients ≥ 65 years of age.
• 術前化学免疫療法1コースで免疫関連有害事象の発熱により外科切除に移行し病理学的奏効を得た肺扁平上皮癌の1例
  鎌田 凌平; 池澤 靖元; 酒井 碧; 宮石 陸; 大塚 紀幸; 榊原 純; 加藤 達哉; 田中 伸哉; 今野 哲
  肺癌, 65, 4, 291, 296, (NPO)日本肺癌学会, Aug. 2025
  Japanese
• Celecoxib has less aggravating effect on cisplatin-induced nephrotoxicity in comparison with non-selective cyclooxygenase inhibitors: a retrospective multi-institutional study
  Keisuke Okamoto; Yoshitaka Saito; Kenta Takahashi; Yoh Takekuma; Jun Sakakibara-Konishi; Katsuya Narumi; Mitsuru Sugawara; Masaki Kobayashi
  International Journal of Clinical Oncology, Springer Science and Business Media LLC, 07 Jul. 2025
  Scientific journal
• Midkine Promotes Tumor Growth and Attenuates the Effect of Cisplatin in Small Cell Lung Cancer.
  Shotaro Ito; Jun Sakakibara-Konishi; Mineyoshi Sato; Tetsuaki Shoji; Megumi Furuta; Hirofumi Takahashi; Kosuke Tsuji; Daisuke Morinaga; Masahiro Kashima; Hidenori Kitai; Junko Kikuchi; Eiki Kikuchi; Kanako C Hatanaka; Yutaka Hatanaka; Kyoko Hida; Takuro Noguchi; Satoshi Konno
  Cancer medicine, 14, 13, e71034, Jul. 2025, [International Magazine]
  English, Scientific journal, PURPOSE: Small cell lung cancer (SCLC) is a highly aggressive disease associated with poor patient survival rates. The addition of an anti-programmed death ligand 1 antibody to platinum combination chemotherapy can improve its prognosis. However, only a few patients achieve a long-term response; thus, establishing new therapies for SCLC is crucial. Midkine (MDK) is a heparin-binding growth factor involved in various biological processes, including cell proliferation and chemotherapeutic resistance, in diverse cancers. MDK has garnered attention as a therapeutic and diagnostic target for several cancers; however, only a few studies have evaluated its expression and function in SCLC. This study aimed to evaluate the MDK expression in human SCLC tissue and human SCLC cell lines, and to clarify its function in tumorigenesis. METHODS: MDK expression was analyzed in vitro and in vivo through ELISA, immunohistochemistry, and western blotting. Its effects on cell proliferation, as well as the effects of cisplatin, were evaluated using the MTT assay. RESULTS: MDK was pathologically expressed in human SCLC tumor tissues but not in normal lung tissues. Serum MDK concentrations in patients with SCLC reflected the SCLC tumor burden and were correlated with response to treatment. Moreover, MDK induced cell proliferation and attenuated the effects of cisplatin in SCLC cell lines. An MDK inhibitor and cisplatin exerted synergistic antitumor effects both in vitro and in vivo. Furthermore, MDK positively regulated the AKT pathway. CONCLUSION: Our findings indicate that MDK promotes cell proliferation and chemotherapeutic resistance by activating the AKT pathway in SCLC cells. Therefore, MDK may be a potential therapeutic and diagnostic target for SCLC.
• Frequency and Prognostic Impact of Local Ablation Therapy for Oligoprogression in Non-Small Cell Lung Cancer.
  Daisuke Morinaga; Jun Sakakibara-Konishi; Ryohei Kamada; Masahiro Kashima; Kosuke Tsuji; Shotaro Ito; Megumi Furuta; Tetsuaki Shoji; Yuta Takashima; Hidenori Kitai; Yasuyuki Ikezawa; Hiroshi Taguchi; Tatsuya Kato; Yoshiki Shinomiya; Kanako C Hatanaka; Yutaka Hatanaka; Satoshi Konno
  Thoracic cancer, 16, 13, e70119, Jul. 2025, [International Magazine]
  English, Scientific journal, BACKGROUND: During the systemic treatment of patients with non-small cell lung cancer (NSCLC), oligoprogression (OP), a condition in which most lesions remain controlled while a few progress or develop, has recently attracted attention. Traditionally, systemic therapy is continued after disease progression; however, advancements in local ablation therapy (LAT), such as radiotherapy and surgery, have demonstrated clinical efficacy in patients with OP. The characteristics of patients who may benefit from LAT or their genetic background remain unclear. This study evaluated the frequency, clinicopathological characteristics, and efficacy of LAT in the treatment of OP. METHODS: A retrospective review was conducted of 510 patients with NSCLC who experienced disease progression after systemic therapy. RESULTS: Overall, 106/510 (23.6%) patients exhibited OP; among these, six patients who received only the best supportive care after OP were excluded. Systemic therapy alone was administered to 79 patients (79.0%), while 21 (21.0%) received LAT. Median local progression-free survival was numerically longer in the LAT group than in the systemic therapy-only group (8.3 and 6.7 months, respectively; p = 0.38). In addition, overall survival was also numerically longer in the LAT group than in the systemic therapy-only group (78.1 and 55.1 months, respectively; p = 0.57). Ribonucleic acid sequencing revealed an increase in extracellular matrix-related gene expression after OP, providing potential molecular insights. CONCLUSIONS: Although this study found no significant prognostic benefit of LAT in patients with OP, future research integrating clinical and molecular data may identify patients most likely to benefit from LAT.
• 低用量のセルペルカチニブが奏効したRET融合遺伝子陽性非小細胞肺癌の1例
  島田 琉海; 庄司 哲明; 高橋 宏典; 猪狩 智生; 高島 雄太; 古田 恵; 北井 秀典; 池澤 靖元; 榊原 純; 今野 哲; 伊藤 健一郎; 福土 将秀
  肺癌, 65, 3, 205, 205, (NPO)日本肺癌学会, Jun. 2025
  Japanese
• 術前化学免疫療法1コースで免疫関連有害事象により外科切除に移行し病理学的奏効を得た肺扁平上皮癌の1例
  鎌田 凌平; 庄司 哲明; 池澤 靖元; 久世 瑞穂; 東 陸; 松永 章宏; 畠山 酉季; 辻 康介; 高橋 宏典; 高島 雄太; 古田 恵; 北井 秀典; 榊原 純; 今野 哲; 宮石 陸; 大塚 紀幸; 田中 伸哉; 加藤 達哉
  肺癌, 65, 3, 207, 207, (NPO)日本肺癌学会, Jun. 2025
  Japanese
• 非小細胞肺がん患者におけるドセタキセル誘発性浮腫の要因分析
  山下 慎介; 齋藤 佳敬; 今井 俊吾; 柏木 仁; 佐藤 夕紀; 梨本 俊亮; 榊原 純; 清水 康; 木下 一郎; 武隈 洋; 菅原 満
  日本臨床腫瘍薬学会雑誌, 41, 139, 139, (一社)日本臨床腫瘍薬学会, May 2025
  Japanese
• 中枢気道病変に対して行った体外式膜型人工肺(ECMO)導入下呼吸器インターベンションの後方視的検討
  高島 雄太; 品川 尚文; 畠山 酉季; 辻 康介; 伊藤 祥太郎; 中村 友彦; 高橋 宏典; 庄司 哲明; 池澤 靖元; 榊原 純; 新垣 雅人; 加藤 達哉; 相川 勝洋; 内田 洋介; 今野 哲
  気管支学, 47, Suppl., S254, S254, (一社)日本呼吸器内視鏡学会, May 2025
  Japanese
• High incidence of immune checkpoint inhibitor-induced pneumonitis in patients with non-small cell lung cancer and interstitial pneumonia, regardless of honeycomb lung or forced vital capacity: results from a multicenter retrospective study.
  Yuriko Ishida; Satoshi Ikeda; Toshiyuki Harada; Jun Sakakibara-Konishi; Keiki Yokoo; Hajime Kikuchi; Tae Iwasawa; Toshihiro Misumi; Satoshi Konno; Takashi Ogura
  International journal of clinical oncology, 30, 5, 904, 913, May 2025, [Domestic magazines]
  English, Scientific journal, BACKGROUND: Interstitial pneumonia (IP) is a common comorbidity with poor prognosis in patients with non-small cell lung cancer (NSCLC) and a risk factor for immune checkpoint inhibitor (ICI)-induced pneumonitis. This study aimed to assess the incidence, severity, and risk factors of ICI-induced pneumonitis in patients with NSCLC and idiopathic IP. METHODS: This multicenter, retrospective study involved patients with advanced or recurrent NSCLC and comorbid idiopathic IP and receiving ICI monotherapy as the second or subsequent line. A board-certified radiologist centrally reviewed all computed tomography images at baseline and at the onset of pneumonitis. Logistic regression analysis with clinical, laboratory, and radiological variables was used to examine the risk factors for pneumonitis. RESULTS: This study included 65 patients with a median age of 71 years, 98.5% of whom had a smoking history. Three ICIs were used and a median of three cycles. Honeycomb lung was present in 23.1% of the patients, and the median % forced vital capacity (FVC) was 95.0%. Notably, 23.1% of the patients exhibited all-grade pneumonitis and 15.4% exhibited grade ≥ 3 pneumonitis. No significant risk factors for pneumonitis were identified after univariate logistic regression analysis. The incidence and severity of ICI-induced pneumonitis did not differ between patients with and without honeycomb lung or with FVC ≥ 80% versus < 80%, respectively. CONCLUSION: In this retrospective analysis of patients with NSCLC, the risk of ICI-induced pneumonitis did not differ based on radiologic patterns of comorbid IP, presence or absence of honeycomb lung, or pulmonary function tests.
• Efficacy of second line and subsequent treatments of small cell lung cancer with and without immune checkpoint inhibitor combination therapy.
  Daisuke Morinaga; Jun Sakakibara-Konishi; Yasutaka Kawai; Yumi Morinaga; Shohei Mizobuchi; Yoshihiro Okamoto; Yasunari Yamanaka; Kei Takahashi; Hajime Kikuchi; Noriaki Sukoh; Taichi Takashina; Hidenori Kitai; Satoshi Konno
  Respiratory investigation, 63, 3, 423, 430, May 2025, [International Magazine]
  English, Scientific journal, BACKGROUND: Immune checkpoint inhibitors (ICIs) combined with platinum-doublet chemotherapy (ICI-chemo) have become the standard of care for extensive-stage small cell lung cancer (ES-SCLC). However, the effect of ICI-chemo on the efficacy of subsequent chemotherapy remains unknown. This study aimed to investigate the efficacy of second and subsequent treatments of SCLC with and without ICI combination therapy. METHODS: We performed an analysis of patients with ES-SCLC between January 2015 and June 2023. The ICI-chemo groups were defined as patients who received ICI-chemo as first-line therapy between September 2019 and June 2023, after ICI-chemo was reimbursed in Japan. The non-ICI-chemo groups were defined as patients who received platinum-doublet therapy between January 2015 and August 2019 and were considered eligible for ICI-chemo. RESULTS: In total, 224 patients were included (91 and 133 patients who received ICI-chemo and non-ICI-chemo, respectively). There were no significant differences in patient characteristics between the groups. There was no significant difference in progression-free survival (PFS) and overall survival (OS) for first-line treatment between the two groups. The median PFS and OS periods for second-line treatment were 3.9 and 3.9 months and 10.3 and 10.7 months in the ICI-chemo and non-ICI-chemo groups, respectively, without significant difference. Most patients in both groups received amrubicin as the second-line treatment. Moreover, the PFS and OS periods for third-line treatment were not significantly different between the ICI-chemo and non-ICI-chemo groups. CONCLUSIONS: In ES-SCLC, there is no significant additive effect on PFS and OS of second- and subsequent line treatments following ICI-chemo at first-line treatment.
• 経過中に腹膜播種による腹水が乳び化を呈した,胸腺腫の1例
  武藤 ほの; 庄司 哲明; 古川 貴啓; 辻 康介; 佐藤 峰嘉; 高島 雄太; 古田 恵; 北井 秀典; 池澤 靖元; 木野田 直也; 阿保 大介; 榊原 純; 今野 哲
  日本呼吸器学会誌, 14, 増刊, 366, 366, (一社)日本呼吸器学会, Mar. 2025
  Japanese
• 気管支狭窄拡張術後にALK-TKIを導入したHIP1-ALK陽性肺癌の1例
  佐藤 祐麻; 北井 秀典; 田上 敬太; 石田 有莉子; 篠崎 鮎香; 佐藤 峰嘉; 高橋 宏典; 古田 恵; 高島 雄太; 庄司 哲明; 池澤 靖元; 榊原 純; 品川 尚文; 今野 哲; 大川 紘弥; 大塚 紀幸; 畑中 佳奈子; 畑中 豊; 横内 浩
  肺癌, 65, 1, 65, 65, (NPO)日本肺癌学会, Feb. 2025
  Japanese
• 全身療法中にoligoprogression/oligorecurrenceを認めた非小細胞肺癌症例の検討
  鎌田 凌平; 森永 大亮; 榊原 純; 古川 貴啓; 酒井 碧; 佐々木 賢太; 畠山 酉季; 辻 康介; 佐藤 峰嘉; 高橋 宏典; 古田 恵; 庄司 哲明; 高島 雄太; 北井 秀典; 池澤 靖元; 今野 哲; 田口 大志; 加藤 達哉
  肺癌, 65, 1, 66, 67, (NPO)日本肺癌学会, Feb. 2025
  Japanese
• 小細胞肺癌との鑑別に苦慮した胸部SMARCA4欠損未分化腫瘍の1例
  溝渕 匠平; 榊原 純; 棟方 奈菜; 庄司 哲明; 古田 恵; 高島 雄太; 北井 秀典; 池澤 靖元; 今野 哲; 加藤 憲士郎; 大塚 紀幸; 種井 善一; 田中 伸哉
  肺癌, 65, 1, 67, 67, (NPO)日本肺癌学会, Feb. 2025
  Japanese
• EGFR遺伝子変異陽性進行再発非小細胞肺癌における免疫チェックポイント阻害剤の治療についての後方視的検討
  古川 貴啓; 庄司 哲明; 酒井 碧; 佐々木 賢太; 畠山 酉季; 辻 康介; 佐藤 峰嘉; 高橋 宏典; 古田 恵; 高島 雄太; 北井 秀典; 池澤 靖元; 榊原 純; 今野 哲
  肺癌, 65, 1, 68, 68, (NPO)日本肺癌学会, Feb. 2025
  Japanese
• Effectiveness of afatinib after long-term gefitinib treatment for EGFR L858R and S768I compound mutation-positive lung adenocarcinoma: A case report.
  Ayuka Dai-Shinozaki; Jun Sakakibara-Konishi; Kanako C Hatanaka; Kento Wakabayashi; Naofumi Shinagawa; Yoshihiro Matsuno; Yutaka Hatanaka; Satoshi Konno
  Respiratory medicine case reports, 57, 102249, 102249, 2025, [International Magazine]
  English, Scientific journal, Afatinib, a second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), irreversibly inhibits the pan-human epidermal growth factor receptor (HER) family. It is effective in patients with lung cancer with various EGFR mutations; however, its efficacy in overcoming resistance following first-line EGFR-TKI treatment remains unclear. Here, we report the case of a 68-year-old woman with lung adenocarcinoma (pStage IA, pT1bN0M0) who underwent surgical resection in March 2012 following several previous lung cancer resections. In November 2012, postoperative recurrence with pleural dissemination led to the detection of the EGFR L858R mutation in the malignant pleural effusion specimen using peptide nucleic acid-locked nucleic acid polymerase chain reaction clamping (PNA-LNA PCR clamp). The patient was treated with gefitinib for 8 years, after disease progression with multiple lung metastases. The metastatic lesions harbored compound EGFR S768I and EGFR L858R mutations, as identified using the Oncomine Dx Target Test Multi-CDx System (ODxTT). Treatment with afatinib resulted in rapid metastatic lesion regression. Reanalysis of the previously resected surgical specimens confirmed the presence of the EGFR S768I and L858R compound mutations in all samples, which suggests that S768I was not an acquired resistance mutation. Furthermore, immunohistochemical analysis revealed an increase in HER2 and HER3 protein expression in the gefitinib-resistant specimens. These findings suggest that HER2 and HER3 upregulation may contribute to gefitinib resistance, and that afatinib may effectively target these resistance mechanisms.
• Efficacy and safety of lenvatinib in a case of thymic carcinoma complicated with interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: A case report.
  Yuki Hatakeyama; Jun Sakakibara-Konishi; Masato Tarumi; Kosuke Tsuji; Hirofumi Takahashi; Megumi Furuta; Yuta Takashima; Hidenori Kitai; Tetsuaki Shoji; Yasuyuki Ikezawa; Satoshi Konno
  Respiratory medicine case reports, 54, 102181, 102181, 2025, [International Magazine]
  English, Scientific journal, Based on the results of a multicenter phase II study of patients with previously treated thymic carcinoma, lenvatinib administration for unresectable thymic cancer has been covered under insurance in Japan since 2021. However, patients with interstitial lung disease (ILD) were excluded from that study; therefore, the efficacy and safety of lenvatinib in these patients remain unknown. Herein, we report the case of a woman in her 50s who was diagnosed with thymic carcinoma complicated with ILD. In August 2016, the patient developed ILD with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM). She received triple therapy comprising prednisolone, tacrolimus and azathioprine. In October 2021, the patient complained of lateral chest pain and back pain. In January 2022, computed tomography (CT) revealed an anterior mediastinal tumor, and percutaneous biopsy resulted in a diagnosis of thymic carcinoma with Masaoka classification IVb. In March 2022, first-line treatment with four cycles of carboplatin (area under the curve, 6) + paclitaxel (200 mg/m2) was initiated. Although a partial response was achieved, in September 2022, CT demonstrated progressive disease (PD). Therefore, in October 2022, Lenvatinib (24 mg) was started as the second-line treatment. The best response was stable disease; moreover, although lenvatinib dose reduction was required owing to adverse events, such as biliary-tract infection and stomatitis. The patient did not experience ILD exacerbation. Lenvatinib (14 mg) was continued until PD was observed in March 2023. Our findings suggest that lenvatinib is a viable treatment option for thymic carcinoma with ILD.
• Severe Hypomagnesemia in a Patient Treated Using Carboplatin Co-Administered with Vonoprazan.
  Osamu Taniguchi; Yoshitaka Saito; Yuka Yamaguchi; Midori Sakai; Yasuyuki Ikezawa; Jun Sakakibara-Konishi; Mina Eguchi; Yoh Takekuma; Mitsuru Sugawara
  Case reports in oncology, 18, 1, 151, 158, 2025, [Peer-reviewed], [International Magazine]
  English, Scientific journal, INTRODUCTION: We describe a case of severe hypomagnesemia that occurred during treatment with carboplatin (CBDCA) and nanoparticle albumin-bound paclitaxel (nab-PTX) for lung adenocarcinoma when co-administered with vonoprazan. CASE PRESENTATION: A man in his 70s was diagnosed with stage IIIA lung adenocarcinoma and received CBDCA and nab-PTX as the first-line treatment. The patient had been taking omeprazole 10 mg once daily (for >3 years) for gastroesophageal reflux disease, but it was switched to lansoprazole 15 mg because of hospital's adopted medication. During the first treatment cycle, his serum creatinine levels increased from 1.0 to 1.5 mg/dL, suggesting CBDCA-associated renal impairment. Because of gastric discomfort on day 15 of the second cycle, lansoprazole was switched to vonoprazan 10 mg once daily. On day 23 of the second cycle, he developed torsades de pointes and was hospitalized; severe hypomagnesemia (0.4 mg/dL) was detected to be causing the symptoms. Discontinuation of vonoprazan and a single intravenous infusion of 60 mEq magnesium sulfate raised serum magnesium levels to 3.7 mg/dL, and the arrhythmia disappeared. Mild hypomagnesemia (1.4 mg/dL) reappeared 5 days later, and an additional intravenous infusion of 20 mEq magnesium sulfate with subsequent oral magnesium oxide (1,980 mg/day) resolved the symptoms. CBDCA was discontinued and nab-PTX monotherapy was continued. Vonoprazan was resumed owing to gastric discomfort relapse; however, grade ≥2 hypomagnesemia did not reappear later. CONCLUSIONS: This case highlights the risk of severe hypomagnesemia in patients with CBDCA and vonoprazan co-administration; therefore, regular monitoring of serum magnesium levels during the treatment is crucial.
• Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer
  Jun Sakakibara-Konishi; Hirofumi Takahashi; Kenichiro Ito; Tomoo Ikari; Yasuyuki Ikezawa; Hidenori Kitai; Megumi Furuta; Yuta Takashima; Tetsuaki Shoji; Masahide Fukudo; Satoshi Konno
  Respiratory Medicine Case Reports, 53, 102176, 102176, Elsevier BV, 2025, [Peer-reviewed]
  Scientific journal
• Impact of baseline renal impairment on severe neutropenia development in pemetrexed and carboplatin thoracic cancer treatment.
  Yoshitaka Saito; Osamu Taniguchi; Yoh Takekuma; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 32, 12, 829, 829, 27 Nov. 2024, [Peer-reviewed], [International Magazine]
  English, Scientific journal, BACKGROUND: Carboplatin (CBDCA) plus pemetrexed (PEM) is a commonly-used thoracic cancer treatment. As both CBDCA and PEM are excreted via the kidneys, renal impairment (RI) can lead to severe neutropenia, the most typical adverse event in the treatment. We aimed to determine the impact of baseline RI on the development of severe neutropenia following real-world CBDCA + PEM-containing treatments. METHODS: Patients with thoracic cancer receiving CBDCA + PEM-containing treatments (n = 155) were divided into a control group (baseline creatinine clearance [CCr] ≥ 60 mL/min) and an RI group (baseline CCr < 60 mL/min) and retrospectively evaluated. The primary endpoint was the incidence of severe neutropenia during the first cycle. We also assessed factors associated with the development of severe neutropenia. RESULTS: Severe neutropenia during the first cycle was confirmed in 41.2% of the patients in the RI group, which was significantly higher than that in the control group (20.7%, P = 0.02). Additionally, severe neutropenia during all evaluation periods was also more prevalent in the RI group compared to the control group (47.1% vs. 24.8%, P = 0.02). In contrast, the incidence of severe thrombocytopenia was not different. Multivariate logistic regression analyses identified RI as a risk factor for severe neutropenia (adjusted odds ratio 2.71; 95% confidence interval 1.18-6.21, P = 0.02 for the first cycle; 2.62, 1.17-5.84, P = 0.02 for all evaluation periods). CONCLUSION: Our study revealed that patients with baseline RI exhibited severe neutropenia after CBDCA + PEM-containing treatments.
• Effect of baseline anemia on the efficacy of docetaxel and ramucirumab for advanced non-small cell lung cancer treatment.
  Yoshitaka Saito; Yoh Takekuma; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara
  BMC cancer, 24, 1, 1301, 1301, 21 Oct. 2024, [Peer-reviewed], [International Magazine]
  English, Scientific journal, BACKGROUND: Docetaxel (DOC) and ramucirumab (RAM) is one of the most effective regimens for advanced non-small cell lung cancer (NSCLC) treatment. In our previous study, baseline anemia was identified as a preventive factor against the development of severe adverse effects during the first treatment cycle. It was hypothesized that anemia directly promotes tumor angiogenesis, leading to the elevation of RAM efficacy with increased DOC delivery to tumors, while reducing DOC delivery to other organs, potentially mitigating severe adverse effects. If this hypothesis is correct, patients with baseline anemia may have better clinical outcomes than those with normal hemoglobin levels. In this study, we aimed to investigate the effect of baseline anemia on the efficacy of DOC + RAM in treating advanced NSCLC in a real-word setting. METHODS: Patients with advanced NSCLC receiving DOC + RAM (n = 72) were retrospectively assessed. They were categorized into a control group with normal baseline hemoglobin levels and an anemia group with baseline anemia. The primary endpoint was progression-free survival (PFS) evaluation. RESULTS: Patients in the anemia group had a significantly shorter PFS than that of patients in the control group (median PFS: 3.2 and 6.2 months; 95% confidence interval [CI]: 2.2-4.8 and 4.3-9.9 months, respectively;P = 0.008). In addition, the disease control rate in the anemia group was 65.8%, which was significantly lower than that in the control group (93.6%; P = 0.007). Overall survival tended to be shorter in patients with anemia than in controls, although the difference was not statistically significant (P = 0.07). Multivariate Cox hazard analysis suggested that baseline anemia was a singular risk factor for poor PFS (adjusted hazard ratio 1.84, 95% CI 1.08-3.13; P = 0.02). The incidence of severe adverse effects did not differ between the two groups. CONCLUSIONS: This study suggests that the PFS of patients with anemia treated with DOC + RAM for advanced NSCLC is shorter than that of those without the symptoms.
• Clinical Significance of a Prospective Large Genomic Screening for SCLC: The Genetic Classification and a Biomarker-Driven Phase 2 Trial of Gedatolisib.
  Shigeki Umemura; Hibiki Udagawa; Takaya Ikeda; Haruyasu Murakami; Haruko Daga; Ryo Toyozawa; Toshiyuki Kozuki; Jun Sakakibara-Konishi; Yuichiro Ohe; Masahiro Morise; Terufumi Kato; Masato Shingyoji; Satoshi Hara; Naoki Furuya; Shuhei Teranishi; Saori Takata; Shingo Miyamoto; Ichiro Nakachi; Masashi Wakabayashi; Shogo Nomura; Akihiro Sato; Genichiro Ishii; Katsuya Tsuchihara; Eri Sugiyama; Keisuke Kirita; Tetsuya Sakai; Yuji Shibata; Hiroki Izumi; Kaname Nosaki; Yoshitaka Zenke; Shingo Matsumoto; Kiyotaka Yoh; Seiji Niho; Koichi Goto
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 10 Oct. 2024, [International Magazine]
  English, Scientific journal, INTRODUCTION: SCLC has been treated as a single entity resulting in limited survival improvement. Developing effective tools for guiding appropriate therapeutic strategies is crucial. METHODS: A total of 1035 SCLCs were prospectively analyzed by a genomic screening platform: LC-SCRUM-Asia. Fresh frozen tumor samples were subjected to a next-generation sequencing system enabling the integrative analysis of cancer-related genes. A phase 2 trial of gedatolisib for SCLC with PI3K/AKT/mTOR pathway mutations was conducted based on this screening. RESULTS: On the basis of the treatment outcomes and therapeutic targets, the following five distinct genetic subgroups were identified in SCLC: NSCLC-subgroup (genetic alterations associated with NSCLC, 8.5%); Hotspot-subgroup (targetable hotspot mutations common in tumors, 3.0%); PI3K-subgroup (PI3K/AKT/mTOR pathway mutations, 7.4%); MYC-subgroup (MYC family amplifications, 13.0%); and HME-subgroup (mutations in the histone-modifying enzymes, 17.6%). The NSCLC-subgroup (hazard ratio = 1.57; 95% confidence interval: 1.22-2.03) and MYC-subgroup (hazard ratio = 1.56; 95% confidence interval: 1.26-1.93) had significantly shorter progression-free survivals after first-line platinum-based treatment. The Hotspot-subgroup and MYC-subgroup were candidates for novel targeted therapies. The HME-subgroup had a favorable survival in patients who received programmed cell death (ligand) 1 inhibitor-based therapies (p = 0.005, log-rank test) regardless of some overlap with other subgroups. There were 15 patients enrolled into the phase 2 trial of gedatolisib in the PI3K-subgroup, and the overall response rate and the disease control rate were 6.7% and 20%, respectively. The MYC-subgroup or NSCLC-subgroup was associated with unfavorable clinical outcomes in this trial. CONCLUSIONS: Molecular classification of SCLC by genetic approach is beneficial for predicting the treatment outcomes and effectively guiding the clinical choices.
• Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older.
  Shigehiro Yagishita; Yuta Yamanaka; Takayasu Kurata; Kageaki Watanabe; Yukio Hosomi; Hidehito Horinouchi; Yuichiro Ohe; Yoshiro Nakahara; Katsuhiko Naoki; Tetsuhiko Asao; Kazuhisa Takahashi; Sho Saeki; Takuro Sakagami; Kazuhisa Nakashima; Yukari Tsubata; Yu Fujita; Hiroshi Wakui; Megumi Furuta; Jun Sakakibara Konishi; Mayu Ohuchi; Yuichi Ando; Hidenori Mizugaki; Akinobu Hamada
  Clinical pharmacology and therapeutics, 17 Jun. 2024, [International Magazine]
  English, Scientific journal, Pembrolizumab is a major treatment for recurrent or advanced non-small-cell lung cancer (NSCLC). However, data on its use and pharmacokinetics (PK) in older patients are limited. This open-label, multicenter, observational study evaluated real-world data on the safety, efficacy, and PK of pembrolizumab in older patients with NSCLC. In 99 patients aged ≥75 years, PK was determined by liquid chromatography-mass spectrometry on pretreatment samples. Performance status (PS), geriatric assessment (GA), overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) were evaluated. The median age was 78 (75-87) years. PS was 2-3 in 14 patients. The median ORR, PFS, and OS were 47.5%, 8.0, and 20.5 months, respectively. Although PK and ORR were not significantly associated, patients with the lowest Cycle 1-trough quartile (Q1) experienced poorer PFS (Q1 vs. Q2-4; 3.4 vs. 11.8 months, P = 0.006) and OS (Q1 vs. Q2-4; 9.9 vs. 21.7 months, P = 0.005) than in other quartiles overall, and even in the PD-L1 ≥50% subset (PFS, Q1 vs. Q2-4; 4.1 vs. 14.7 months, P = 0.005; OS, Q1 vs. Q2-4; 9.4 vs. 22.1 months, P = 0.010). The Q1 subgroup was characterized by poor PS and lower albumin, and more frequent "weight loss ≥ 10%" on the GA. Pembrolizumab therapy had similar PK and efficaciousness in older as well as younger patients. In patients with PS ≥2, low albumin, and vulnerable GA, early increases in PK levels are less likely, potentially diminishing efficacy even when PD-L1 ≥50%.
• Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas.
  Yusuke Okuma; Shogo Nomura; Jun Sakakibara-Konishi; Yoko Tsukita; Shuji Murakami; Yukio Hosomi; Yuichi Tambo; Yoshihito Kogure; Hiroshige Yoshioka; Motohiro Tamiya; Kiichiro Ninomiya; Eiji Iwama
  Clinical lung cancer, 25, 4, 389, 394, Jun. 2024, [International Magazine]
  English, Scientific journal, BACKGROUND: Thymic carcinoma is a rare cancer with an aggressive clinical presentation and no organotypic symptoms. Despite using platinum-based chemotherapy as first-line treatment, the prognosis remains poor, necessitating a novel therapeutic strategy. METHODS: The artemis trial is a Phase II, single-arm, multicenter study designed to evaluate the efficacy and safety of carboplatin, paclitaxel, lenvatinib, and pembrolizumab as first-line chemotherapy for patients with advanced or recurrent thymic carcinoma. A total of 35 patients will be enrolled in this study and will receive induction therapy every 3 weeks for up to 4 cycles, followed by pembrolizumab every 3 weeks, and daily lenvatinib as maintenance therapy for up to 31 cycles (for 2 years). Lenvatinib will be continued until disease progression or unacceptable toxicity based on the discretion of the attending physician. CONCLUSION: The primary endpoint of the study is the objective response rate, with secondary endpoints including progression-free survival, overall survival, duration of response, disease control rate, and safety profile. TRIAL REGISTRATION: ClinicalTrials.gov NCT05832827 Registered on April 27, 2023, https://classic. CLINICALTRIALS: gov/ct2/show/NCT05832827. Japan Registry of Clinical Trials (jRCT), jRCT2031230114. Registered on May 22, 2023, https://jrct.niph.go.jp/latest-detail/jRCT2031230114.
• Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.
  Kaname Nosaki; Kiyotaka Yoh; Ryo Toyozawa; Hidehito Horinouchi; Masahiro Morise; Kadoaki Ohashi; Haruyasu Murakami; Miyako Satouchi; Jun Sakakibara-Konishi; Seiji Yano; Fumihiko Okumura; Shingo Matsumoto; Mototsugu Shimokawa; Takashi Seto; Koichi Goto
  International journal of clinical oncology, 17 May 2024, [Domestic magazines]
  English, Scientific journal, BACKGROUND: MET exon 14 skipping mutations occur in 3-4% and MET high amplifications occur in < 1% of patients with non-small-cell lung cancer (NSCLC). Crizotinib, a selective ATP-competitive small-molecule inhibitor of c-Met, ALK, and ROS1 tyrosine kinases, has shown activity in cancer models with various types of MET activation. METHODS: The Co-MET study is a single-arm phase 2 trial to assess the safety and efficacy of crizotinib in MET inhibitor-naïve patients with advanced NSCLC harboring MET exon 14 skipping mutation (cohort 1) or high MET gene copy number of ≥ 7 (cohort 2). The primary endpoint was the objective response rate (ORR) per RECIST v1.1 by independent radiology review in cohort 1. The key secondary endpoints were the duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: A total of 28 patients (23 in cohort 1 and 5 in cohort 2) were enrolled between March 2018 and February 2020. The primary endpoint was met as the ORR (90% confidence interval: CI) in cohort 1 was 38.1% (20.6-58.3). Median DoR, PFS, and OS (95% CI) were 7.6 (1.9-NE), 5.7 (2.1-11.3), 9.1 (4.0-19.9) months, respectively, in cohort 1. ORR in cohort 2 was 40.0% (18.9-92.4). The safety signals were generally consistent with the known safety profile of crizotinib. CONCLUSIONS: Crizotinib showed a clinical activity similar to that of tepotinib and capmatinib in patients with NSCLC harboring MET exon 14 skipping mutations. CLINICAL TRIAL INFORMATION: UMIN000031623.
• Acute onset of constrictive pericarditis due to acute myelomonocytic leukemia: A case and literature review.
  Naoki Kosaka; Takanori Uchiyama; Masahiro Onozawa; Jun Nagai; Jiro Koya; Suguru Ishizaka; Toshiyuki Nagai; Yohei Ikebe; Kenjiro Kato; Zen-Ichi Tanei; Jun Sakakibara-Konishi; Yuta Hasegawa; Hiroyuki Ohigashi; Hideki Goto; Daigo Hashimoto; Hideki Ujiie; Satoshi Hirano; Satoshi Konno; Toshihisa Anzai; Koji Taniguchi; Shinya Tanaka; Takanori Teshima
  Internal medicine (Tokyo, Japan), 16 Apr. 2024, [Domestic magazines]
  English, Scientific journal, We herein present a fatal case of constrictive pericarditis (CP) due to acute myelomonocytic leukemia (AMML) in a patient who initially complained of an acute onset of chest pain two days after COVID-19 vaccination. An autopsy revealed pericardial infiltration of leukemic cells. CP is rarely associated with leukemia and only 14 cases have been reported in the literature. The etiology of CP in previous reports included leukemic infiltration, graft-versus-host disease, drug-induced, post-radiation, autoimmune, and otherwise unidentified. This case indicates that leukemic infiltration can cause CP and that clinicians should include leukemia in the differential diagnosis of CP.
• 肺カルチノイド術後再発に対して放射性核種標識ペプチド療法を行った1例
  佐藤 祐麻; 榊原 純; 黒木 俊宏; 松野 吉宏; 平田 健司; 今野 哲
  日本呼吸器学会誌, 13, 2, 49, 53, (一社)日本呼吸器学会, Mar. 2024
  Japanese
• Evaluation of Prediabetes in Cisplatin-induced Nephrotoxicity in the Short Hydration Method: A Subgroup Analysis
  YOSHITAKA SAITO; TATSUHIKO SAKAMOTO; MASAKI KOBAYASHI; YOH TAKEKUMA; ISSEI HIGUCHI; KEISUKE OKAMOTO; JUN SAKAKIBARA-KONISHI; YASUSHI SHIMIZU; ICHIRO KINOSHITA; MITSURU SUGAWARA
  In Vivo, 38, 2, 800, 806, Anticancer Research USA Inc., 28 Feb. 2024, [International Magazine]
  English, Scientific journal, BACKGROUND/AIM: Cisplatin-induced nephrotoxicity (CIN) is one of the most attention-requiring adverse effects. We have reported that diabetes mellitus significantly increases the incidence of CIN in a short hydration method in real-world lung cancer treatment. However, the effect of prediabetes on CIN development remains unclear. This study investigated whether patients with prediabetes exhibit CIN at a greater rate during real-world cisplatin-including treatments as a subgroup analysis. PATIENTS AND METHODS: This retrospective observational study enrolled patients with lung cancer receiving cisplatin treatment (≥75 mg/m2) from May 2014 to January 2021 (n=169). Patients were divided into a prediabetes group (baseline HbA1c 5.7-6.4%) and a control group (baseline HbA1c <5.7%). The primary endpoint of this study was the incidence of CIN in all treatment cycles between the two groups. We also assessed variations in serum creatinine (SCr) levels and creatinine clearance (CCr). RESULTS: CIN occurred in 4.7% of controls and 8.3% of patients with prediabetes in all cycles, with no significant difference (p=0.37). In contrast, variation of SCr levels and CCr was significantly worse in the prediabetes group [median variation level (range) 0.11 mg/dl (-0.11-0.46 mg/dl) and 0.12 mg/dl (-0.02-1.08 mg/d) in controls and prediabetes, p=0.04 for SCr; -12.9 ml/min (-54.1-4.9 ml/min) and -16.3 ml/min (-49.4-3.0 ml/min), p=0.02 for CCr, respectively]. These results were also confirmed during the first cycle of treatment. CONCLUSION: Patients with prediabetes did not develop problematic CIN, although they exhibited significant increases in SCr and decreases in CCr.
• 化学免疫療法が著効し著明な虚脱線維化を呈した肺扁平上皮癌の一例
  若林 健人; 中里 信一; 大川 紘弥; 加藤 憲士郎; 宮石 陸; 池澤 靖元; 榊原 純; 加藤 達哉; 外丸 詩野; 松野 吉宏
  日本病理学会会誌, 113, 1, 360, 360, (一社)日本病理学会, Feb. 2024
  Japanese
• Association Between Multisystem Immune-related Adverse Events and Progression-free Survivals in PD-1/PD-L1 Inhibitor Monotherapy.
  Atsushi Yamaguchi; Yoshitaka Saito; Keisuke Okamoto; Ayako Furugen; Katsuya Narumi; Yoh Takekuma; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara; Masaki Kobayashi
  In vivo (Athens, Greece), 38, 6, 2886, 2896, 2024, [International Magazine]
  English, Scientific journal, BACKGROUND/AIM: Immune-related adverse events (irAEs) occur in various organs, and sometimes multiply following treatment with immune checkpoint inhibitors (ICIs). This study aimed to determine the association between the number of irAEs and clinical outcomes. PATIENTS AND METHODS: This was a retrospective study that included patients with lung cancer, melanoma, and head and neck cancer who were treated with anti-programmed cell death (ligand) 1 (PD-1/PD-L1) monotherapy. We evaluated the association between the number of irAEs and progression-free survival (PFS) in the simple Cox regression analysis. To eliminate the immortal-time bias, an additional landmark analysis was performed. RESULTS: In total, 92, 69, and 37 patients were allocated to the no, single, and multisystem irAEs groups, respectively. The multisystem irAEs were associated with better PFS compared to the no irAE group. In contrast, at the 12-week landmark, multisystem irAEs were associated with poor PFS compared to the no irAEs group. Furthermore, the rate of treatment suspension owing to irAEs in the multisystem irAEs group (62.5%) was higher than that in the single irAE group (17.3%) at the 12-week landmark. CONCLUSION: The incidence of multisystem irAEs was associated with improved clinical outcomes in patients with lung cancer, melanoma, and head and neck cancer treated with PD-1/PD-L1 inhibitor monotherapy. However, these results may be influenced by a potential immortal-time bias. When accounting for this bias, the early development of multisystem irAEs within 12 weeks was linked to treatment suspension and poorer clinical outcomes.
• Drop finger caused by lung cancer metastasis.
  Toshiyuki Sumi; Jun Sakakibara-Konishi; Keito Suzuki; Hirofumi Chiba
  Respirology case reports, 12, 1, e01280, Jan. 2024, [International Magazine]
  English, Skeletal muscle metastasis of lung cancer is rare. However, clinicians should be aware that tumour-induced nerve compression symptoms may develop.
• Evaluation of Efficacy of Adding Aprepitant to Palonosetron and Dexamethasone in Carboplatin and Etoposide Therapy.
  Tatsuhiko Sakamoto; Moeko Kado; Yoshitaka Saito; Kazuki Uchiyama; Ryota Kanno; Osamu Taniguchi; Yoh Takekuma; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 47, 6, 1189, 1195, 2024, [Domestic magazines]
  English, Scientific journal, Although carboplatin (CBDCA) is classified as a moderately emetogenic agent, the majority of guidelines recommend the use of a neurokinin-1 receptor antagonist in addition to a 5-hydroxytryptamine type 3 receptor antagonist with dexamethasone (DEX) for CBDCA-containing chemotherapy because of its higher emetogenic risk. However, the additional efficacy of aprepitant (APR) in CBDCA-containing treatment remains controversial, and data on multiple-day treatments are limited. Etoposide (ETP) was administered on days 1-3 in the CBDCA + ETP regimen, and it is important to evaluate suitable antiemetic therapy for the regimen. Therefore, we evaluated the efficacy of additional APR in CBDCA + ETP. Patients were divided into two groups and retrospectively evaluated. One was the control group, which was prophylactically administered palonosetron (PALO) and DEX, and the other was the APR group, which received APR orally with PALO and DEX. The primary endpoint was complete response (CR) between the groups. The overall CR rates were 75.0 and 76.4% in the control and APR groups, respectively, with no significant difference (p = 1.00). In the acute phase, it was 88.9 and 97.2%, respectively, and 86.1 and 79.2% in the delayed phase, respectively, without significant differences (p = 0.10 and 0.38, respectively). The incidence and severity of nausea, vomiting, and anorexia were not significantly different between the two groups in the acute and delayed phases. Our findings suggest that combining APR with PALO and DEX does not improve the CR rate in CBDCA + ETP therapy.
• Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment.
  Yoshitaka Saito; Shinya Tamaki; Daisuke Hirate; Shinya Takada; Kenta Takahashi; Yoh Takekuma; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara
  Scientific reports, 13, 1, 19457, 19457, 09 Nov. 2023, [Peer-reviewed], [International Magazine]
  English, Scientific journal, Treatment using docetaxel (DOC) and ramucirumab (RAM) is an effective regimen in second or later line advanced non-small cell lung carcinoma (NSCLC) treatment. However, it induces severe adverse effects, resulting in treatment reduction such as dose reduction and/or discontinuation. This study aimed to reveal the factor(s) associated with treatment reduction in DOC + RAM. We retrospectively evaluated patients with advanced NSCLC (n = 155). Treatment reduction of the second course due to severe adverse effects was conducted in 25.8% of the participants, and relative dose intensity at the second course was 95.7 ± 8.4% for DOC and 91.9 ± 24.8% for RAM. Multivariate logistic regression analyses identified that baseline anemia and prophylactic granulocyte colony-stimulating factor (G-CSF) administration are preventive factors for the reduction (adjusted odds ratio, 0.29; 95% confidence interval, 0.12-0.66; P = 0.004 for baseline anemia, 0.18; 0.08-0.42; P < 0.0001 for prophylactic G-CSF administration). The primary cause of the reduction was febrile neutropenia, and the same factors were identified. Our study revealed that patients with baseline anemia and prophylactic G-CSF administration have less risk for treatment reduction in DOC + RAM for NSCLC treatment.
• 薄壁空洞性病変を呈した原発性肺扁平上皮内癌の1例
  佐々木 明洋; 新垣 雅人; 竹野 巨樹; 山崎 洋; 野村 俊介; 大高 和人; 藤原 晶; 氏家 秀樹; 榊原 純; 大川 紘弥; 松野 吉宏; 加藤 達哉
  気管支学, 45, 6, 443, 443, (一社)日本呼吸器内視鏡学会, Nov. 2023
  Japanese
• 80歳以上の高齢者に対する経気管支生検の安全性と有用性の検討
  畠山 酉季; 高島 雄太; 鈴木 孝敏; 棟方 奈菜; 中村 友彦; 高橋 宏典; 古田 恵; 北井 秀典; 庄司 哲明; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 品川 尚文; 今野 哲
  気管支学, 45, 6, 444, 444, (一社)日本呼吸器内視鏡学会, Nov. 2023
  Japanese
• Risk factor analysis for cisplatin-induced nephrotoxicity with the short hydration method in diabetic patients.
  Yoshitaka Saito; Masaki Kobayashi; Shinya Tamaki; Katsuyuki Nakamura; Daisuke Hirate; Kenta Takahashi; Yoh Takekuma; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara
  Scientific reports, 13, 1, 17126, 17126, 10 Oct. 2023, [International Magazine]
  English, Scientific journal, The occurrence of cisplatin (CDDP)-induced nephrotoxicity (CIN) has decreased with advancements in supportive care. In contrast, we reported that baseline diabetes mellitus (DM) complications significantly worsen CIN. This study aimed to determine further risk factors associated with CIN development in DM patients. Patients with thoracic cancer requiring DM pharmacotherapy, who received CDDP (≥ 60 mg/m2)-containing regimens using the short hydration method (n = 140), were enrolled in this retrospective multicenter observational study. The primary endpoint of the present study was the elucidation of risk factors (patient factors, DM medication influence, and treatment-related factors) associated with CIN development in patients with DM. Cisplatin-induced nephrotoxicity occurred in 22.1% of patients with DM. The median worst variation of serum creatinine levels and creatinine clearance (worst level - baseline level) was 0.16 mg/dL (range: - 0.12-1.41 mg/dL) and - 15.9 mL/min (- 85.5-24.3 mL/min), respectively. Multivariate logistic regression analyses identified female sex as the singular risk factor for CIN development in the DM population (adjusted odds ratio; 2.87, 95% confidence interval; 1.08-7.67, P = 0.04). Diabetes mellitus medication and treatment-related factors did not affect CIN development. In conclusion, our study revealed that female sex is significantly associated with CIN development in patients with DM and thoracic cancer.
• 75歳以上の非小細胞肺癌患者におけるペムブロリズマブの薬物動態と高齢者機能評価に関する多施設共同研究
  津端 由佳里; 山中 雄太; 倉田 宝保; 渡邊 景明; 細見 幸生; 堀之内 秀仁; 大江 裕一郎; 中原 善朗; 朝尾 哲彦; 佐伯 祥; 藤田 雄; 榊原 純; 水柿 秀紀; 大内 麻由; 柳下 薫寛; 濱田 哲暢
  肺癌, 63, 5, 451, 451, (NPO)日本肺癌学会, Oct. 2023
  Japanese
• 標的治療耐性後の治療戦略 耐性克服治療の開発を目指した非小細胞肺癌における薬剤耐性遺伝子スクリーニング研究(LC-SCRUM-TRY)
  泉 大樹; 松本 慎吾; 西野 和美; 加藤 晃史; 原 聡志; 中村 敦; 榊原 純; 山本 将一朗; 大江 裕一郎; 仲地 一郎; 酒井 徹也; 杉山 栄里; 善家 義貴; 梅村 茂樹; 葉 清隆; 後藤 功一
  肺癌, 63, 5, 396, 396, (NPO)日本肺癌学会, Oct. 2023
  Japanese
• 全トランスクリプトーム解析による非小細胞肺癌の新規・稀少ドライバー遺伝子のスクリーニング(Comprehensive analysis for gene fusions by whole-transcriptome sequencing in non-small cell lung cancer)
  泉 大樹; 松本 慎吾; 渡邉 香奈; 古屋 直樹; 西野 和美; 中野 恭幸; 坂下 博之; 臼井 一裕; 榊原 純; 小谷 昌広; 金山 雅俊; 柴田 祐司; 葉 清隆; 後藤 功一
  日本癌学会総会記事, 82回, 858, 858, (一社)日本癌学会, Sep. 2023
  English
• Inhibition of non-homologous end joining mitigates paclitaxel resistance resulting from mitotic slippage in non-small cell lung cancer.
  Kosuke Tsuji; Eiki Kikuchi; Yuta Takashima; Tetsuaki Shoji; Hirofumi Takahashi; Shotaro Ito; Daisuke Morinaga; Masahiro Kashima; Makie Maeda; Hidenori Kitai; Junko Kikuchi; Jun Sakakibara-Konishi; Satoshi Konno
  Cell cycle (Georgetown, Tex.), 22, 17, 1, 11, 17 Aug. 2023, [International Magazine]
  English, Scientific journal, Mitotic slippage, which enables cancer cells to bypass cell death by transitioning from mitosis to the G1 phase without undergoing normal cytokinesis, is one likely mechanism of paclitaxel (PTX) resistance. DNA double-strand breaks (DSBs) in the G1 phase are mainly repaired through non-homologous end joining (NHEJ). Therefore, inhibiting NHEJ could augment the PTX-induced cytotoxicity by impeding the repair of PTX-induced DSBs during the G1 phase following mitotic slippage. We aimed to evaluate the effects of NHEJ inhibition on mitotic slippage after PTX treatment in non-small cell lung cancer (NSCLC). H1299, A549, H1975, and H520 NSCLC cell lines were employed. In addition, A-196 and JQ1 were used as NHEJ inhibitors. H1299 cells were PTX-resistant and exhibited an increased frequency of mitotic slippage upon PTX treatment. NHEJ inhibitors significantly augmented the PTX-induced cytotoxicity, DSBs, and apoptosis in H1299 cells. The newly generated PTX-resistant cells were even more prone to mitotic slippage following PTX treatment and susceptible to the combined therapy. Docetaxel further demonstrated synergistic effects with the NHEJ inhibitor in PTX-resistant cells. NHEJ inhibition may overcome intrinsic or acquired PTX resistance resulting from mitotic slippage by synergistically increasing the cytotoxic effects of antimitotic drugs in NSCLC.
• 80歳以上の高齢者に対する経気管支生検の安全性と有用性の検討
  畠山 酉季; 高島 雄太; 鈴木 孝敏; 棟方 奈菜; 中村 友彦; 高橋 宏典; 古田 恵; 北井 秀典; 庄司 哲明; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 品川 尚文; 今野 哲
  気管支学, 45, Suppl., S217, S217, (一社)日本呼吸器内視鏡学会, Jun. 2023
  Japanese
• Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial.
  Yongfeng Yu; Jianya Zhou; Xingya Li; Koichi Goto; Xuhong Min; Kazumi Nishino; Jiuwei Cui; Lin Wu; Jun Sakakibara; Yongqian Shu; Xiaorong Dong; Lu Li; Yasuto Yoneshima; Chengzhi Zhou; Xiaoling Li; Yiping Zhang; Dingzhi Huang; Aimin Zang; Wei Zhang; Xiuwen Wang; Li Zhang; Chong Bai; Jian Fang; Lejie Cao; Yanqiu Zhao; Yan Yu; Meiqi Shi; Diansheng Zhong; Fugen Li; Meng Li; Qiuxia Wu; Jun Zhou; Minghui Sun; Shun Lu
  EClinicalMedicine, 59, 101952, 101952, May 2023, [International Magazine]
  English, Scientific journal, BACKGROUND: Approximately 3-4% of patients with non-small-cell lung cancer (NSCLC) have MET exon 14 (METex14) skipping mutations. We report primary results from the phase 2 stage of a phase 1b/2 study of gumarontinib, a selective, potent, oral MET inhibitor, in patients with METex14 skipping mutation-positive (METex14-positive) NSCLC. METHODS: The single-arm, multicentre, open-label, phase 2 stage of the GLORY study was conducted at 42 centres across China and Japan. Adults with locally advanced or metastatic METex14-positive NSCLC received oral gumarontinib 300 mg once daily in continuous 21-day cycles until disease progression, intolerable toxicity, or withdrawal of consent. Eligible patients had failed one or two prior lines of therapy (not including a MET inhibitor), were ineligible for/refused chemotherapy, and had no genetic alterations targetable with standard therapies. The primary endpoint was objective response rate in patients with a valid baseline tumour assessment, by blinded independent review. The study was registered at ClinicalTrials.gov (NCT04270591). FINDINGS: Between Aug 2, 2019 and Apr 28, 2021, 84 patients were enrolled and received gumarontinib (median follow-up 13.5 months [IQR 8.7-17.1]), at data cut-off (Apr 28, 2022) five patients whose METex14 status could not be confirmed by a central laboratory were excluded from the efficacy analysis. The objective response rate was 66% (95% CI 54-76) overall (n = 79), 71% (95% CI 55-83) in treatment-naïve patients (n = 44), and 60% (95% CI 42-76) in previously-treated patients (n = 35). The most common treatment-related adverse events (any grade) were oedema (67/84 patients, 80%) and hypoalbuminuria (32/84, 38%). Grade ≥3 treatment-emergent adverse events occurred in 45 (54%) patients. Treatment-related adverse events leading to permanent discontinuation occurred in 8% (7/84) of patients. INTERPRETATION: Gumarontinib monotherapy had durable antitumour activity with manageable toxicity in patients with locally advanced or metastatic METex14-positive NSCLC when used in first line or later. FUNDING: Haihe Biopharma Co., Ltd. Supported in part by grants from the National Science and Technology Major Project of China for "Clinical Research of Gumarontinib, a highly selective MET inhibitor" (2018ZX09711002-011-003); the National Natural Science Foundation of China (82030045 to S.L. and 82172633 to YF.Y); Shanghai Municipal Science & Technology Commission Research Project (19411950500 to S.L.); Shanghai Shenkang Action Plan (16CR3005A to S.L.) and Shanghai Chest Hospital Project of Collaborative Innovation (YJXT20190105 to S.L.).
• 当科におけるPD-L1陰性非小細胞肺癌に対する免疫チェックポイント阻害薬治療についての後方視的検討
  田上 敬太; 菊地 英毅; 庄司 哲明; 吉川 修平; 黒木 俊宏; 嘉島 相裕; 高木 統一郎; 三浦 瞬; 猪狩 智生; 小熊 昂; 古田 恵; 高島 雄太; 朝比奈 肇; 菊地 順子; 榊原 純; 品川 尚文; 今野 哲
  肺癌, 63, 2, 126, 127, (NPO)日本肺癌学会, Apr. 2023
  Japanese
• 化学放射線療法+デュルバルマブ療法を施行後に病勢進行となった非小細胞肺癌の次治療の後方視的検討
  嘉島 相裕; 庄司 哲明; 古田 恵; 吉川 修平; 黒木 俊宏; 田上 敬太; 高木 統一郎; 三浦 瞬; 小熊 昂; 猪狩 智生; 高島 雄太; 朝比奈 肇; 菊地 順子; 菊地 英毅; 榊原 純; 品川 尚文; 今野 哲
  肺癌, 63, 2, 127, 127, (NPO)日本肺癌学会, Apr. 2023
  Japanese
• RET融合遺伝子陽性肺腺癌に対してセルペルカチニブ投与後に多彩な有害事象を呈した症例
  関 萌花; 猪狩 智生; 榊原 純; 吉川 修平; 黒木 俊宏; 田上 敬太; 嘉島 相裕; 高木 統一郎; 三浦 瞬; 小熊 昂; 高島 雄太; 古田 恵; 庄司 哲明; 朝比奈 肇; 菊地 順子; 菊地 英毅; 品川 尚文; 今野 哲; 伊藤 健一郎
  肺癌, 63, 2, 128, 128, (NPO)日本肺癌学会, Apr. 2023
  Japanese
• ICI 75歳以上の高齢者非小細胞肺がんに対するペムブロリズマブの多施設共同薬物動態研究
  渡邊 景明; 細見 幸生; 山中 雄太; 倉田 宝保; 堀之内 秀仁; 大江 裕一郎; 朝尾 哲彦; 中原 善朗; 佐伯 祥; 津端 由佳里; 藤田 雄; 榊原 純; 水柿 秀紀; 大内 麻由; 柳下 薫寛; 濱田 哲暢
  日本呼吸器学会誌, 12, 増刊, 168, 168, (一社)日本呼吸器学会, Mar. 2023
  Japanese
• EGFR変異陽性肺癌におけるCD24発現の検討
  椎谷 研彦; 野口 卓郎; 外丸 詩野; 有賀 伸; 高島 雄太; 品川 尚文; 木下 一郎; 松野 吉宏; 榊原 純; 秋田 弘俊
  日本病理学会会誌, 112, 1, 247, 247, (一社)日本病理学会, Mar. 2023
  Japanese
• 非小細胞肺癌での化学放射線+デュルバルマブ療法後の免疫チェックポイント阻害剤再投与の後方視的検討
  嘉島 相裕; 庄司 哲明; 古田 恵; 猪狩 智生; 高島 雄太; 朝比奈 肇; 菊地 順子; 菊地 英毅; 榊原 純; 今野 哲
  日本呼吸器学会誌, 12, 増刊, 278, 278, (一社)日本呼吸器学会, Mar. 2023
  Japanese
• Angiogenic inhibitor pre-administration improves the therapeutic effects of immunotherapy.
  Mineyoshi Sato; Nako Maishi; Yasuhiro Hida; Aya Yanagawa-Matsuda; Mohammad Towfik Alam; Jun Sakakibara-Konishi; Jin-Min Nam; Yasuhito Onodera; Satoshi Konno; Kyoko Hida
  Cancer medicine, 12, 8, 9760, 9773, 19 Feb. 2023, [International Magazine]
  English, Scientific journal, In lung cancer, immune checkpoint inhibitors (ICIs) are often inadequate for tumor growth inhibition. Angiogenic inhibitors (AIs) are required to normalize tumor vasculature for improved immune cell infiltration. However, in clinical practice, ICIs and cytotoxic antineoplastic agents are simultaneously administered with an AI when tumor vessels are abnormal. Therefore, we examined the effects of pre-administering an AI for lung cancer immunotherapy in a mouse lung cancer model. Using DC101, an anti-vascular endothelial growth factor receptor 2 (VEGFR2) monoclonal antibody, a murine subcutaneous Lewis lung cancer (LLC) model was used to determine the timing of vascular normalization. Microvessel density (MVD), pericyte coverage, tissue hypoxia, and CD8-positive cell infiltration were analyzed. The effects of an ICI and paclitaxel after DC101 pre-administration were investigated. On Day 3, increased pericyte coverage and alleviated tumor hypoxia represented the highest vascular normalization. CD8+ T-cell infiltration was also highest on Day 3. When combined with an ICI, DC101 pre-administration significantly reduced PD-L1 expression. When combined with an ICI and paclitaxel, only DC101 pre-administration significantly inhibited tumor growth, but simultaneous administration did not. AI pre-administration, and not simultaneous administration, may increase the therapeutic effects of ICIs due to improved immune cell infiltration.
• EGFR inhibition in EGFR-mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment.
  Akihiko Shiiya; Takuro Noguchi; Utano Tomaru; Shin Ariga; Yuta Takashima; Yoshihito Ohhara; Jun Taguchi; Satoshi Takeuchi; Yasushi Shimizu; Ichiro Kinoshita; Tomonobu Koizumi; Yoshihiro Matsuno; Naofumi Shinagawa; Jun Sakakibara-Konishi; Hirotoshi Dosaka-Akita
  Cancer science, 114, 4, 1270, 1283, 18 Dec. 2022, [International Magazine]
  English, Scientific journal, Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) elicit potent cell cycle arrest in EGFR-mutant non-small-cell lung cancer (NSCLC) cells. However, little is known about the mechanisms through which these drugs alter the tumor phenotype that contributes to the immune escape of EGFR-mutant cells. Using EGFR-mutant NSCLC cell lines and tissue samples from patients, we investigated the changes in immune checkpoints expressed in tumor cells following EGFR inhibition. Subsequently, we also analyzed the role of soluble factors from the dying tumor cells in the activation of immune signaling pathways involved in therapy resistance. Upon EGFR-TKI treatment, we found that EGFR-mutant cells upregulated the expression of innate immune checkpoint CD24 in vitro. We then analyzed biopsy samples from six patients who developed resistance to a first-generation EGFR-TKI without the acquired T790M mutation. Immunohistochemistry revealed that levels of tumor CD24 expression were increased upon treatment compared with those from pre-treatment samples. Monocyte-derived macrophages facilitated antibody-dependent cellular phagocytosis when EGFR-TKI-treated EGFR-mutant cells were incubated with anti-CD24 antibodies in vitro, suggesting that CD24 may be a therapeutical target for EGFR-mutant lung cancer. Moreover, EGFR inhibition accelerated the release of cell-free DNA (cfDNA) from dying tumor cells, which activated the type I interferon signaling pathways in human THP-1 monocytes in a stimulator of interferon genes-dependent manner. Our study indicates that EGFR inhibition in EGFR-mutant NSCLC cells fosters a tumor microenvironment associated with immune escape. Thus, CD24 targeted therapy and cfDNA monitoring may contribute to improved treatment outcomes in patients with EGFR-mutant NSCLC.
• Risk of bleeding associated with transbronchial biopsy using flexible bronchoscopy in patients with echocardiographic or chest CT evidence of pulmonary hypertension.
  Yuta Takashima; Naofumi Shinagawa; Daisuke Morinaga; Junichi Nakamura; Megumi Furuta; Tetsuaki Shoji; Hajime Asahina; Eiki Kikuchi; Junko Kikuchi; Jun Sakakibara-Konishi; Ichizo Tsujino; Satoshi Konno
  BMC pulmonary medicine, 22, 1, 449, 449, 28 Nov. 2022, [Peer-reviewed], [International Magazine]
  English, Scientific journal, BACKGROUND: Endobronchial ultrasound (EBUS)-guided transbronchial biopsy (TBB) facilitates the diagnosis of various respiratory diseases. The safety of performing EBUS-guided TBB in patients with a finding of pulmonary hypertension (PH) is controversial. Little is known about the relationship between the risk of bleeding associated with EBUS-guided TBB in the presence of PH suspected on echocardiography or chest CT. METHODS: To assess the risk of bleeding associated with EBUS-guided TBB in patients with presumed PH per echocardiography or chest CT, we retrospectively reviewed the medical records of 314 consecutive patients who underwent EBUS-guided TBB using a guide sheath (GS), as well as echocardiography and chest CT. Bleeding complication was defined as over one minute of suctioning; repeated wedging of the bronchoscope; instillation of cold saline, diluted vasoactive substances, or thrombin due to persistent bleeding. Findings of suspected PH were defined as peak tricuspid regurgitation velocity (TRV) > 2.8 m/s on echocardiography or pulmonary artery to aorta ratio (PA:A ratio) > 0.9 on chest CT. RESULTS: In total, 35 (11.1%) patients developed bleeding, and all cases were managed safely. Furthermore, 17 (5.4%) and 59 (18.8%) patients were suspected to have PH based on echocardiography and chest CT, respectively. Among the patients suspected to have PH on echocardiography, five (5/17 = 29.4%) patients developed bleeding. Among the patients suspected to have PH on chest CT, 11 (11/59 = 18.6%) patients developed bleeding. Univariate analysis revealed that long diameter (≥ 30 mm) of the lesion, lesion location (the biopsy site was inner than the segmental bronchus), bronchoscopic diagnosis of malignancy, and additional biopsy were potential predictive factors for bleeding. The finding of suspected PH on echocardiography correlated significantly with bleeding (p = 0.03). On multivariate analysis, long diameter (≥ 30 mm) of the lesion (p = .021) and findings of suspected PH on echocardiography (p = .049) were significantly associated with bleeding. CONCLUSION: All cases of bleeding in the present study were managed safely. The risk of bleeding is moderately elevated when PH is suspected by echocardiography in patients undergoing EBUS-guided TBB using a GS.
• Notch pathway regulates osimertinib drug-tolerant persistence in EGFR-mutated non-small-cell lung cancer.
  Hirofumi Takahashi; Jun Sakakibara-Konishi; Megumi Furuta; Tetsuaki Shoji; Kosuke Tsuji; Daisuke Morinaga; Eiki Kikuchi; Junko Kikuchi; Takuro Noguchi; Kanako C Hatanaka; Yutaka Hatanaka; Naofumi Shinagawa; Satoshi Konno
  Cancer science, 114, 4, 1635, 1650, 21 Nov. 2022, [International Magazine]
  English, Scientific journal, Osimertinib is a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that has shown marked antitumor activity in patients with EGFR-mutated non-small-cell lung cancer (NSCLC). However, these effects are transient and most patients develop resistance. Reversible drug-tolerant persister (DTP) cells are defined as a small subpopulation of cells with markedly reduced sensitivity and non-genetic acquired resistance to EGFR-TKIs. Notch is a transmembrane receptor that plays an important role in tumorigenesis. We previously reported that there is significant crosstalk between the Notch and EGFR pathways in NSCLC. Moreover, the Notch pathway is associated with resistance to previous-generation EGFR-TKIs. However, the role of Notch in osimertinib resistance is not fully understood. In this study, we evaluated whether Notch is involved in osimertinib resistance. We show that NOTCH1 and Notch target genes are upregulated in osimertinib DTP cells, and that the addition of a γ-secretase inhibitor (GSI), a Notch inhibitor, impairs drug-tolerant persistence in vitro and in vivo. Compared with osimertinib, combined GSI and osimertinib suppress phospho-ERK partly by enhancing DUSP1 expression. Furthermore, Notch1 and HES1 were upregulated after EGFR-TKI treatment in half of human EGFR-mutated NSCLC tumor tissues. These results suggest that the combination of GSI and osimertinib may be a potential therapy for EGFR-mutated NSCLC.
• EGFR変異陽性非小細胞肺癌におけるosimertinib耐性とNotch経路の関わり
  高橋 宏典; 榊原 純; 古田 恵; 庄司 哲明; 辻 康介; 森永 大亮; 菊地 英毅; 菊地 順子; 野口 卓郎; 畑中 佳奈子; 畑中 豊; 品川 尚文; 今野 哲
  肺癌, 62, 6, 715, 715, (NPO)日本肺癌学会, Nov. 2022
  Japanese
• EBUS-GS-TBB検体の腫瘍細胞含有率に関連する臨床因子についての検討
  高島 雄太; 品川 尚文; 有里 仁希; 嘉島 相裕; 庄司 哲明; 古田 恵; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 畑中 佳奈子; 松野 吉宏; 畑中 豊; 今野 哲
  気管支学, 44, 6, 459, 459, (一社)日本呼吸器内視鏡学会, Nov. 2022
  Japanese
• 非小細胞肺癌のmitotic slippageに対するDNA修復阻害の有用性についての基礎的検討
  辻 康介; 菊地 英毅; 高島 雄太; 庄司 哲明; 森永 大亮; 伊藤 祥太郎; 高橋 宏典; 朝比奈 肇; 菊地 順子; 品川 尚文; 榊原 純; 今野 哲
  肺癌, 62, 6, 754, 754, (NPO)日本肺癌学会, Nov. 2022
  Japanese
• A large-scale prospective concordance study of plasma- and tissue-based next-generation targeted sequencing for advanced non-small cell lung cancer (LC-SCRUM-Liquid).
  Akira Sugimoto; Shingo Matsumoto; Hibiki Udagawa; Ryo Itotani; Yuko Usui; Shigeki Umemura; Kazumi Nishino; Ichiro Nakachi; Shoichi Kuyama; Haruko Daga; Satoshi Hara; Shingo Miyamoto; Terufumi Kato; Jun Sakakibara-Konishi; Eriko Tabata; Taku Nakagawa; Tomoya Kawaguchi; Tetsuya Sakai; Yuji Shibata; Hiroki Izumi; Kaname Nosaki; Yoshitaka Zenke; Kiyotaka Yoh; Koichi Goto
  Clinical cancer research : an official journal of the American Association for Cancer Research, 29, 8, 1506, 1514, 06 Oct. 2022, [International Magazine]
  English, Scientific journal, PURPOSE: We evaluated plasma cell-free DNA (cfDNA) and tissue-based sequencing concordance for comprehensive oncogenic driver detection in non-small cell lung cancer (NSCLC) using a large-scale prospective screening cohort (LC-SCRUM-Liquid). METHODS: Blood samples were prospectively collected within four weeks of corresponding tumor tissue sampling from advanced NSCLC patients to investigate plasma cfDNA sequencing concordance for alterations in eight oncogenes (EGFR, KRAS, BRAF, HER2, MET, ALK, RET, and ROS1) compared to tissue-based next-generation targeted sequencing. RESULTS: Paired blood and tissue samples were obtained in 1062/1112 enrolled NSCLC patients. Oncogenic alteration was detected by plasma cfDNA sequencing and tissue assay in 455 (42·8%) and 537 (50·5%) patients, respectively. The positive percent agreement (PPA) of plasma cfDNA sequencing compared with tissue DNA and RNA assays were 77% (EGFR, 78%; KRAS, 75%; BRAF, 85%; HER2, 72%) and 47% (ALK, 46%; RET, 57%; ROS1, 18%; MET 66%), respectively. Oncogenic drivers were positive for plasma cfDNA and negative for tissue due to unsuccessful genomic analysis from poor-quality tissue samples (70%), and were negative for plasma cfDNA and positive for tissue due to low sensitivity of cfDNA analysis (61%). In patients with positive oncogenic drivers by plasma cfDNA sequencing but negative by tissue assay, response rate of genotype-matched therapy was 85% and median progression-free survival was 12·7 months. CONCLUSIONS: Plasma cfDNA sequencing in advanced NSCLC patients showed relatively high sensitivity for detecting gene mutations but low sensitivity for gene fusions and MET exon 14 skipping. This may be an alternative only when tissue assay is unavailable due to insufficient DNA and RNA.
• 非小細胞肺癌のmitotic slippageに対するDNA修復阻害の有用性についての基礎的検討(Inhibition of DNA damage repair for mitotic slippage after paclitaxel treatment in non-small cell lung cancer)
  辻 康介; 菊地 英毅; 高島 雄太; 庄司 哲明; 朝比奈 肇; 菊地 順子; 品川 尚文; 榊原 純; 今野 哲
  日本癌学会総会記事, 81回, P, 1063, (一社)日本癌学会, Sep. 2022
  English
• Effects of obesity on CC16 and their potential role in overweight/obese asthma.
  Houman Goudarzi; Hirokazu Kimura; Hiroki Kimura; Hironi Makita; Munehiro Matsumoto; Nozomu Takei; Kaoruko Shimizu; Masaru Suzuki; Taku Watanabe; Eiki Kikuchi; Hiroshi Ohira; Ichizo Tsujino; Jun Sakakibara-Konishi; Naofumi Shinagawa; Noriharu Shijubo; Hirokazu Sato; Katsunori Shigehara; Kichizo Kaga; Yasuhiro Hida; Soichi Murakami; Yuma Ebihara; Akinobu Nakamura; Hideaki Miyoshi; Satoshi Hirano; Nobuyuki Hizawa; Tatsuya Atsumi; Shau-Ku Huang; Yoichi M Ito; Masaharu Nishimura; Satoshi Konno
  Respiratory research, 23, 1, 174, 174, 29 Jun. 2022, [International Magazine]
  English, Scientific journal, INTRODUCTION: Club cell secretory protein-16 (CC16) is a major anti-inflammatory protein expressed in the airway; however, the potential role of CC16 on overweight/obese asthma has not been assessed. In this study, we examined whether obesity reduces airway/circulatory CC16 levels using experimental and epidemiological studies. Then, we explored the mediatory role of CC16 in the relationship of overweight/obesity with clinical asthma measures. METHODS: Circulating CC16 levels were assessed by ELISA in three independent human populations, including two groups of healthy and general populations and asthma patients. The percentage of cells expressing club markers in obese vs. non-obese mice and human airways was determined by immunohistochemistry. A causal mediation analysis was conducted to determine whether circulatory CC16 acted as a mediator between overweight/obesity and clinical asthma measures. RESULTS: BMI was significantly and monotonously associated with reduced circulating CC16 levels in all populations. The percentage of CC16-expressing cells was reduced in the small airways of both mice and humans with obesity. Finally, mediation analysis revealed significant contributions of circulatory CC16 in the association between BMI and clinical asthma measures; 21.8% of its total effect in BMI's association with airway hyperresponsiveness of healthy subjects (p = 0.09), 26.4% with asthma severity (p = 0.030), and 23% with the required dose of inhaled corticosteroid (p = 0.042). In logistic regression analysis, 1-SD decrease in serum CC16 levels of asthma patients was associated with 87% increased odds for high dose ICS requirement (p < 0.001). CONCLUSIONS: We demonstrate that airway/circulating CC16, which is inversely associated with BMI, may mediate development and severity in overweight/obese asthma.
• EBUS-GS-TBB検体の腫瘍細胞含有率に関連する臨床因子についての検討
  高島 雄太; 品川 尚文; 有里 仁希; 嘉島 相裕; 庄司 哲明; 古田 恵; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 畑中 佳奈子; 松野 吉宏; 畑中 豊; 今野 哲
  気管支学, 44, Suppl., S250, S250, (NPO)日本呼吸器内視鏡学会, May 2022
  Japanese
• オシメルチニブ長期内服中に亜鉛欠乏に伴う壊死性遊走性紅斑様皮疹を生じた一例
  山本 岳; 朝比奈 肇; 岩田 浩明; 高桑 恵美; 伊藤 祥太郎; 國崎 守; 高島 雄太; 菊地 順子; 菊地 英毅; 榊原 純; 品川 尚文; 今野 哲
  日本呼吸器学会誌, 11, 増刊, 303, 303, (一社)日本呼吸器学会, Apr. 2022
  Japanese
• 小細胞肺癌転化を来したEGFR遺伝子変異陽性肺癌の3例
  森永 大亮; 榊原 純; 古田 恵; 品川 尚文; 合田 智宏; 若林 健人; 高桑 恵美; 高階 太一; 今野 哲
  肺癌, 62, 2, 107, 114, (NPO)日本肺癌学会, Apr. 2022
  Japanese
• 肺癌の再発・転移が疑われた後縦隔FDG陽性病変の診断に骨髄シンチグラフィが有用であった一例
  眞島 隆成; 竹中 淳規; 渡邊 史郎; 内山 裕子; 木村 理奈; 榊原 純; 平田 健司; 工藤 與亮
  北海道放射線医学雑誌, 2, 29, 33, (NPO)メディカルイメージラボ, Mar. 2022
  Japanese
• 当科における非小細胞肺癌術後局所再発に対する化学放射線療法後のデュルバルマブ使用症例の後方視的検討
  三浦 瞬; 古田 恵; 千葉 葵; 三田 明音; 有里 仁希; 森永 大亮; 辻 康介; 高島 雄太; 庄司 哲明; 朝比奈 肇; 菊地 順子; 菊地 英毅; 榊原 純; 品川 尚文; 今野 哲
  肺癌, 62, 1, 70, 70, (NPO)日本肺癌学会, Feb. 2022
  Japanese
• 当科における小細胞肺癌に対する免疫チェックポイント阻害剤+プラチナ製剤併用療法の後方視的検討
  有里 仁希; 庄司 哲明; 千葉 葵; 三田 明音; 三浦 瞬; 森永 大亮; 高島 雄太; 古田 恵; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 品川 尚文; 今野 哲
  肺癌, 62, 1, 71, 71, (NPO)日本肺癌学会, Feb. 2022
  Japanese
• The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
  Hiroki Izumi; Shingo Matsumoto; Jie Liu; Kosuke Tanaka; Shunta Mori; Kumiko Hayashi; Shogo Kumagai; Yuji Shibata; Takuma Hayashida; Kana Watanabe; Tatsuro Fukuhara; Takaya Ikeda; Kiyotaka Yoh; Terufumi Kato; Kazumi Nishino; Atsushi Nakamura; Ichiro Nakachi; Shoichi Kuyama; Naoki Furuya; Jun Sakakibara-Konishi; Isamu Okamoto; Kageaki Taima; Noriyuki Ebi; Haruko Daga; Akira Yamasaki; Masahiro Kodani; Hibiki Udagawa; Keisuke Kirita; Yoshitaka Zenke; Kaname Nosaki; Eri Sugiyama; Tetsuya Sakai; Tokiko Nakai; Genichiro Ishii; Seiji Niho; Atsushi Ohtsu; Susumu S Kobayashi; Koichi Goto
  Nature, 600, 7888, 319, 323, Dec. 2021, [International Magazine]
  English, Scientific journal, Lung cancer is one of the most aggressive tumour types. Targeted therapies stratified by oncogenic drivers have substantially improved therapeutic outcomes in patients with non-small-cell lung cancer (NSCLC)1. However, such oncogenic drivers are not found in 25-40% of cases of lung adenocarcinoma, the most common histological subtype of NSCLC2. Here we identify a novel fusion transcript of CLIP1 and LTK using whole-transcriptome sequencing in a multi-institutional genome screening platform (LC-SCRUM-Asia, UMIN000036871). The CLIP1-LTK fusion was present in 0.4% of NSCLCs and was mutually exclusive with other known oncogenic drivers. We show that kinase activity of the CLIP1-LTK fusion protein is constitutively activated and has transformation potential. Treatment of Ba/F3 cells expressing CLIP1-LTK with lorlatinib, an ALK inhibitor, inhibited CLIP1-LTK kinase activity, suppressed proliferation and induced apoptosis. One patient with NSCLC harbouring the CLIP1-LTK fusion showed a good clinical response to lorlatinib treatment. To our knowledge, this is the first description of LTK alterations with oncogenic activity in cancers. These results identify the CLIP1-LTK fusion as a target in NSCLC that could be treated with lorlatinib.
• A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
  Hiroyuki Yasuda; Eiki Ichihara; Jun Sakakibara-Konishi; Yoshitaka Zenke; Shinji Takeuchi; Masahiro Morise; Katsuyuki Hotta; Mineyoshi Sato; Shingo Matsumoto; Azusa Tanimoto; Reiko Matsuzawa; Katuyuki Kiura; Yuta Takashima; Seiji Yano; Junji Koyama; Takahiro Fukushima; Junko Hamamoto; Hideki Terai; Shinnosuke Ikemura; Ryo Takemura; Koichi Goto; Kenzo Soejima
  Lung cancer (Amsterdam, Netherlands), 162, 140, 146, Dec. 2021, [International Magazine]
  English, Scientific journal, OBJECTIVES: Several preclinical data proposed a potential efficacy of osimertinib, a third-generation EGFR tyrosine kinase inhibitor, for EGFR exon 20 insertion (EGFR ex20ins)-positive non-small cell lung cancer (NSCLC). However, reported case series and a retrospective study proposed controversial efficacy. The efficacy of osimertinib in EGFR ex20ins-positive NSCLC have not been well evaluated in prospective clinical trials. In this study, we performed a prospective, single-arm, multi-center, open-label, non-randomized phase I/II study to evaluate efficacy of osimertinib for EGFR ex20ins-positive NSCLC. MATERIALS AND METHODS: From August 2018 to January 2020, 14 NSCLC patients with EGFR ex20ins were enrolled, of whom 2 were excluded because they did not meet the inclusion criteria. Efficacy and safety of 80 mg osimertinib were evaluated. In addition, we performed a translational exploratory study to clarify the association of mutation type-specific drug sensitivity, osimertinib pharmacokinetic data, and clinical efficacy. RESULTS: Of the evaluated patients, none experienced objective response, 7 experienced stable disease (58.3%), and 5 experienced disease progression (41.7%). The median progression free survival (PFS) was 3.8 months, and the median overall survival was 15.8 months. Interestingly, the exploratory study demonstrated statistically significant positive correlation between plasma osimertinib concentration/in vitro IC50 ratio and PFS (R = 0.9912, P = 0.0001), highlighting the mutation type-specific concentration-dependent efficacy of osimertinib for EGFR ex20ins-positive NSCLC. CONCLUSIONS: Regular dose, 80 mg/day, of osimertinib has limited clinical activity in NSCLC patients with EGFR ex20ins. The translational study proposed the potential efficacy of higher dose osimertinib in a subgroup of EGFR ex20ins-positive NSCLC.
• 肺動脈圧の上昇が疑われる症例でのEBUS-GS-TBBに伴う出血に関する検討
  高島 雄太; 品川 尚文; 山本 岳; 森永 大亮; 古田 恵; 庄司 哲明; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 中村 順一; 辻野 一三; 今野 哲
  気管支学, 43, 6, 690, 690, (一社)日本呼吸器内視鏡学会, Nov. 2021
  Japanese
• 肺動脈圧の上昇が疑われる症例でのEBUS-GS-TBBに伴う出血に関する検討
  高島 雄太; 品川 尚文; 山本 岳; 森永 大亮; 古田 恵; 庄司 哲明; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 中村 順一; 辻野 一三; 今野 哲
  気管支学, 43, 6, 690, 690, (NPO)日本呼吸器内視鏡学会, Nov. 2021
  Japanese
• OMLAとF1におけるTumor mutation burden(TMB)推定精度の評価
  大井 肇; 松本 慎吾; 池田 喬哉; 牛尾 良太; 西野 和美; 中村 敦; 仲地 一郎; 久山 彰一; 榊原 純; 岩間 映二; 古屋 直樹; 駄賀 晴子; 當麻 景章; 葉 清隆; 善家 義貴; 野崎 要; 泉 大樹; 柴田 祐司; 酒井 徹也; 後藤 功一
  肺癌, 61, 6, 683, 683, (NPO)日本肺癌学会, Oct. 2021
  Japanese
• クリゾチニブ既治療のROS1融合遺伝子陽性非小細胞肺癌に対するブリグチニブの第2相試験(Barossaコホート2)
  田中 洋史; 仁保 誠治; 駄賀 晴子; 榊原 純; 後藤 悌; 大橋 圭明; 豊澤 亮; 小谷 昌広; 高橋 利明; 服部 剛弘; 森瀬 昌宏; 池田 喬哉; 松本 慎吾; 葉 清隆; 野村 尚吾; 後藤 功一
  肺癌, 61, 6, 597, 597, (NPO)日本肺癌学会, Oct. 2021
  Japanese
• 非小細胞肺癌における薬剤耐性遺伝子異常の同定と耐性克服治療の開発(LC-SCRUM-TRY)
  泉 大樹; 松本 慎吾; 池田 喬哉; 西野 和美; 大江 裕一郎; 中村 敦; 榊原 純; 久山 彰一; 原 聡志; 瀧 玲子; 中尾 美香; 大橋 圭明; 柴田 祐司; 野崎 要; 善家 義貴; 葉 清隆; 後藤 功一
  肺癌, 61, 6, 630, 630, (NPO)日本肺癌学会, Oct. 2021
  Japanese
• 当科における小細胞肺癌に対する免疫チェックポイント阻害剤+プラチナ製剤併用療法の後方視的検討
  有里 仁希; 庄司 哲明; 千葉 葵; 三田 明音; 三浦 瞬; 森永 大亮; 高島 雄太; 古田 恵; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 品川 尚文; 今野 哲
  肺癌, 61, 6, 634, 634, (NPO)日本肺癌学会, Oct. 2021
  Japanese
• 当科における非小細胞肺癌術後局所再発に対する化学放射線療法後のデュルバルマブ使用症例の後方視的検討
  三浦 瞬; 古田 恵; 千葉 葵; 三田 明音; 有里 仁希; 森永 大亮; 辻 康介; 高島 雄太; 庄司 哲明; 朝比奈 肇; 菊地 順子; 菊地 英毅; 榊原 純; 品川 尚文; 今野 哲
  肺癌, 61, 6, 685, 685, (NPO)日本肺癌学会, Oct. 2021
  Japanese
• 当院で経験した小細胞肺癌転化したEGFR遺伝子変異陽性肺癌症例の検討
  森永 大亮; 榊原 純; 古田 恵; 高島 雄太; 朝比奈 肇; 菊地 順子; 菊地 英毅; 合田 智宏; 高階 太一; 若林 健人; 高桑 恵美; 品川 尚文; 今野 哲
  肺癌, 61, 6, 759, 759, (NPO)日本肺癌学会, Oct. 2021
  Japanese
• 非小細胞肺癌における新規ドライバー遺伝子
  松本 慎吾; 泉 大樹; 森 俊太; 渡邉 香奈; 福原 達朗; 葉 清隆; 林 久美子; 加藤 晃史; 西野 和美; 中村 敦; 仲地 一郎; 久山 彰一; 古屋 直樹; 榊原 純; 岡本 勇; 山崎 章; 小谷 昌広; 石井 源一郎; 仁保 誠治; 小林 進; 後藤 功一
  肺癌, 61, 6, 512, 512, (NPO)日本肺癌学会, Oct. 2021
  Japanese
• クリゾチニブ既治療のROS1融合遺伝子陽性非小細胞肺癌に対するブリグチニブの第2相試験(Barossaコホート2)
  田中 洋史; 仁保 誠治; 駄賀 晴子; 榊原 純; 後藤 悌; 大橋 圭明; 豊澤 亮; 小谷 昌広; 高橋 利明; 服部 剛弘; 森瀬 昌宏; 池田 喬哉; 松本 慎吾; 葉 清隆; 野村 尚吾; 後藤 功一
  肺癌, 61, 6, 597, 597, (NPO)日本肺癌学会, Oct. 2021
  Japanese
• Phase II study of brigatinib in ROS1 positive non-small cell lung cancer (NSCLC) patients previously treated with crizotinib: Barossa cohort 2.
  Haruko Daga; Seiji Niho; Jun Sakakibara-Konishi; Hiroshi Tanaka; Yasushi Goto; Kadoaki Ohashi; Ryo Toyozawa; Masahiro Kodani; Toshiaki Takahashi; Yoshihiro Hattori; Masahiro Morise; Takaya Ikeda; Shingo Matsumoto; Kiyotaka Yoh; Shogo Nomura; Koichi Goto
  Journal of Clinical Oncology, 39, 15_suppl, 9040, 9040, American Society of Clinical Oncology (ASCO), 20 May 2021
  Scientific journal, 9040
  
  Background: Brigatinib is a next-generation tyrosine kinase inhibitor targeting ALK and ROS1. Crizotinib is the first drug approved for the treatment of ROS1 fusion-positive NSCLC. Standard treatment for crizotinib-resistant ROS1 positive NSCLC is not established. Barossa is a multicenter, phase II basket, study of brigatinib in patients with ROS1 positive solid tumors. This study is composed of three cohorts. ROS1 inhibitor-naïve ROS1 positive NSCLC patients were enrolled in the cohort 1, and ROS1 positive NSCLC patients previously treated with crizotinib were enrolled in the cohort 2. Patients with ROS 1 positive solid tumors other than NSCLC were enrolled in the cohort 3. This time we report the cohort 2 results. Methods: Patients with advanced, previously treated with crizotinib, ROS1 positive NSCLC received brigatinib at a dose of 180 mg once daily with a 7-day lead-in period at 90 mg. The primary end point was objective response rate (ORR; RECIST 1.1) by independent review. Key secondary endpoint was PFS, OS, and safety. The sample size was set at 19 patients, with a one-sided alpha of 0.05, beta of 0.2, and threshold and expected values for primary endpoint of 20% and 50%, respectively. Results: From July 2019 and Jan 2020, 19 patients were enrolled from 9 institutions. Baseline characteristics as follows: median age (range): 60 (31-75) years; women, n = 10 (53%); ECOG PS of 0 to 1, n = 18 (95%); never smoker, n = 11 (58%); tumor histopathological type: adenocarcinoma, n = 18 (95%). Five and 6 patients achieved PR and SD, respectively at data cutoff date of 30 Oct 2020. The ORR was 26.3% (90%CI, 11.0-47.6), and the disease control rate was 57.9% (95%CI, 33.5-79.7). The median duration of follow-up for PFS was 12.0 months. The median PFS was 7.3 months (95% CI, 1.3-9.3), and the 1-year PFS rate was 26.9% (95%CI, 9.2-48.6). Grade ≥3 TRAEs were CPK increased (21.1%), infection (5.3%), AST and/or ALT increased (5.3%), hypercalcemia (5.3%), anorexia (5.3%), hypoxia (5.3%), erythema (5.3%), hypertension (5.3%). Pneumonitis was observed in one patient (5.3%, Grade 2). No treatment-related death was observed. Conclusions: Brigatinib has modest activity for ROS1 positive NSCLC patients previously treated with crizotinib. The safety profile of brigatinib was consistent with previous studies. Enrollment of the cohort 1 for ROS1 inhibitor-naïve NSCLC patients is ongoing, and the data will be presented at a future congress. Clinical trial information: JapicCTI-194851.
• Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using 125I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004).
  Hironori Takagi; Songji Zhao; Satoshi Muto; Hiroshi Yokouchi; Hiroshi Nishihara; Toshiyuki Harada; Hikaru Yamaguchi; Hayato Mine; Masayuki Watanabe; Yuki Ozaki; Takuya Inoue; Takumi Yamaura; Mitsuro Fukuhara; Naoyuki Okabe; Yuki Matsumura; Takeo Hasegawa; Jun Osugi; Mika Hoshino; Mitsunori Higuchi; Yutaka Shio; Ryuzo Kanno; Miho Aoki; Chengbo Tan; Saki Shimoyama; Shigeo Yamazaki; Hajime Kikuchi; Jun Sakakibara-Konishi; Satoshi Oizumi; Masao Harada; Kenji Akie; Fumiko Sugaya; Yuka Fujita; Kei Takamura; Tetsuya Kojima; Osamu Honjo; Yoshinori Minami; Masaharu Nishimura; Hirotoshi Dosaka-Akita; Koji Nakamura; Akihiro Inano; Hiroshi Isobe; Hiroyuki Suzuki
  Lung cancer (Amsterdam, Netherlands), 153, 134, 142, Mar. 2021, [International Magazine]
  English, Scientific journal, OBJECTIVES: Delta-like 1 homolog (DLK1) is a non-canonical Notch ligand known to be expressed in several cancers but whose role in lung cancer is not yet fully understood. We sought to confirm DLK1 expression in small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), and to examine DLK1's clinical significance. Furthermore, we examined the possible utility of DLK1 as a novel target in radioimmunotherapy (RIT). METHODS: We retrospectively assessed the correlation between clinical features and DLK1 expression by immunohistochemistry in resected specimens from 112 patients with SCLC and 101 patients with NSCLC. Moreover, we performed cell and animal experiments, and examined the possibility of RIT targeting DLK1 in SCLC using iodine-125 (125I) -labeled anti-DLK1 antibody, knowing that 125I can be replaced with the alpha-particle-emitter astatine-211 (211At). RESULTS: In SCLC and NSCLC, 20.5 % (23/112) and 16.8 % (17/101) of patients (respectively) had DLK1-positive tumors. In NSCLC, DLK1 expression was associated with recurrence-free survival (P < 0.01) but not with overall survival. In SCLC, there was no association between DLK1 expression and survival. In addition, 125I-labeled anti-DLK1 antibody specifically targeted DLK1 on human SCLC tumor cell lines. Furthermore, 125I-labeled anti-DLK1 antibody was incorporated into tumor tissue in a mouse model. CONCLUSION: A proportion of SCLC and NSCLC exhibits DLK1 expression. As a clinical feature, DLK1 expression could be a promising prognostic factor for recurrence in patients with resected NSCLC. In addition, DLK1 could serve as a new therapeutic target, including RIT, as suggested by our pilot study using a radiolabeled anti-DLK1 antibody in SCLC.
• 当科における悪性胸膜中皮腫に対するニボルマブ投与症例の検討
  西村 弘基; 古田 恵; 辻 康介; 葛巻 哲; 児島 裕一; 山本 岳; 伊藤 祥太郎; 國崎 守; 高島 雄太; 庄司 哲明; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 品川 尚文; 今野 哲
  肺癌, 61, 1, 64, 64, (NPO)日本肺癌学会, Feb. 2021
  Japanese
• 高齢者の未治療EGFR遺伝子変異陽性非小細胞肺癌に対するオシメルチニブの有効性・安全性に関する後ろ向き検討
  山本 岳; 朝比奈 肇; 伊藤 祥太郎; 古田 恵; 水柿 秀紀; 菊地 順子; 菊地 英毅; 榊原 純; 品川 尚文; 今野 哲
  肺癌, 61, 1, 66, 66, (NPO)日本肺癌学会, Feb. 2021
  Japanese
• Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCG1001.
  Kana Watanabe; Yukihiro Toi; Atsushi Nakamura; Ryosuke Chiba; Masachika Akiyama; Jun Sakakibara-Konishi; Hisashi Tanaka; Naruo Yoshimura; Eisaku Miyauchi; Taku Nakagawa; Ryotaro Igusa; Hiroyuki Minemura; Yoshiaki Mori; Keisuke Fujimoto; Haruo Matsushita; Fumiaki Takahashi; Tatsuro Fukuhara; Akira Inoue; Shunichi Sugawara; Makoto Maemondo
  Translational lung cancer research, 10, 2, 712, 722, Feb. 2021, [International Magazine]
  English, Scientific journal, Background: The optimal regimen for concurrent chemoradiotherapy (CCRT) of locally advanced non-squamous non-small cell lung cancer (NSCLC) was not definitive. We conducted randomized phase II study, NJLCG0601, and chemoradiotherapy with uracil/tegafur (UFT) and cisplatin achieved promising efficacy without severe toxicities. Here, we evaluated between this regimen and pemetrexed plus cisplatin in chemoradiotherapy for stage III non-squamous NSCLC. Methods: Patients with inoperable stage III non-squamous NSCLC were randomly assigned in a 1:1 ratio to UFT 400 mg/m2 on days 1-14 and 29-42, and cisplatin 80 mg/m2 on days 8 and 36 (UP), or cisplatin 75 mg/m2 and pemetrexed 500 mg/m2 on days 1, 22, and 43 (PP). Involved-field radiotherapy (IFRT) underwent from day 1 to a total dose of 66 Gy in 33 fractions. Consolidation chemotherapy after CCRT was prohibited for this study. The primary endpoint was defined as 2-year overall survival (OS). This trial was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN000003948). Results: From November 2010 to June 2017, 86 patients were entered from 11 institutions. Median follow-up was 54 months. Of the 85 eligible patients, the 2-year OS rate was 78.6% (95% CI, 62.8-88.3%) in UP and 85.5% (95% CI, 70.5-93.2%) in PP. Median PFS and OS was 12.3 and 64.2 months in UP, 26.2 months and not reached in PP, respectively. Grade 3/4 febrile neutropenia was more frequent in the UP group (14.0% vs. 2.0%). Conclusions: Both UP and PP with IFRT achieved the expected 2-year OS. PP engendered more favorable OS and PFS compared to UP in terms.
• A case of radio-insensitive SMARCA4-deficient thoracic undifferentiated carcinoma with severe right heart failure.
  Shotaro Ito; Hajime Asahina; Naoko Yamaguchi; Utano Tomaru; Tadashi Hasegawa; Yutaka Hatanaka; Kanako C Hatanaka; Hiroshi Taguchi; Taisuke Harada; Hiroshi Ohira; Daisuke Ikeda; Hidenori Mizugaki; Eiki Kikuchi; Junko Kikuchi; Jun Sakakibara-Konishi; Naofumi Shinagawa; Satoshi Konno
  Respiratory medicine case reports, 32, 101364, 101364, 2021, [International Magazine]
  English, SMARCA4-deficient thoracic sarcomatoid tumors were characterized by inactivating mutations of SMARCA4 and often found in the chest of young and middle-aged males with a smoking history. Recently, SMARCA4-deficient thoracic sarcomatoid tumors were reported to represent primarily smoking-associated undifferentiated/de-differentiated carcinomas rather than primary thoracic sarcomas. The main complication of this tumor is compression of the respiratory tract and/or blood vessels. A 39-year-old man presented with a 2-month history of fever and dyspnea. Computed tomography revealed a mediastinal tumor invading the right and left pulmonary arteries. Because of severe right heart failure, we considered him ineligible for bronchoscopy. We scheduled palliative irradiation with 40 Gy/20 Fr to improve hemodynamics and perform endobronchial ultrasound transbronchial needle aspiration later. However, irradiation was ineffective, and his general condition deteriorated quickly and he died after a 7-week hospitalization. An autopsy revealed that the diagnosis was SMARCA4-deficient thoracic undifferentiated carcinoma. It has been reported that this tumor is insensitive to radiotherapy and there were some cases which responded to an immune checkpoint inhibitor. Therefore, when caring for patients with mediastinal tumors that invade and compress the trachea and large vessels, it is important to consider this tumor as a differential diagnosis and try to make a pathological diagnosis as soon as possible.
• Immune checkpoint inhibitor-induced enteritis assessed using capsule endoscopy.
  Shinsuke Otagiri; Takehiko Katsurada; Kana Yamanashi; Kensuke Sakurai; Michiko T Sato; Jun Sakakibara-Konishi; Naoya Sakamoto
  JGH open : an open access journal of gastroenterology and hepatology, 4, 6, 1231, 1232, Dec. 2020, [International Magazine]
  English, Scientific journal, We performed capsule endoscopy for a patient with immune checkpoint inhibitor-induced enteritis and found multiple erosions or small ulcers in the small intestine. No reports demonstrated the effectiveness of capsule endoscopy for immune checkpoint inhibitor-induced gastrointestinal adverse events, and our case suggests that capsule endoscopy may be useful to evaluate immune checkpoint inhibitor-induced enteritis.
• 動体追跡陽子線照射における気管支内視鏡的放射線治療用マーカー留置術の検討
  伊藤 祥太郎; 品川 尚文; 高島 雄太; 國崎 守; 古田 恵; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 加藤 徳雄; 田口 大志; 青山 英史; 今野 哲
  気管支学, 42, 6, 576, 576, (NPO)日本呼吸器内視鏡学会, Nov. 2020
  Japanese
• 気管支鏡ナビゲーションにおけるAIの活用
  國崎 守; 品川 尚文; 山本 岳; 辻 康介; 伊藤 祥太郎; 佐藤 峰嘉; 高橋 宏典; 高島 雄太; 古田 恵; 庄司 哲明; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 今野 哲
  気管支学, 42, 6, 575, 576, (NPO)日本呼吸器内視鏡学会, Nov. 2020
  Japanese
• 動体追跡陽子線照射における気管支内視鏡的放射線治療用マーカー留置術の検討
  伊藤 祥太郎; 品川 尚文; 高島 雄太; 國崎 守; 古田 恵; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 加藤 徳雄; 田口 大志; 青山 英史; 今野 哲
  気管支学, 42, 6, 576, 576, (NPO)日本呼吸器内視鏡学会, Nov. 2020
  Japanese
• 当科におけるEGFR遺伝子変異陽性非小細胞肺癌に対するデュルバルマブ使用症例の後方視的検討
  辻 康介; 水柿 秀紀; 伊藤 祥太郎; 猪狩 智生; 佐藤 峰嘉; 高橋 宏典; 國崎 守; 高島 雄太; 古田 恵; 庄司 哲明; 朝比奈 肇; 菊地 順子; 菊地 英毅; 榊原 純; 品川 尚文; 今野 哲
  肺癌, 60, 6, 638, 638, (NPO)日本肺癌学会, Oct. 2020
  Japanese
• 高齢者未治療EGFR遺伝子変異陽性非小細胞肺癌に対するオシメルチニブの有効性・安全性に関する後ろ向き検討
  山本 岳; 朝比奈 肇; 伊藤 祥太郎; 古田 恵; 水柿 秀紀; 菊地 順子; 菊地 英毅; 榊原 純; 品川 尚文; 今野 哲
  肺癌, 60, 6, 564, 564, (NPO)日本肺癌学会, Oct. 2020
  Japanese
• PD-L1高発現非小細胞肺癌患者におけるペムブロリズマブ単剤療法およびペムブロリズマブ併用化学療法の検討
  古田 恵; 水柿 秀紀; 伊藤 祥太郎; 辻 康介; 佐藤 峰嘉; 高橋 宏典; 國崎 守; 高島 雄太; 庄司 哲明; 朝比奈 肇; 菊地 順子; 菊地 英毅; 榊原 純; 品川 尚文; 今野 哲
  肺癌, 60, 6, 631, 631, (NPO)日本肺癌学会, Oct. 2020
  Japanese
• 当科におけるEGFR遺伝子変異陽性非小細胞肺癌に対するデュルバルマブ使用症例の後方視的検討
  辻 康介; 水柿 秀紀; 伊藤 祥太郎; 猪狩 智生; 佐藤 峰嘉; 高橋 宏典; 國崎 守; 高島 雄太; 古田 恵; 庄司 哲明; 朝比奈 肇; 菊地 順子; 菊地 英毅; 榊原 純; 品川 尚文; 今野 哲
  肺癌, 60, 6, 638, 638, (NPO)日本肺癌学会, Oct. 2020
  Japanese
• Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
  Takashi Kitagataya; Goki Suda; Kazunori Nagashima; Takehiko Katsurada; Koji Yamamoto; Megumi Kimura; Osamu Maehara; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Machiko Umemura; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Yoshito Komatsu; Hiroo Hata; Satoshi Takeuchi; Takashige Abe; Jun Sakakibara-Konishi; Takanori Teshima; Akihiro Homma; Naoya Sakamoto
  Journal of gastroenterology and hepatology, 35, 10, 1782, 1788, Oct. 2020, [International Magazine]
  English, Scientific journal, BACKGROUND AND AIM: Immune checkpoint inhibitors (ICI) have revolutionized anti-malignancy therapy and thus have been increasingly used. Although ICI may cause immune-related adverse events (irAE) in various organs, including the liver, the prevalence and predictive factors of irAE have not been clarified. METHODS: In this retrospective study, consecutive patients who had malignancies and were treated with ICI without other chemotherapeutic agents at Hokkaido University Hospital between 2014 and 2019 were screened. Patients were excluded if they were < 20 years old and had insufficient clinical data. RESULTS: Of the 233 patients screened, 202 patients met the inclusion criteria and were included in the analysis. The patients were aged 25-92 years, and 60.9% were male. The patients received nivolumab (n = 137), pembrolizumab (n = 45), ipilimumab (n = 17), atezolizumab (n = 2), and avelumab (n = 1). The prevalence of any grade and grade ≥ 3 irAE hepatitis was 8.4% (17/202) and 4.0% (8/202), respectively. irAE hepatitis occurred at a median duration of 42 days in any grade and 36 days in grade ≥ 3 after ICI initiation. The clinical course of grade ≥ 3 irAE hepatitis was generally favorable; however, 50% required corticosteroid treatment and two patients required additional mycophenolate mofetil. Female sex and history of ICI treatment were significantly associated with the incidence of grade ≥ 3 irAE hepatitis. CONCLUSIONS: Grade ≥ 3 irAE hepatitis was observed in 4.0% of the patients who were treated with ICI. Female sex and history of ICI treatment were significantly associated with the incidence of grade ≥ 3 irAE hepatitis.
• Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
  Takashi Seto; Hidetoshi Hayashi; Miyako Satouchi; Yasushi Goto; Seiji Niho; Naoyuki Nogami; Toyoaki Hida; Toshiaki Takahashi; Jun Sakakibara-Konishi; Masahiro Morise; Takashi Nagasawa; Mie Suzuki; Masayuki Ohkura; Kei Fukuhara; Holger Thurm; Gerson Peltz; Makoto Nishio
  Cancer science, 111, 10, 3726, 3738, Oct. 2020, [International Magazine]
  English, Scientific journal, Lorlatinib is a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK)/ROS proto-oncogene 1 (ROS1) tyrosine kinase inhibitor (TKI) that is active against most known resistance mutations. This is an ongoing phase 1/2, multinational study (NCT01970865) investigating the efficacy, safety and pharmacokinetics of lorlatinib in ALK-rearranged/ROS1-rearranged advanced non-small cell lung cancer (NSCLC) with or without intracranial (IC) metastases. Because patterns of ALK TKI use in Japan differ from other regions, we present a subgroup analysis of Japanese patients. Patients were enrolled into six expansion (EXP) cohorts based on ALK/ROS1 mutation status and treatment history. The primary endpoint was the objective response rate (ORR) and the IC-ORR based on independent central review. Secondary endpoints included pharmacokinetic evaluations. At data cutoff, 39 ALK-rearranged/ROS1-rearranged Japanese patients were enrolled across the six expansion cohorts; all received lorlatinib 100 mg once daily. Thirty-one ALK-rearranged patients previously treated with ≥1 ALK TKI (EXP2 to EXP5) were evaluable for ORR and 15 were evaluable for IC-ORR. The ORR and the IC-ORR for Japanese patients in EXP2-5 were 54.8% (95% confidence interval [CI]: 36.0-72.7) and 46.7% (95% CI: 21.3-73.4), respectively. Among patients who had received prior alectinib only (EXP3B), the ORR was 42.9%; 95% CI: 9.9-81.6). The most common treatment-related adverse event (TRAE) was hypercholesterolemia (79.5%). Hypertriglyceridemia was the most common grade 3/4 TRAE (25.6%). Single-dose and multiple-dose pharmacokinetic profiles among Japanese patients were similar to those in non-Japanese patients. Lorlatinib showed clinically meaningful responses and IC responses among ALK-rearranged Japanese patients with NSCLC who received ≥1 prior ALK TKI, including meaningful responses among those receiving prior alectinib only. Lorlatinib was generally well tolerated.
• 当科におけるadolescent and young adult世代胸部悪性腫瘍患者に関する検討
  塩泡 亜衣; 榊原 純; 國崎 守; 古田 恵; 高島 雄太; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 品川 尚文; 今野 哲
  日本呼吸器学会誌, 9, 5, 319, 324, (一社)日本呼吸器学会, Sep. 2020
  Japanese
• A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703).
  Shin-Ichi Fukumoto; Satoshi Oizumi; Masao Harada; Noriaki Sukoh; Kosuke Nakano; Satoshi Fuke; Jun Sakakibara-Konishi; Kei Takamura; Kenichiro Ito; Yuka Fujita; Yutaka Nishigaki; Toshiyuki Harada; Kenji Akie; Ichiro Kinoshita; Toraji Amano; Hiroshi Isobe; Hirotoshi Dosaka-Akita; Masaharu Nishimura
  Cancer chemotherapy and pharmacology, 86, 1, 117, 127, Jul. 2020, [International Magazine]
  English, Scientific journal, PURPOSE: This study evaluated the efficacy and safety of platinum plus gemcitabine (P/G) combinations as postoperative adjuvant chemotherapies for non-small cell lung cancer. METHODS: Patients with postoperative stage IB-IIIA non-small cell lung cancer were randomly assigned to receive either cisplatin plus gemcitabine (GP arm) or carboplatin plus gemcitabine (GC arm) every 3 weeks for four cycles. The primary endpoint was 2-year disease-free survival (DFS). Secondary endpoints were safety, feasibility, overall survival (OS), and biomarker analyses. RESULTS: A total of 102 patients were randomized (stage IB, 22%; II, 36%; IIIA, 42%; histology: 74% adenocarcinoma). Of the 51 patients in each arm, 37 (73%) completed 4 cycles. During follow-up (median 5.8 years; range 0.1-9.7 years), estimated DFS and OS rates at 2 years were 59.6% and 86.3% with GP and 68.0% and 86.3% with GC, respectively. No significant difference in DFS was noted between arms (P = 0.163), although 3-, 4-, and 5-year DFS rates were higher with GC. Hematological toxic effects were comparable and non-hematological toxic effects were infrequent. DFS was significantly higher in the excision repair cross-complementation group 1 (ERCC1)-low group than in the ERCC1-high group for the GP arm (P = 0.045). CONCLUSION: Both P/G combination regimens were feasible and well-tolerated, and thus may represent valid options for postoperative adjuvant treatment of non-small cell lung cancer. Although no significant differences in DFS were evident between regimens, the present data favor the adoption of GC for further evaluation. CLINICAL TRIAL REGISTRATION: UMIN-CTR ( https://www.umin.ac.jp/ctr/ ) identifier: UMIN000000913.
• 動体追跡陽子線照射における気管支内視鏡的放射線治療用マーカー留置術の検討
  伊藤 祥太郎; 品川 尚文; 高島 雄太; 國崎 守; 古田 恵; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 加藤 徳雄; 田口 大志; 青山 英史; 今野 哲
  気管支学, 42, Suppl., S277, S277, (NPO)日本呼吸器内視鏡学会, Jun. 2020
  Japanese
• 気管支鏡ナビゲーションにおけるAIの活用
  國崎 守; 品川 尚文; 辻 康介; 伊藤 祥太郎; 佐藤 峰嘉; 高橋 宏典; 高島 雄太; 古田 恵; 庄司 哲明; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 今野 哲
  気管支学, 42, Suppl., S241, S241, (NPO)日本呼吸器内視鏡学会, Jun. 2020
  Japanese
• Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study.
  Mototsugu Shimokawa; Kaname Nosaki; Takashi Seto; Kadoaki Ohashi; Masahiro Morise; Hidehito Horinouchi; Jun Sakakibara; Haruyasu Murakami; Seiji Yano; Miyako Satouchi; Shingo Matsumoto; Koichi Goto; Kiyotaka Yoh
  Trials, 21, 1, 298, 298, 30 Mar. 2020, [International Magazine]
  English, Scientific journal, BACKGROUND: MET-deregulated non-small cell lung cancer represents an urgent clinical need because of the lack of specific therapies. Although recent studies have suggested a potential role for crizotinib in patients harboring MET gene alterations, no conclusive data are currently available. Therefore, we designed the Co-MET study, a single-arm phase II study to assess the efficacy and safety of crizotinib in patients with advanced non-small cell lung cancers harboring MET gene alterations. METHODS: Co-MET is an open-label, multi-center, single-arm, phase II trial to assess the safety and efficacy of oral crizotinib in patients with advanced non-small cell lung cancer harboring MET exon 14 skipping mutation (cohort 1) or a high MET gene copy number of ≥ 7 (cohort 2). We will identify MET gene alterations using RT-PCR and/or next-generation sequencing. Oral crizotinib 250 mg BID will be administered until disease progression or unacceptable toxicity. A radiology committee will review tumor scans according to the RECIST criteria. The primary endpoint is the objective response rate. Assuming a null hypothesis of 20% objective response rate and an alternative hypothesis of 50% objective response rate for cohort 1, and a one-sided alpha error of 0.05 and 80% power based on the exact binomial distribution, the required number of evaluable patients is 19. We set the exploratory sample size for cohort 2 at 10 patients. DISCUSSION: The results of this study are expected to provide evidence regarding the usefulness of oral crizotinib for advanced MET exon 14 skipping mutation-positive or MET high gene copy number-positive non-small cell lung cancer. TRIAL REGISTRATION: This study was registered with the University Hospital Medical Information Network Clinical Trials Registry as UMIN000031623 on 3 March 2018.
• Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer.
  Tetsuaki Shoji; Eiki Kikuchi; Junko Kikuchi; Yuta Takashima; Megumi Furuta; Hirofumi Takahashi; Kosuke Tsuji; Makie Maeda; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Jun Sakakibara-Konishi; Satoshi Konno
  Cancer chemotherapy and pharmacology, 85, 5, 843, 853, 30 Mar. 2020, [Peer-reviewed], [International Magazine]
  English, Scientific journal, PURPOSE: We evaluated the expression of proteasome subunits to assess whether the proteasome could be a therapeutic target in cisplatin-resistant lung cancer cells. METHODS: Cisplatin-resistant (CR) variants were established from three non-small cell lung cancer (NSCLC) cell lines (A549, H1299, and H1975) and two small cell lung cancer (SCLC) cell lines (SBC3 and SBC5). The expression of proteasome subunits, the sensitivity to immunoproteasome inhibitors, and 20S proteasomal proteolytic activity were examined in the CR variants of the lung cancer cell lines. RESULTS: All five CR cell lines highly expressed one or both of the immunoproteasome subunit genes, PSMB8 and PSMB9, while no clear trend was observed in the expression of constitutive proteasome subunits. The CR cells expressed significantly higher levels of PSMB8 and PSMB9 proteins, as well. The CR variants of the H1299 and SBC3 cell lines were more sensitive to immunoproteasome inhibitors, and had significantly more proteasomal proteolytic activity than their parental counterparts. CONCLUSIONS: The immunoproteasome may be an effective therapeutic target in a subset of CR lung cancers. Proteasomal proteolytic activity may be a predictive marker for the efficacy of immunoproteasome inhibitors in cisplatin-resistant SCLC and NSCLC.
• Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
  Yuta Takashima; Eiki Kikuchi; Junko Kikuchi; Motofumi Suzuki; Hajime Kikuchi; Makie Maeda; Tetsuaki Shoji; Megumi Furuta; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Jun Sakakibara-Konishi; Satoshi Konno
  International journal of cancer, 146, 4, 1114, 1124, 15 Feb. 2020, [Peer-reviewed], [International Magazine]
  English, Scientific journal, Bromodomain and extraterminal domain (BET) inhibitors are broadly active against distinct types of cancer, including nonsmall cell lung cancer (NSCLC). Previous studies have addressed the effect of BET-inhibiting drugs on the expression of oncogenes such as c-Myc, but DNA damage repair pathways have also been reported to be involved in the efficacy of these drugs. AZD1775, an inhibitor of the G2-M cell cycle checkpoint kinase WEE1, induces DNA damage by promoting premature mitotic entry. Thus, we hypothesized that BET inhibition would increase AZD1775-induced cytotoxicity by impairing DNA damage repair. Here, we demonstrate that combined inhibition of BET and WEE1 synergistically suppresses NSCLC growth both in vitro and in vivo. Two BET inhibitors, JQ1 and AZD5153, increased and prolonged AZD1775-induced DNA double-strand breaks (DSBs) and concomitantly repressed genes related to nonhomologous end joining (NHEJ), including XRCC4 and SHLD1. Furthermore, pharmaceutical inhibition of BET or knockdown of the BET protein BRD4 markedly diminished NHEJ activity, and the BET-inhibitor treatment also repressed myelin transcription factor 1 (MYT1) expression and promoted mitotic entry with subsequent mitotic catastrophe when combined with WEE1 inhibition. Our findings reveal that BET proteins, predominantly BRD4, play an essential role in DSB repair through the NHEJ pathway, and further suggest that combined inhibition of BET and WEE1 could serve as a novel therapeutic strategy for NSCLC.
• ニボルマブ投与継続が可能であった尿細管間質性腎炎を発症した膜性腎症合併肺癌の1例
  佐々木 真知子; 水柿 秀紀; 榊原 純; 近藤 桂一; 深澤 雄一郎; 今野 哲
  日本呼吸器学会誌, 9, 1, 71, 75, (一社)日本呼吸器学会, Jan. 2020
  Japanese
• Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma.
  Jun Sakakibara-Konishi; Mineyoshi Sato; Michiko Takimoto Sato; Kohei Kasahara; Masahiro Onozawa; Hidenori Mizugaki; Eiki Kikuchi; Hajime Asahina; Naofumi Shinagawa; Satoshi Konno
  Respiratory medicine case reports, 31, 101170, 101170, 2020, [Peer-reviewed], [International Magazine]
  English, Malignant pleural mesothelioma (MPM) is a rare and highly aggressive tumor. Nivolumab showed durable antitumor effect in patients with recurrent MPM and was approved for those patients in Japan in 2018. Immune related adverse event (irAE) is occurred in various organs and is suggestive to be related to better outcome of nivolumab. Frequency of hematological irAE is low and there are few reports about hematological irAE and association between irAE and outcome of nivolumab in patients with MPM. We present a case of recurrent MPM who responded to nivolumab treatment and experienced nivolumab-induced immune thrombocytopenia (ITP). Although high dose dexamethasone was administered and platelet count increased transiently, re-administration of dexamethasone was required to maintain normal count of platelet. The careful and intensive management of ITP treatment is necessary in cases who show no response or relapse to initial glucocorticoids treatment. This is the first report about nivolumab-induced ITP and association with response to nivolumab in MPM.
• Combination of FDG-PET and FMISO-PET as a treatment strategy for patients undergoing early-stage NSCLC stereotactic radiotherapy.
  Shiro Watanabe; Tetsuya Inoue; Shozo Okamoto; Keiichi Magota; Ayumi Takayanagi; Jun Sakakibara-Konishi; Norio Katoh; Kenji Hirata; Osamu Manabe; Takuya Toyonaga; Yuji Kuge; Hiroki Shirato; Nagara Tamaki; Tohru Shiga
  EJNMMI research, 9, 1, 104, 104, 04 Dec. 2019, [Peer-reviewed], [International Magazine]
  English, Scientific journal, BACKGROUND: We investigated the prognostic predictive value of the combination of fluorodeoxyglucose (FDG)- and fluoromisonidazole (FMISO)-PET in patients with non-small cell lung carcinoma (NSCLC) treated with stereotactic body radiation therapy (SBRT). PATIENTS AND METHODS: We prospectively examined patients with pathologically proven NSCLC; all underwent FDG and FMISO PET/CT scans before SBRT. PET images were acquired using a whole-body time-of-flight PET-CT scanner with respiratory gating. We classified them into recurrent and non-recurrent groups based on their clinical follow-ups and compared the groups' tumor diameters and PET parameters (i.e., maximum of the standardized uptake value (SUVmax), metabolic tumor volume, tumor-to-muscle ratio, and tumor-to-blood ratio). We performed univariate analysis to evaluate the impact of the PET variables on the patients' progression-free survival (PFS). We divided the patients by thresholds of FDG SUVmax and FMISO SUVmax obtained from receiver operating characteristic analysis for assessment of recurrence rate and PFS. RESULTS: Thirty-two NSCLC patients (19 male and 13 females; median age, 83 years) were enrolled. All received SBRT. At the study endpoint, 23 patients (71.9%) were non-recurrent and nine patients (28.1%) had recurrent disease. Significant between-group differences were observed in tumor diameter and all the PET parameters, demonstrating that those were significant predictors of the recurrence in all patients. In the 22 patients with tumors > 2 cm, tumor diameter and FDG SUVmax were not significant predictors. Thirty-two patients were divided into three patterns from the thresholds of FDG SUVmax (6.81) and FMISO SUVmax (1.89); A, low FDG and low FMISO (n = 14); B, high FDG and low FMISO (n = 8); C, high FDG and high FMISO (n = 10). No pattern A patient experienced tumor recurrence, whereas two pattern B patients (25%) and seven pattern C patients (70%) exhibited recurrence. A Kaplan-Meier analysis of all patients revealed a significant difference in PFS between patterns A and B (p = 0.013) and between patterns A and C (p < 0.001). In the tumors > 2 cm patients, significant differences in PFS were demonstrated between pattern A and C patients (p = 0.002). CONCLUSION: The combination of FDG- and FMISO-PET can identify patients with a baseline risk of recurrence and indicate whether additional therapy might be performed to improve survival.
• ロルラチニブ治療後にクリゾチニブ再投与が著効したALK融合遺伝子陽性肺腺癌の1例
  辻 康介; 榊原 純; 北井 秀典; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 菊地 英毅; 品川 尚文; 今野 哲; 池澤 靖元; 畑中 豊; 佐々木 高明; 吉田 遼平; 千葉 伸一; 松本 慎吾; 後藤 功一
  肺癌, 59, 7, 1200, 1200, (NPO)日本肺癌学会, Dec. 2019
  Japanese
• 当科におけるデュルバルマブ使用症例の後方視的検討
  辻 康介; 水柿 秀紀; 猪狩 智生; 佐藤 峰嘉; 國崎 守; 高島 雄太; 古田 恵; 朝比奈 肇; 菊地 順子; 菊地 英毅; 榊原 純; 品川 尚文; 今野 哲
  肺癌, 59, 6, 776, 776, (NPO)日本肺癌学会, Nov. 2019
  Japanese
• 当科におけるクライオバイオプシーの使用経験
  國崎 守; 品川 尚文; 辻 康介; 佐藤 理子; 猪狩 智生; 佐藤 峰嘉; 高橋 宏典; 高島 雄太; 古田 恵; 庄司 哲明; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 今野 哲; 松野 吉宏
  気管支学, 41, 6, 678, 678, (NPO)日本呼吸器内視鏡学会, Nov. 2019
  Japanese
• ALK融合遺伝子陽性の局所進行非小細胞肺癌に対する術前セリチニブの第II相試験 SAKULA試験
  榊原 純; 善家 善貴; 葉 清隆; 駄賀 晴子; 細見 幸生; 野上 尚之; 岡本 勇; 松本 慎吾; 黒田 咲子; 若林 将史; 野村 省吾; 石井 源一郎; 坪井 正博; 後藤 功一
  肺癌, 59, 6, 867, 867, (NPO)日本肺癌学会, Nov. 2019
  Japanese
• 気管支鏡検査におけるFFPE組織検体および細胞検体を用いたROS1融合遺伝子の検査成功率の検証
  辻 康介; 榊原 純; 北井 秀典; 猪狩 智生; 佐藤 峰嘉; 高橋 宏典; 國崎 守; 庄司 哲明; 高島 雄太; 古田 恵; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 菊地 英毅; 品川 尚文; 樋田 泰浩; 加賀 基知三; 大井 優子; 中條 聖子; 畑中 佳奈子; 畑中 豊; 松野 吉宏; 今野 哲
  気管支学, 41, 6, 678, 678, (NPO)日本呼吸器内視鏡学会, Nov. 2019
  Japanese
• 小細胞肺癌の大規模全国がんゲノムスクリーニングシステム(LC-SCRUM-Japan)(Large-scale nationwide genomic screening system for small cell lung cancer(LC-SCRUM-Japan))
  Kato Terufumi; 池田 喬哉; 梅村 茂樹; 宇田川 響; 仲地 一郎; 宮本 信吾; 榊原 純; 菅原 俊一; 西野 和美; 大橋 圭明; 中尾 美香; 松本 慎吾; 後藤 功一
  肺癌, 59, 6, 537, 537, (NPO)日本肺癌学会, Nov. 2019
  English
• 切除不能III期NSCLCに対するUFT+CDDP+胸部放射線併用療法とPEM+CDDP+TRT併用療法のランダム化第II相試験
  宮内 栄作; 渡邉 香奈; 戸井 之裕; 中村 敦; 福原 達朗; 千葉 亮祐; 秋山 真親; 榊原 純; 田中 寿志; 吉村 成央; 中川 拓; 井草 龍太郎; 峯村 浩之; 守 義明; 藤本 圭介; 松下 晴雄; 高橋 史朗; 井上 彰; 菅原 俊一; 前門戸 任
  肺癌, 59, 6, 672, 672, (NPO)日本肺癌学会, Nov. 2019
  Japanese
• Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer.
  Jun Sakakibara-Konishi; Hidenori Kitai; Yasuyuki Ikezawa; Yutaka Hatanaka; Takaaki Sasaki; Ryohei Yoshida; Shinichi Chiba; Shingo Matsumoto; Koichi Goto; Hidenori Mizugaki; Naofumi Shinagawa
  Clinical lung cancer, 20, 5, e555-e559, Sep. 2019, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• Response to First-Line Osimertinib Treatment in Non-Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations.
  Tomoo Ikari; Jun Sakakibara-Konishi; Gaku Yamamoto; Hidenori Kitai; Hidenori Mizugaki; Hajime Asahina; Eiki Kikuchi; Naofumi Shinagawa
  Clinical lung cancer, 20, 4, e531-e533, Jul. 2019, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• Response of BRAFV600E-Mutant Lung Adenocarcinoma With Brain Metastasis and Leptomeningeal Dissemination to Dabrafenib Plus Trametinib Treatment.
  Gaku Yamamoto; Jun Sakakibara-Konishi; Tomoo Ikari; Hidenori Kitai; Hidenori Mizugaki; Hajime Asahina; Eiki Kikuchi; Naofumi Shinagawa
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 14, 5, e97-e99, May 2019, [Peer-reviewed], [International Magazine]
  English
• DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail.
  Megumi Furuta; Hajime Kikuchi; Tetsuaki Shoji; Yuta Takashima; Eiki Kikuchi; Junko Kikuchi; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Jun Sakakibara-Konishi
  Cancer science, 110, 5, 1599, 1608, May 2019, [Peer-reviewed], [International Magazine]
  English, Scientific journal, Delta-like protein 3 (DLL3) is a ligand of Notch signaling, which mediates cell-fate decisions and is tumor-suppressive or oncogenic depending on the cellular context. Previous studies show that DLL3 is highly expressed in small cell lung cancer (SCLC) but not in normal lung tissue, suggesting that DLL3 might be associated with neuroendocrine tumorigenesis. However, its role in SCLC remains unclear. To investigate the role of DLL3 in tumorigenesis in SCLC, we performed loss-of-function and gain-of-function assays using SCLC cell lines. In vitro analysis of cell migration and invasion by transwell assay showed that DLL3 knockdown reduced migration and invasion of SCLC cells, whereas DLL3 overexpression increased these activities. In addition, DLL3 positively regulated SNAI1 expression and knockdown of SNAI1 attenuated the migration and invasion ability of SCLC cells. Moreover, upregulated DLL3 expression induced subcutaneous tumor growth in mouse models. These results indicate that DLL3 promoted tumor growth, migration and invasion in an SCLC model by modulating SNAI1/Snail.
• Efficacy of additional dexamethasone administration for the attenuation of paclitaxel-associated acute pain syndrome.
  Saito Y; Kobayashi M; Yamada T; Sakakibara-Konishi J; Shinagawa N; Kinoshita I; Dosaka-Akita H; Iseki K
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 28, 1, 221, 227, Apr. 2019, [Peer-reviewed], [International Magazine]
  English, Scientific journal, PURPOSE: Paclitaxel-associated acute pain syndrome (P-APS) affects 80% of patients undergoing therapy. Although it has been shown that prednisone administration for 5 days relieves P-APS, detailed results have not been reported thus far. Therefore, in this study, we evaluated the preventive effect of dexamethasone (DEX) administration against P-APS. METHODS: A total of 60 patients who received carboplatin (area under the curve; AUC = 5-6) plus paclitaxel (200 mg/m2) (plus bevacizumab 15 mg/kg, if non-squamous carcinoma of lung) were enrolled. Eight milligrams of DEX was orally administered on days 2 and 3 to the DEX group patients, and the frequency, severity, duration of P-APS, and other adverse effects in the first cycle were retrospectively evaluated and compared to those observed in control group patients, who were not administered DEX on days 2 and 3. RESULTS: No difference in terms of patient characteristics, except for type of cancer, was observed between groups. The results showed that the frequency of all grade P-APS was approximately 70% and there was no difference between groups. Frequency of ≥ G2 P-APS was 40% in the control group and 14% in the DEX group, demonstrating a significant reduction. Duration of P-APS was 5.8 days in the control group and 4.3 days in the DEX group, which tended to become shorter following additional DEX administration, although this was not significant. Adverse effects other than P-APS induced by chemotherapy were similar between the two groups. CONCLUSION: Additional DEX administration is safe and useful for the attenuation of the severity of P-APS.
• 当院におけるFFPE検体、細胞診検体を用いたROS1融合遺伝子の検査成功率の検証
  北井 秀典; 榊原 純; 高橋 宏典; 國崎 守; 庄司 哲明; 高島 雄太; 古田 恵; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 品川 尚文; 畑中 佳奈子; 畑中 豊; 松野 吉宏; 大井 優子
  肺癌, 59, 1, 112, 112, (NPO)日本肺癌学会, Feb. 2019, [Peer-reviewed]
  Japanese
• Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702)
  Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H
  Oncologist, 24, 11, e1172-e1179, Oncologist, 2019, [International Magazine]
  English, Scientific journal, © AlphaMed Press 2019 Background: Delta-like protein 3 (DLL3) is a Notch ligand that has an important role in the tumorigenesis of small cell lung cancer (SCLC). Recently, rovalpituzumab tesirine (Rova-T), a DLL3-targeted antibody-drug conjugate, has been developed for treating SCLC. DLL3 is a transcriptional target of the achaete-scute homolog-1 (ASCL1) transcription factor, which is involved in pulmonary neuroendocrine cell development. However, the relationship between DLL3 and/or ASCL1 expression and the clinical features of SCLC remains unknown, especially for early-stage resected SCLC. This study aimed to investigate the expression of DLL3 and ASCL1 in resected SCLC samples using immunohistochemical analysis. Materials and Methods: We collected 95 surgically resected SCLC samples, which were formalin fixed and paraffin embedded. Immunohistochemistry staining was performed to investigate the correlation between the expression of either DLL3 or ASCL1 and clinicopathological features of study patients. Results: Seventy-seven (83%) of 93 immunohistochemically evaluable samples were positive for DLL3 (expression in ≥1% of tumor cells), and DLL3-high expression (≥75%) was obse
• [Paclitaxel-associated Acute Pain Syndrome Similarly Occurs in the Patients with or without Previously Administered Non-steroidal Anti-inflammatory Drugs Prior to Paclitaxel Administration].
  Saito Y; Yamada T; Kobayashi M; Sakakibara-Konishi J; Shinagawa N; Kinoshita I; Dosaka-Akita H; Iseki K
  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 139, 12, 1601, 1608, 2019, [Peer-reviewed], [Domestic magazines]
  Japanese, Scientific journal, Paclitaxel (PTX)-associated acute pain syndrome (P-APS) is characterized by disabling but transient arthralgia and myalgia in up to 80% of patients administered with PTX. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely administered to patients with cancer who have pain or fever, and are mainly used to manage P-APS. In this study, we investigated how P-APS appear in the patients who were administered NSAIDs prior to PTX injection. The incidence or severity and duration of P-APS in patients previously administered NSAIDs were compared to those of patients who were not administered NSAIDs. The relationship between previously administered NSAIDs and rescue administration for the relief of P-APS was also evaluated. It was revealed that the incidence and duration of P-APS were 72% and 4.67±2.30 d, respectively, in the control group and 84% and 6.19±3.30 d, respectively, in the NSAIDs group. There was no significant difference in the incidence and duration and the severity of P-APS between the two groups. Patients who were previously administered NSAIDs tended to obtain less pain relief from NSAIDs administered as rescue medications, and needed other medication. Univariate and multivariate analysis revealed no correlation between previously administered NSAIDs or patient characteristics and the incidence of P-APS. In this study, it was found that clinical condition that needs NSAIDs and previously administered NSAIDs prior to PTX injection do not affect the incidence, severity, and duration of P-APS. These results will help in educating patients about their medications and will contribute to the management of P-APS.
• EGFR-TKI初期耐性におけるPD-L1発現や腫瘍浸潤Tリンパ球についての検討
  高島 雄太; 榊原 純; 畑中 豊; 畑中 佳奈子; 大原 克仁; 大泉 聡史; 樋田 泰浩; 加賀 基知三; 木下 一郎; 秋田 弘俊; 松野 吉宏; 品川 尚文
  肺癌, 58, 6, 633, 633, (NPO)日本肺癌学会, Oct. 2018, [Peer-reviewed]
  Japanese
• Stereotactic body radiotherapy to treat small lung lesions clinically diagnosed as primary lung cancer by radiological examination: A prospective observational study
  Tetsuya Inoue; Norio Katoh; Yoichi M Ito; Tomoki Kimura; Yasushi Nagata; Kengo Kuriyama; Hiroshi Onishi; Tadamasa Yoshitake; Yoshiyuki Shioyama; Yusuke Iizuka; Koji Inaba; Koji Konishi; Masaki Kokubo; Katsuyuki Karasawa; Takuyo Kozuka; Kensuke Tanaka; Jun Sakakibara-Konishi; Ichiro Kinoshita; Hiroki Shirato
  Lung Cancer, 122, 107, 112, Elsevier Ireland Ltd, 01 Aug. 2018, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
  Yuta Takashima; Jun Sakakibara-Konishi; Yutaka Hatanaka; Kanako C Hatanaka; Yoshihito Ohhara; Satoshi Oizumi; Yasuhiro Hida; Kichizo Kaga; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Yoshihiro Matsuno; Masaharu Nishimura
  Clinical lung cancer, 19, 4, 352, 359, Jul. 2018, [Peer-reviewed], [International Magazine]
  English, Scientific journal, BACKGROUND: Approximately 20% to 30% of non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)-activating mutations are not responsive to EGFR tyrosine kinase inhibitors (TKIs). Although primary resistance to EGFR-TKIs has been attributed to various genetic alterations, little is known about the clinical and immunopathologic features of patients with primary resistance. The tumor immune microenvironment, including tumor-infiltrating lymphocytes (TILs) and programmed cell death ligand 1 (PD-L1), has been reported to play an important role in tumor progression in those with NSCLC. However, few studies have directly focused on the relationship between the tumor immune microenvironment and primary resistance to EGFR-TKIs. MATERIALS AND METHODS: The characteristics of 124 NSCLC patients with EGFR mutations who had received EGFR-TKIs were analyzed. Primary resistance was defined as disease progression within 3 months after EGFR-TKI treatment. Tumor specimens obtained before EGFR-TKI treatment were assessed for the density of TILs expressing CD4 or CD8 and for the expression rate of PD-L1 on tumor cells and tumor-infiltrating immune cells, immunohistochemically. RESULTS: Primary resistance was observed in 13.7% of the patients (17 of 124). A significant difference in smoking history was observed between patients with primary resistance and those with non-primary resistance. A lower density of total TILs and negative PD-L1 expression on immunohistochemical analysis correlated significantly with primary resistance, in contrast to that with non-primary resistance. Moreover, the negative PD-L1 expression with low TIL density, indicating immune ignorant phenotype of tumor microenvironment, was observed in those with primary resistance with a significant difference. CONCLUSION: Smoking and immune ignorance in the tumor microenvironment might result in primary resistance to EGFR-TKIs.
• Numb has distinct function in lung adenocarcinoma and squamous cell carcinoma.
  Hajime Kikuchi; Jun Sakakibara-Konishi; Megumi Furuta; Eiki Kikuchi; Junko Kikuchi; Satoshi Oizumi; Yasuhiro Hida; Kichizo Kaga; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Masaharu Nishimura
  Oncotarget, 9, 50, 29379, 29391, 29 Jun. 2018, [Peer-reviewed], [International Magazine]
  English, Scientific journal, Some reports suggest that Numb is a potential tumor suppressor. However, its role in non-small cell lung cancer remains unclear. Non-small cell lung cancer comprises two major histological subtypes, adenocarcinoma and squamous cell carcinoma. To investigate the role of Numb in tumorigenesis of lung adenocarcinoma and squamous cell carcinoma, we firstly performed loss-of-function and gain-of-function assays. Moreover, Numb expression was investigated in surgically resected lung adenocarcinoma and squamous cell carcinoma tissues by immunohistochemistry and correlations with prognosis were analyzed. Numb suppressed the proliferation, migration, and invasion of adenocarcinoma cells and inhibited Notch signaling and epithelial-mesenchymal transition in vitro. Numb overexpression also inhibited subcutaneous adenocarcinoma tumor growth. In contrast, Numb promoted the proliferation, migration, and invasion of squamous cell carcinoma cells, but did not induce any consistent changes in Notch signaling. High Numb expression was associated with favorable prognosis in patients with lung adenocarcinoma, but not in those with squamous cell carcinoma. Collectively, our data demonstrate that Numb plays distinct roles in lung adenocarcinoma and squamous cell carcinoma. In lung adenocarcinoma, Numb impairs tumor growth and inhibits the Notch pathway and epithelial-mesenchymal transition, whereas in lung squamous cell carcinoma it may promote proliferation.
• Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage.
  Tetsuaki Shoji; Hidenori Mizugaki; Yasuyuki Ikezawa; Megumi Furuta; Yuta Takashima; Hajime Kikuchi; Houman Goudarzi; Hajime Asahina; Junko Kikuchi; Eiki Kikuchi; Jun Sakakibara-Konishi; Naofumi Shinagawa; Ichizo Tsujino; Masaharu Nishimura
  Internal medicine (Tokyo, Japan), 57, 12, 1769, 1772, 15 Jun. 2018, [Peer-reviewed], [Domestic magazines]
  English, Scientific journal, This report describes the case of a 66-year-old man with non-small cell lung cancer and venous thromboembolism (VTE). Unfractionated heparin (UFH) was initially used to control VTE before chemotherapy. However, switching UFH to warfarin or edoxaban, a novel oral anticoagulant (NOAC), failed. Chemotherapy was then administered to control the tumor which was thought to have been the main cause of VTE, which had been treated by UFH. After tumor shrinkage was achieved by chemotherapy, we were able to successfully switch from UFH to edoxaban. Controlling the tumor size and activity enabled the use of edoxaban as maintenance therapy for VTE.
• A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)
  Yasuyuki Ikezawa; Hajime Asahina; Satoshi Oizumi; Masahiro Watanabe; Kei Takamura; Yasutaka Kawai; Noriyuki Yamada; Toshiyuki Harada; Ichiro Kinoshita; Yuka Fujita; Eisaku Miyauchi; Takahiro Ogi; Toraji Amano; Megumi Furuta; Jun Sakakibara-Konishi; Hiroshi Nishihara; Hirotoshi Dosaka-Akita; Hiroshi Isobe; Masaharu Nishimura
  CANCER CHEMOTHERAPY AND PHARMACOLOGY, 80, 5, 955, 963, Nov. 2017, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naIve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901
  Naoto Morikawa; Akira Inoue; Shunichi Sugawara; Makoto Maemondo; Toshiyuki Harada; Masao Harada; Yuka Fujita; Terufumi Katoh; Hiroshi Yokouchi; Hiroshi Watanabe; Kazuhiro Usui; Toshiro Suzuki; Jun Sakakibara-Konishi; Hiroki Nagai; Mariko Kanbe; Toshihiro Nukiwa
  LUNG CANCER, 111, 38, 42, Sep. 2017, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• Improvements of visual function and outer retinal morphology following spontaneous regression of cancer in anti-recoverin cancer-associated retinopathy
  Yuka Suimon; Wataru Saito; Kiriko Hirooka; Atsuhiro Kanda; Hidenori Kitai; Jun Sakakibara-Konishi; Susumu Ishida
  American Journal of Ophthalmology Case Reports, 5, 137, 140, Elsevier Inc, 01 Apr. 2017, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• Combined antitumor effect of gamma-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer
  Jun Sakakibara-Konishi; Yasuyuki Ikezawa; Satoshi Oizumi; Junko Kikuchi; Eiki Kikuchi; Hidenori Mizugaki; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Masaharu Nishimura
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 22, 2, 257, 268, Apr. 2017, [Peer-reviewed], [Domestic magazines]
  English, Scientific journal
• Inhibition of Notch and HIF enhances the antitumor effect of radiation in Notch expressing lung cancer
  Yasuyuki Ikezawa; Jun Sakakibara-Konishi; Hidenori Mizugaki; Satoshi Oizumi; Masaharu Nishimura
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 22, 1, 59, 69, Feb. 2017, [Peer-reviewed], [Domestic magazines]
  English, Scientific journal
• Expression of Notch1 and Numb in small cell lung cancer
  Hajime Kikuchi; Jun Sakakibara-Konishi; Megumi Furuta; Hiroshi Yokouchi; Hiroshi Nishihara; Shigeo Yamazaki; Hidetaka Uramoto; Fumihiro Tanaka; Masao Harada; Kenji Akie; Fumiko Sugaya; Yuka Fujita; Kei Takamura; Tetsuya Kojima; Toshiyuki Harada; Mitsunori Higuchi; Osamu Honjo; Yoshinori Minami; Naomi Watanabe; Satoshi Oizumi; Hiroyuki Suzuki; Takashi Ishida; Hirotoshi Dosaka-Akita; Hiroshi Isobe; Mitsuru Munakata; Masaharu Nishimura
  ONCOTARGET, 8, 6, 10348, 10358, Feb. 2017, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells
  Taichi Takashina; Ichiro Kinoshita; Junko Kikuchi; Yasushi Shimizu; Jun Sakakibara-Konishi; Satoshi Oizumi; Masaharu Nishimura; Hirotoshi Dosaka-Akita
  CANCER SCIENCE, 107, 7, 955, 962, Jul. 2016, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma
  Tomoaki Naka; Yutaka Hatanaka; Katsuji Marukawa; Hiromi Okada; Kanako C. Hatanaka; Jun Sakakibara-Konishi; Satoshi Oizumi; Yasuhiro Hida; Kichizo Kaga; Tomoko Mitsuhashi; Yoshihiro Matsuno
  DIAGNOSTIC PATHOLOGY, 11, 38, 38, Apr. 2016, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma
  Tomoaki Naka; Yutaka Hatanaka; Katsuji Marukawa; Hiromi Okada; Kanako C. Hatanaka; Jun Sakakibara-Konishi; Satoshi Oizumi; Yasuhiro Hida; Kichizo Kaga; Tomoko Mitsuhashi; Yoshihiro Matsuno
  DIAGNOSTIC PATHOLOGY, 11, 38, Apr. 2016, [Peer-reviewed]
  English, Scientific journal
• 指尖転移を来たした肺扁平上皮癌の1例
  池澤 靖元; 水柿 秀紀; 庄司 哲明; 高島 雄太; 森本 恵; 高階 太一; 菊地 英毅; 菊地 順子; 榊原 純; 品川 尚文; 大泉 聡史; 西村 正治; 岡田 宏美; 松野 吉宏; 七戸 龍司
  肺癌, 55, 7, 1108, 1108, (NPO)日本肺癌学会, Dec. 2015
  Japanese
• Spontaneous regression of small cell lung cancer combined with cancer associated retinopathy
  Hidenori Kitai; Jun Sakakibara-Konishi; Satoshi Oizumi; Yoshihiko Hirohashi; Wataru Saito; Atsuhiro Kanda; Noriyuki Sato; Masaharu Nishimura
  LUNG CANCER, 87, 1, 73, 76, Jan. 2015, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• CD133 expression: a potential prognostic marker for non-small cell lung cancers
  Hidenori Mizugaki; Jun Sakakibara-Konishi; Junko Kikuchi; Jun Moriya; Kanako C. Hatanaka; Eiki Kikuchi; Ichiro Kinoshita; Satoshi Oizumi; Hirotoshi Dosaka-Akita; Yoshihiro Matsuno; Masaharu Nishimura
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 19, 2, 254, 259, Apr. 2014, [Peer-reviewed], [Domestic magazines]
  English, Scientific journal
• 当院における悪性胸膜中皮腫27例の検討
  菊池 創; 朝比奈 肇; 北井 秀典; 池澤 靖元; 高階 太一; 品川 尚文; 榊原 純; 大泉 聡史; 西村 正治; 樋田 泰浩; 加賀 基知三; 井上 哲也; 加藤 徳雄
  肺癌, 53, 7, 918, 918, (NPO)日本肺癌学会, Dec. 2013, [Peer-reviewed]
  Japanese
• Stereotactic body radiotherapy using gated radiotherapy with real-time tumor-tracking for stage I non-small cell lung cancer
  Tetsuya Inoue; Norio Katoh; Rikiya Onimaru; Shinichi Shimizu; Kazuhiko Tsuchiya; Ryusuke Suzuki; Jun Sakakibara-Konishi; Naofumi Shinagawa; Satoshi Oizumi; Hiroki Shirato
  Radiation Oncology, 8, 1, 69, 69, 21 Mar. 2013, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells
  Junko Kikuchi; Taichi Takashina; Ichiro Kinoshita; Eiki Kikuchi; Yasushi Shimizu; Jun Sakakibara-Konishi; Satoshi Oizumi; Victor E. Marquez; Masaharu Nishimura; Hirotoshi Dosaka-Akita
  LUNG CANCER, 78, 2, 138, 143, Nov. 2012, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• Expression of Bim, Noxa, and Puma in non-small cell lung cancer
  Jun Sakakibara-Konishi; Satoshi Oizumi; Junko Kikuchi; Eiki Kikuchi; Hidenori Mizugaki; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Masaharu Nishimura
  BMC CANCER, 12, 286, 286, Jul. 2012, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer
  Mizugaki H.; Sakakibara-Konishi J.; Ikezawa Y.; Kikuchi J.; Kikuchi E.; Oizumi S.; Dang T. P.; Nishimura M.
  British Journal of Cancer, 106, 12, 1953, 1959, Cancer Research UK, 05 Jun. 2012
  English, BACKGROUND: Notch receptor has an important role in both development and cancer. We previously reported that inhibition of the Notch3 by γ-secretase inhibitor (GSI) induces apoptosis and suppresses tumour proliferation in non-small-cell lung cancer. Although radiation is reported to induce Notch activation, little is known about the relationship between radiation and Notch pathway. METHODS: We examined the effect of combining GSI and radiation at different dosing in three Notch expressing lung cancer cell lines. The cytotoxic effect of GSI and radiation was evaluated using MTT assay and clonogenic assay in vitro and xenograft models. Expressions of Notch pathway, mitogen-activated protein kinase (MAPK) pathway and Bcl-2 family proteins were investigated using western blot analysis. RESULTS: We discovered that the antitumour effect of combining GSI and radiation was dependent on treatment schedule. γ-Secretase inhibitor administration after radiation had the greatest growth inhibition of lung cancer in vitro and in vivo. We showed that the combination induced apoptosis of lung cancer cell lines through the regulation of MAPK and Bcl-2 family proteins. Furthermore, activation of Notch after radiation was ameliorated by GSI administration, suggesting that treatment with GSI prevents Notch-induced radiation resistance. CONCLUSION: Notch has an important role in lung cancer. Treatment with GSI after radiation can significantly enhance radiation-mediated tumour cytotoxicity.
• The Peptide Nucleic Acid-Locked Nucleic Acid Polymerase Chain Reaction Clamp-Based Test for Epidermal Growth Factor Receptor Mutations in Bronchoscopic Cytological Specimens of Non-Small Cell Lung Cancer
  Noriyuki Yamada; Satoshi Oizumi; Hajime Asahina; Naofumi Shinagawa; Eiki Kikuchi; Junko Kikuchi; Jun Sakakibara-Konishi; Tomoaki Tanaka; Kunihiko Kobayashi; Koichi Hagiwara; Masaharu Nishimura
  ONCOLOGY, 82, 6, 341, 346, 2012, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• Stereotactic Body Radiation Therapy (SBRT) Using Real-time Tracking Radiation Therapy (RTRT) System for Patients With Lung Cancer Aged 80+
  Onimaru R; Katoh N; Inoue T; Shimizu S; Shinagawa N; Sakakibara-Konishi J; Oizumi S; Shirato H
  International Journal of Radiation Oncology Biology Physics, 84, 3, S575, 2012, [Peer-reviewed]
• Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer
  Jun Sakakibara-Konishi; Satoshi Oizumi; Ichiro Kinoshita; Naofumi Shinagawa; Junko Kikuchi; Mototsugu Kato; Tetsuya Inoue; Norio Katoh; Rikiya Onimaru; Hiroki Shirato; Hirotoshi Dosaka-Akita; Masaharu Nishimura
  LUNG CANCER, 74, 2, 248, 252, Nov. 2011, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancer
  Junko Kikuchi; Ichiro Kinoshita; Yasushi Shimizu; Eiki Kikuchi; Kayoko Takeda; Hiroyuki Aburatani; Satoshi Oizumi; Jun Konishi; Kichizo Kaga; Yoshihiro Matsuno; Michael J. Birrer; Masaharu Nishimura; Hirotoshi Dosaka-Akita
  LUNG CANCER, 72, 2, 229, 237, May 2011, [Peer-reviewed]
  English, Scientific journal
• 2.GGO病変に対するEBUS-GS法の有用性の検討(第32回 日本呼吸器内視鏡学会北海道支部会)
  池澤 靖元; 品川 尚文; 高階 太一; 小倉 粋; 伊藤 健一郎; 竹内 裕; 水柿 秀紀; 山田 範幸; 菊地 英毅; 菊地 順子; 小西 純; 大泉 聡史; 西村 正治; 須甲 憲明
  気管支学, 33, 1, 58, 58, 特定非営利活動法人 日本呼吸器内視鏡学会, 2011
  Japanese
• Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer.
  Sakakibara-Konishi J; Oizumi S; Kinoshita I; Shinagawa N; Kikuchi J; Kato M; Inoue T; Katoh N; Onimaru R; Shirato H; Dosaka-Akita H; Nishimura M
  Lung Cancer, 74, 2, 248, 52, 2011, [Peer-reviewed]
• CD8(+) tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
  Noriyuki Yamada; Satoshi Oizumi; Eiki Kikuchi; Naofumi Shinagawa; Jun Konishi-Sakakibara; Atsushi Ishimine; Keisuke Aoe; Kenichi Gemba; Takumi Kishimoto; Toshihiko Torigoe; Masaharu Nishimura
  CANCER IMMUNOLOGY IMMUNOTHERAPY, 59, 10, 1543, 1549, Oct. 2010, [Peer-reviewed]
  English, Scientific journal
• Distinctive Expression of the Polycomb Group Proteins Bmi1 Polycomb Ring Finger Oncogene and Enhancer of Zeste Homolog 2 in Nonsmall Cell Lung Cancers and Their Clinical and Clinicopathologic Significance
  Junko Kikuchi; Ichiro Kinoshita; Yasushi Shimizu; Eiki Kikuchi; Jun Konishi; Satoshi Oizumi; Kichizo Kaga; Yoshihiro Matsuno; Masaharu Nishimura; Hirotoshi Dosaka-Akita
  CANCER, 116, 12, 3015, 3024, Jun. 2010, [Peer-reviewed]
  English, Scientific journal
• Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim
  J. Konishi; F. Yi; X. Chen; H. Vo; D. P. Carbone; T. P. Dang
  ONCOGENE, 29, 4, 589, 596, Jan. 2010, [Peer-reviewed]
  English, Scientific journal
• Primary Mediastinal Liposarcoma, with 6 Years of Follow-up to Autopsy, Revealed Histopathological Features of Primary and Metastatic Lesions
  Satoshi Konno; Satoshi Oizumi; Naofumi Shinagawa; Eiki Kikuchi; Jun Konishi; Kenichiro Ito; Nobuyuki Hizawa; Akihiro Takiyama; Shinya Tanaka; Masaharu Nishimura
  INTERNAL MEDICINE, 49, 8, 771, 775, 2010, [Peer-reviewed]
  English, Scientific journal
• OR13-3 気管支鏡検体による組織型診断の妥当性と検査手技についての検討(病理・EGFR,一般口演13,第33回日本呼吸器内視鏡学会学術集会)
  竹内 裕; 菊地 英毅; 品川 尚文; 池澤 靖元; 高階 太一; 小倉 粋; 伊藤 健一郎; 水柿 秀紀; 山田 範幸; 朝比奈 肇; 菊地 順子; 小西 純; 大泉 聡史; 松野 吉宏; 西村 正治
  気管支学, 32, S155, 特定非営利活動法人 日本呼吸器内視鏡学会, 2010
  Japanese
• OR22-1 GGO病変に対するEBUS-GS法の有用性の検討(ガイドシース,一般口演22,第33回日本呼吸器内視鏡学会学術集会)
  池澤 靖元; 品川 尚文; 高階 太一; 小倉 粋; 伊藤 健一郎; 竹内 裕; 水柿 秀紀; 山田 範幸; 菊地 英毅; 菊地 順子; 小西 純; 大泉 聡史; 須甲 憲明; 西村 正治
  気管支学, 32, S173, 特定非営利活動法人 日本呼吸器内視鏡学会, 2010
  Japanese
• OR22-2 肺末梢病変に対するEBUS-GS併用経気管支鏡下針生検の有用性の検討(ガイドシース,一般口演22,第33回日本呼吸器内視鏡学会学術集会)
  高階 太一; 品川 尚文; 池澤 靖元; 小倉 粋; 伊藤 健一郎; 竹内 裕; 水柿 秀紀; 山田 範幸; 朝比奈 肇; 菊地 英毅; 菊地 順子; 小西 純; 大泉 聡史; 西村 正治
  気管支学, 32, S173, 特定非営利活動法人 日本呼吸器内視鏡学会, 2010
  Japanese
• 2.動体追跡放射線照射(RTRT)における金球標識(金マーカー)留置キットの使用経験(第31回 日本呼吸器内視鏡学会北海道支部会)
  竹内 裕; 品川 尚文; 小倉 粋; 河井 康孝; 伊藤 健一郎; 水柿 秀紀; 山田 範幸; 菊地 英毅; 菊地 順子; 小西 純; 大泉 聡史; 西村 正治; 井上 哲也; 加藤 徳雄; 鬼丸 力也; 白土 博樹
  気管支学, 32, 1, 80, 80, 特定非営利活動法人 日本呼吸器内視鏡学会, 2010
  Japanese
• 8.抗凝固療法中の気道出血に対し気道バルーンとトロンビン,ベリプラスト^[○!R]散布が有効であった1例(第31回 日本呼吸器内視鏡学会北海道支部会)
  品川 尚文; 小倉 粋; 河井 康孝; 伊藤 健一郎; 竹内 裕; 水柿 秀紀; 山田 範幸; 菊地 順子; 菊地 英毅; 小西 純; 大泉 聡史; 西村 正治; 大岡 智学; 松居 喜郎
  気管支学, 32, 1, 82, 82, 特定非営利活動法人 日本呼吸器内視鏡学会, 2010
  Japanese
• 3.転移性肺腫瘍におけるVBN併用EBUS-GS経気管支生検とCT透視下極細径気管支鏡下生検の診断率の検討(第31回 日本呼吸器内視鏡学会北海道支部会)
  小倉 粋; 品川 尚文; 河井 康孝; 伊藤 健一郎; 竹内 裕; 水柿 秀紀; 山田 範幸; 菊地 英毅; 菊地 順子; 小西 純; 大泉 聡史; 西村 正治
  気管支学, 32, 1, 80, 81, 特定非営利活動法人 日本呼吸器内視鏡学会, 2010
  Japanese
• 肝転移にて再発し、肝動脈化学塞栓療法が奏功した肺カルチノイドの1例
  竹内 裕; 菊地 英毅; 竹中 芳子; 河井 康孝; 小西 純; 大泉 聡史; 西村 正治; 中馬 誠; 中西 満; 作原 祐介; 阿保 大介
  肺癌, 49, 7, 1056, 1056, (NPO)日本肺癌学会, Dec. 2009
  Japanese
• Phase I study of amrubicin and vinorelbine in non-small cell lung cancer previously treated with platinum-based chemotherapy
  Satoshi Oizumi; Koichi Yamazaki; Hiroshi Yokouchi; Jun Konishi; Fumihiro Hommura; Tetsuya Kojima; Hiroshi Isobe; Masaharu Nishimura
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 14, 2, 125, 129, Apr. 2009, [Peer-reviewed]
  English, Scientific journal
• OR16-3 気管支鏡下細胞診検体を用いたPNA-LNA PCR clamp法による上皮成長因子受容体(EGFR)遺伝子変異検出の検討(診断・他,一般口演16,第32回日本呼吸器内視鏡学会学術集会)
  山田 範幸; 大泉 聡史; 朝比奈 肇; 菊地 英毅; 菊地 順子; 小西 純; 品川 尚文; 小林 国彦; 宮澤 仁志; 田中 知明; 萩原 弘一; 西村 正治
  気管支学, 31, S117, 特定非営利活動法人 日本呼吸器内視鏡学会, 2009
  Japanese
• OR16-6 動体追跡放射線照射(RTRT)における金球標識(金マーカー)留置キットの使用経験(診断・他,一般口演16,第32回日本呼吸器内視鏡学会学術集会)
  竹内 裕; 品川 尚文; 小倉 粋; 河井 康孝; 伊藤 健一郎; 水柿 秀紀; 山田 範幸; 菊地 英毅; 菊地 順子; 小西 純; 井上 哲也; 加藤 徳雄; 鬼丸 力也; 白土 博樹; 大泉 聡史; 西村 正治
  気管支学, 31, S118, 特定非営利活動法人 日本呼吸器内視鏡学会, 2009
  Japanese
• OR5-1 転移性肺腫瘍に対するVBN併用EBUS-GS経気管支生検とCT透視下極細径気管支鏡下生検の診断率の検討(極細径気管支鏡,一般口演5,第32回日本呼吸器内視鏡学会学術集会)
  小倉 粋; 品川 尚文; 河井 康孝; 伊藤 健一郎; 竹内 裕; 水柿 秀紀; 山田 範幸; 菊地 英毅; 菊地 順子; 小西 純; 大泉 聡史; 西村 正治
  気管支学, 31, S95, 特定非営利活動法人 日本呼吸器内視鏡学会, 2009
  Japanese
• 4.気管硬性鏡を用いて気道拡張術を施行した3例(第30回日本呼吸器内視鏡学会北海道支部会)
  品川 尚文; 大泉 聡史; 山田 範幸; 水柿 秀紀; 伊藤 健一郎; 竹内 裕; 菊地 英毅; 菊地 順子; 小西 純; 西村 正治
  気管支学, 31, 1, 40, 41, 特定非営利活動法人 日本呼吸器内視鏡学会, 2009
  Japanese
• 9.肺サルコイドーシスに対するコンベックス走査式超音波気管支鏡ガイド下生検と経気管支肺生検の有用性の検討(第30回日本呼吸器内視鏡学会北海道支部会)
  水柿 秀紀; 品川 尚文; 今野 哲; 伊藤 健一郎; 竹内 裕; 山田 範幸; 朝比奈 肇; 菊地 英毅; 菊地 順子; 小西 純; 大泉 聡史; 西村 正治
  気管支学, 31, 1, 42, 42, 特定非営利活動法人 日本呼吸器内視鏡学会, 2009
  Japanese
• Recurrent gefitinib-induced interstitial lung disease
  Masaru Suzuki; Hajime Asahina; Jun Konishi; Koichi Yamazaki; Masaharu Nishimura
  INTERNAL MEDICINE, 47, 6, 533, 536, 2008, [Peer-reviewed]
  English, Scientific journal
• gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers
  Jun Konishi; Keiko S. Kawaguchi; Huan Vo; Nobuhiro Haruki; Adriana Gonzalez; David P. Carbone; Thao P. Dang
  CANCER RESEARCH, 67, 17, 8051, 8057, Sep. 2007, [Peer-reviewed]
  English, Scientific journal
• Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
  Hiroshi Yokouchi; Koichi Yamazaki; Ichiro Kinoshita; Jun Konishi; Hajime Asahina; Noriaki Sukoh; Masao Harada; Kenji Akie; Shigeaki Ogura; Takashi Ishida; Mitsuru Munakata; Hirotoshi Dosaka-Akita; Hiroshi Isobe; Masaharu Nishimura
  BMC CANCER, 7, 51, Mar. 2007, [Peer-reviewed]
  English, Scientific journal
• Combination tumor immunotherapy with radiotherapy and Th1 cell therapy against murine lung carcinoma.
  Yokouchi H; Chamoto K; Wakita D; Yamazaki K; Shirato H; Takeshima T; Dosaka-Akita H; Nishimura M; Yue Z; Kitamura H; Nishimura T
  Clinical & experimental metastasis, 24, 533, 540, 7, 2007, [Peer-reviewed]
• Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer
  Megumi Nakadate; Koichi Yamazaki; Jun Konishi; Ichiro Kinoshita; Noriaki Sukoh; Masao Harada; Kenji Akie; Shigeaki Ogura; Takashi Ishida; Mitsuru Munakata; Hirotoshi Dosaka-Akita; Hiroshi Isobe; Masaharu Nishimura
  ANTICANCER RESEARCH, 26, 5B, 3767, 3772, Sep. 2006, [Peer-reviewed]
  English, Scientific journal
• Analysis of the response and toxicity to gefitinib of non-small cell lung cancer
  J Konishi; K Yamazaki; Kinoshita, I; H Isobe; S Ogura; S Sekine; T Ishida; R Takashima; M Nakadate; S Nishikawa; T Hattori; H Asahina; M Imura; E Kikuchi; J Kikuchi; N Shinagawa; H Yokouchi; M Munakata; H Dosaka-Akita; M Nishimura
  ANTICANCER RESEARCH, 25, 1B, 435, 441, Jan. 2005, [Peer-reviewed]
  English, Scientific journal
• S3-5 バーチャル気管支鏡及び気管支腔内超音波断層法の併用による診断と分子標的薬剤選択への応用(<シンポジウム3>Virtual Bronchoscopyの臨床応用)(第28回 日本呼吸器内視鏡学会総会)
  朝比奈 肇; 山崎 浩一; 高島 理央; 中舘 恵; 西川 就; 猪村 帝; 菊地 英毅; 菊地 順子; 品川 尚文; 小西 純; 横内 浩; 西村 正治; 小野寺 祐也; 浅野 文祐
  気管支学, 27, 3, 170, 170, 特定非営利活動法人 日本呼吸器内視鏡学会, 2005
  Japanese
• Endobronchial Ultrasonography With a Guide-sheath(EBUS-GS) for Peripheral Pulmonary Lesions
  Kikuchi Eiki; Yamazaki Koichi; Asahina Hajime; Imura Mikado; Kikuchi Junko; Konishi Jun; Shinagawa Naofumi; Yokouchi Hiroshi; Onodera Yuya; Nishimura Masaharu
  The Journal of the Japan Society for Respiratory Endoscopy, 27, 1, 43, 49, The Japan Society for Respiratory Endoscopy, 2005
  Japanese, Background. We previously reported the usefulness of endobronchial ultrasonography with a guide-sheath (EBUS-GS) as a guide for transbronchial biopsy (TBB) for diagnosing peripheral pulmonary lesions using an ultrasound probe with a diameter of 1.4 mm (XUM-S20-17R, Olympus). In a total of 24 peripheral pulmonary lesions of 30 nun or less undergoing EBUS-GS-guided TBB and bronchial brushing, 19 Iesions (79%) were visualized by EBUS and 14 lesions (58%) were diagnosed cyiopathologically. However, several problems were found: the curette was hard to manipulate and only small insufficient specimens were obtained in some cases. Purpose. In order to alleviate these problems we attempted to re-evaluate the usefulness of EBUS-GS-guided TBB for diagnosing peripheral pulmonary lesions using an improved curette or a probe with a diameter of 1.7 mm (UM-S20-20R, Olympus) . Subjects.
• OR3-4 極細径気管支鏡を用いたCT透視下生検における病変部位別診断率の検討(<一般口演3>気管支鏡診断3)(第28回 日本呼吸器内視鏡学会総会)
  品川 尚文; 山崎 浩一; 高島 理央; 中舘 恵; 西川 就; 朝比奈 肇; 菊地 英毅; 菊地 順子; 小西 純; 横内 浩; 福元 伸一; 西村 正治; 小野寺 裕也; 浅野 文祐
  気管支学, 27, 3, 206, 206, 特定非営利活動法人 日本呼吸器内視鏡学会, 2005
  Japanese
• Lung adenocarcinoma presenting with enlarged and multiloculated cystic lesions over 2 years.
  Yoshida T; Harada T; Fuke S; Konishi J; Yamazaki K; Kaji M; Morikawa T; Ota S; Itoh T; Dosaka-Akita H; Nishimura M
  Respiratory care, 49, 12, 1522, 1524, 12, Dec. 2004, [Peer-reviewed], [International Magazine]
  English, Scientific journal, We report a case of lung adenocarcinoma in which cystic lesions enlarged and multiloculated over 2 years. Histological examination of the resected specimen found proliferation of nonmucinous adenocarcinoma cells along the alveolar walls, revealing bronchioloalveolar cell carcinoma type extension. In cystic lesions, particularly those not associated with inflammation, lung adenocarcinoma, particularly bronchioloalveolar cell carcinoma type, should be a diagnostic consideration. .
• The characteristics of human NKT cells in lung cancer - CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients
  J Konishi; K Yamazaki; H Yokouchi; N Shinagawa; K Iwabuchi; M Nishimura
  HUMAN IMMUNOLOGY, 65, 11, 1377, 1388, Nov. 2004, [Peer-reviewed]
  English, Scientific journal
• Phase I trial of carboplatin and weekly paclitaxel in patients with advanced non-small-cell lung cancer
  J Kikuchi; K Yamazaki; Kinoshita, I; H Asahina; M Imura; E Kikuchi; J Konishi; N Shinagawa; H Oki; H Dosaka-Akita; M Nishimura
  JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 34, 9, 505, 509, Sep. 2004, [Peer-reviewed]
  English, Scientific journal
• B7-h1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression
  J Konishi; K Yamazaki; M Azuma; Kinoshita, I; H Dosaka-Akita; M Nishimura
  CLINICAL CANCER RESEARCH, 10, 15, 5094, 5100, Aug. 2004, [Peer-reviewed]
  English, Scientific journal
• Paraneoplastic cerebellar degeneration (PCD) associated with squamous cell carcinoma of the lung
  J Konishi; K Yamazaki; K Chikai; K Nagashima; K Sakai; Kinoshita, I; H Dosaka-Akita; M Nishimura
  INTERNAL MEDICINE, 43, 7, 602, 606, Jul. 2004, [Peer-reviewed]
  English, Scientific journal
• Assistance by Virtual Bronchoscopy for Diagnosing and Treating Small Peripheral Pulmonary Lesions
  Yamazaki Koichi; Shinagawa Naofumi; Onodera Yuya; Asahina Hajime; Imura Mikado; Kikuchi Eiki; Kikuchi Junko; Konishi Jun; Asano Fumihiro; Nishimura Masaharu
  The Journal of the Japan Society for Respiratory Endoscopy, 26, 8, 689, 693, The Japan Society for Respiratory Endoscopy, 2004
  Japanese, The methods to simulate the proper bronchi to reach the small peripheral pulmonary lesions by virtual bronchoscopy has been reported. We have also reported the usefulness of virtual bronchoscopy to simulate the proper bronchi to reach the small peripheral pulmonary lesions for CT-guided transbronchial biopsy. In addition, we have developed the new system, the VBS navigation system, to navigate the proper bronchi to reach the small peripheral pulmonary lesions during transbronchial biopsy on real time. The navigation of the bronchi by virtual bronchoscopy is expected to improve the diagnostic yields, and reduce the time for examination and irradiation exposure, when it is applied to CT-guided transbronchial biopsy as well as endobronchial ultrasonography with guide-sheath ( EBUS-GS ) guided transbronchial biopsy. Furthermore, the use of virtual bronchoscopic navigation and an ultrathin bronchoscope could enhance the accuracy of preoperable barium marking around the lesions. In this symposium, we discuss the advantages, disadvantages and future directions of virtual bronchoscopy.
• S1-2 肺末梢小型病変の診断と治療におけるバーチャル内視鏡による診療支援(シンポジウム1 最新の呼吸器内視鏡)
  山崎 浩一; 品川 尚文; 朝比奈 肇; 猪村 帝; 菊地 英毅; 菊地 順子; 小西 純; 西村 正治; 小野寺 祐也; 浅野 文祐
  気管支学, 26, 3, 211, 211, 特定非営利活動法人 日本呼吸器内視鏡学会, 2004
  Japanese
• Granulocyte-macrophage colony-stimulating factor gene-transduced tumor cells combined with tumor-derived gp96 inhibit tumor growth in mice
  T Kojima; K Yamazaki; Y Tamura; S Ogura; K Tani; J Konishi; N Shinagawa; Kinoshita, I; N Hizawa; E Yamaguchi; H Dosaka-Akita; M Nishimura
  HUMAN GENE THERAPY, 14, 8, 715, 728, May 2003, [Peer-reviewed]
  English, Scientific journal
• Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: Analysis of false-positive FDG-PET findings
  J Konishi; K Yamazaki; E Tsukamoto; N Tamaki; Y Onodera; T Otake; T Morikawa; Kinoshita, I; H Dosaka-Akita; M Nishimura
  RESPIRATION, 70, 5, 500, 506, 2003, [Peer-reviewed]
  English, Scientific journal
• 1.極細径気管支鏡を用いたCT透視下生検における検査中SpO_2低下に関する検討(第24回日本気管支学会北海道支部会)(支部会(記録))
  品川 尚文; 山崎 浩一; 菊地 英毅; 大室 順子; 小西 純; 白間 信行; 原田 敏之; 木下 一郎; 西村 正治; 秋田 弘悛; 小野寺 祐也; 宮坂 和男
  気管支学, 25, 4, 310, 310, 特定非営利活動法人 日本呼吸器内視鏡学会, 2003
  Japanese
• Enhanced complement sensitivity of NK-T cells in murine, thymus and spleen associated with presence of serum immunoglobulin
  K Onoe; K Iwabuchi; C Iwabuchi; S Tone; J Konishi; Y Kawakami; M Nishimura; K Onoe
  IMMUNOBIOLOGY, 206, 4, 377, 391, Oct. 2002, [Peer-reviewed]
  English, Scientific journal
• Thymic epithelial cells responsible for impaired generation of NK-T thymocytes in Alymphoplasia mutant mice
  J Konishi; K Iwabuchi; C Iwabuchi; M Ato; J Nagata; K Onoe; K Nakagawa; M Kasai; K Ogasawara; K Kawakami; K Onoe
  CELLULAR IMMUNOLOGY, 206, 1, 26, 35, Nov. 2000, [Peer-reviewed]
  English, Scientific journal
• Different influence of macrophage migration inhibitory factor (MIF) in signal transduction pathway of various T cell subsets
  Nobuyoshi Kitaichi; Kazumasa Ogasawara; Kazuya Iwabuchi; Jun Nishihira; Ken-Ichi Namba; Kazuyuki Onoé; Jun Konishi; Satoshi Kotake; Hidehiko Matsuda; Kazunori Onoé
  Immunobiology, 201, 3-4, 356, 367, Elsevier GmbH, 2000, [Peer-reviewed]
  English, Scientific journal
• Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting
  N. Tamaki; Y. Yonekura; K. Yamashita; H. Saji; Y. Magata; M. Senda; Y. Konishi; K. Hirata; T. Ban; J. Konishi
  The American Journal of Cardiology, 64, 14, 860, 865, 1989, [Peer-reviewed]
  English

• Identification of TROP2 as an adaptive resistance mechanism in KRAS G12C inhibition and its therapeutic targeting.
  Masahiro Kashima; Hidenori Kitai; Yukiko Yoshida; Yuriko Ishida; Yuma Sato; Daisuke Morinaga; Kosuke Tsuji; Shotaro Ito; Kanako C. Hatanaka; Takuma Kobayashi; Yoshiki Shinomiya; Teppei Konishi; Yutaka Hatanaka; Jun Sakakibara-Konishi; Satoshi Konno, CANCER RESEARCH, 86, 7, 03 Apr. 2026
  English, Summary international conference
• 気管支狭窄拡張術後にALK-TKIを導入したHIP1-ALK陽性肺癌の1例
  佐藤祐麻; 北井秀典; 田上敬太; 石田有莉子; 篠崎鮎香; 佐藤峰嘉; 高橋宏典; 古田恵; 高島雄太; 庄司哲明; 池澤靖元; 榊原純; 品川尚文; 今野哲; 品川尚文; 大川紘弥; 大塚紀幸; 畑中佳奈子; 畑中豊; 横内浩, 肺癌(Web), 65, 1, 2025
• 全身療法中にoligoprogression/oligorecurrenceを認めた非小細胞肺癌症例の検討
  鎌田凌平; 森永大亮; 榊原純; 古川貴啓; 酒井碧; 佐々木賢太; 畠山酉季; 辻康介; 佐藤峰嘉; 高橋宏典; 古田恵; 庄司哲明; 高島雄太; 北井秀典; 池澤靖元; 今野哲; 田口大志; 加藤達哉, 肺癌(Web), 65, 1, 2025
• EGFR遺伝子変異陽性進行再発非小細胞肺癌における免疫チェックポイント阻害剤の治療についての後方視的検討
  古川貴啓; 庄司哲明; 酒井碧; 佐々木賢太; 畠山酉季; 辻康介; 佐藤峰嘉; 高橋宏典; 古田恵; 高島雄太; 北井秀典; 池澤靖元; 榊原純; 今野哲, 肺癌(Web), 65, 1, 2025
• ALK融合遺伝子陽性非小細胞肺癌患者における治療シークエンスについて
  高橋宏典; 榊原純; 辻康介; 佐藤峰嘉; 庄司哲明; 高島雄太; 古田恵; 北井秀典; 池澤靖元; 今野哲, 肺癌(Web), 65, 1, 2025
• 当科におけるPD-L1低発現非小細胞肺癌に対する免疫チェックポイント阻害薬治療についての後方視的検討
  佐々木賢太; 池澤靖元; 酒井碧; 畠山酉季; 辻康介; 佐藤峰嘉; 高橋宏典; 庄司哲明; 古田恵; 高島雄太; 北井秀典; 榊原純; 今野哲, 肺癌(Web), 65, 1, 2025
• 当科におけるKRASG12C遺伝子変異陽性非小細胞肺癌に対するSotorasib投与症例の検討
  三田明音; 高橋宏典; 庄司哲明; 高島雄太; 古田恵; 北井秀典; 池澤靖元; 榊原純; 今野哲, 肺癌(Web), 65, 1, 2025
• 気管・気管支狭窄拡張術を要した気管・気管支原発腺様嚢胞癌の6例
  佐藤峰嘉; 高島雄太; 品川尚文; 品川尚文; 池澤靖元; 高橋宏典; 石田有莉子; 佐藤祐麻; 田上敬太; 篠崎鮎香; 辻康介; 北井秀典; 古田恵; 榊原純; 若林健人; 加藤達哉; 松野吉宏; 今野哲, 気管支学, 47, 1, 2025
• 当科におけるクライオ生検の検討
  田上敬太; 高島雄太; 石田有莉子; 佐藤祐麻; 臺鮎香; 辻康介; 佐藤峰嘉; 中村友彦; 高橋宏典; 庄司哲明; 池澤靖元; 榊原純; 品川尚文; 今野哲, 気管支学, 47, 1, 2025
• 非小細胞肺癌におけるoligoprogressionの頻度および局所治療が予後に与える影響についての検討
  森永大亮; 榊原純; 北井秀典; 池澤靖元; 加藤達哉; 四宮義貴; 畑中佳奈子; 畑中豊; 田口大志; 今野哲, 日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集, 38th, 2025
• 小細胞肺癌との鑑別に苦慮した胸部SMARCA4欠損未分化腫瘍の1例
  溝渕匠平; 榊原純; 棟方奈菜; 庄司哲明; 古田恵; 高島雄太; 北井秀典; 池澤靖元; 今野哲; 加藤憲士郎; 大塚紀幸; 種井善一; 田中伸哉, 肺癌(Web), 65, 1, 2025
• Comparing predictors of radiation-induced lymphopenia in various timeframes in NSCLC radiotherapy
  Takahiro Kanehira; Hiroshi Taguchi; Jun Sakakibara-Konishi; Norio Katoh; Yusuke Uchinami; Keiji Kobashi; Takayuki Hashimoto; Hidefumi Aoyama, RADIOTHERAPY AND ONCOLOGY, 194, S5012, S5015, May 2024
  English, Summary international conference
• 当科におけるPD-L1低発現非小細胞肺癌に対する免疫チェックポイント阻害薬治療についての後方視的検討
  佐々木賢太; 池澤靖元; 酒井碧; 畠山酉季; 辻康介; 佐藤峰嘉; 高橋宏典; 庄司哲明; 古田恵; 高島雄太; 北井秀典; 榊原純; 今野哲, 日本肺癌学会学術集会号(CD-ROM), 65th, 2024
• ALK融合遺伝子陽性非小細胞肺癌患者における治療シークエンスについて
  高橋宏典; 榊原純; 辻康介; 佐藤峰嘉; 庄司哲明; 高島雄太; 古田恵; 北井秀典; 池澤靖元; 今野哲, 日本肺癌学会学術集会号(CD-ROM), 65th, 2024
• 当科におけるKRAS G12C遺伝子変異陽性非小細胞肺癌に対するSotorasib投与症例の検討
  三田明音; 高橋宏典; 庄司哲明; 高島雄太; 古田恵; 北井秀典; 池澤靖元; 榊原純; 今野哲, 日本肺癌学会学術集会号(CD-ROM), 65th, 2024
• ニボルマブ+イピリムマブ併用療法が著効し胸膜切除/肺剥皮術を施行できた上皮型胸膜中皮腫の1例
  佐藤祐麻; 古田恵; 田上敬太; 石田有莉子; 佐藤峰嘉; 高橋宏典; 高島雄太; 庄司哲明; 北井秀典; 池澤靖元; 榊原純; 今野哲; 加藤達哉; 大野桜子; 松野吉宏, 肺癌(Web), 64, 1, 2024
• アレクチニブ耐性癌性髄膜炎に対し全脳照射とロルラチニブが有効であったALK融合遺伝子陽性肺腺癌の1例
  篠崎鮎香; 古田恵; 伊藤昴哉; 大崎智史; 佐藤祐麻; 高橋宏典; 庄司哲明; 高島雄太; 北井秀典; 池澤靖元; 榊原純; 今野哲, 肺癌(Web), 64, 1, 2024
• 当科におけるクライオ生検の検討
  田上敬太; 高島雄太; 石田有莉子; 佐藤祐麻; 臺鮎香; 辻康介; 佐藤峰嘉; 中村友彦; 高橋宏典; 庄司哲明; 池澤靖元; 品川尚文; 品川尚文; 榊原純; 今野哲, 気管支学, 46, 2024
• 気管・気管支狭窄拡張術を要した気管・気管支原発腺様嚢胞癌の6例
  佐藤峰嘉; 高島雄太; 品川尚文; 品川尚文; 池澤靖元; 庄司哲明; 高橋宏典; 石田有莉子; 田上敬太; 佐藤祐麻; 篠崎鮎香; 辻康介; 北井秀典; 古田恵; 榊原純; 若林健人; 加藤達哉; 松野吉宏; 今野哲, 気管支学, 46, 2024
• Study of the efficacy of second-line treatment after initial chemotherapy with or without immune checkpoint inhibitor in extensive stage small cell lung cancer
  森永大亮; 北井秀典; 庄司哲明; 古田恵; 高島雄太; 池澤靖元; 榊原純; 今野哲, 日本呼吸器学会誌(Web), 13, 2024
• 血管新生阻害剤先行投与による免疫療法の治療効果増強
  佐藤峰嘉; 佐藤峰嘉; 間石奈湖; 樋田泰浩; 松田彩; 榊原純; 今野哲; 樋田京子, 日本肺癌学会学術集会号(CD-ROM), 64th, 2023
• ニボルマブ+イピリムマブ併用療法が著効し胸膜切除/肺剥皮術を施行できた上皮型胸膜中皮腫の1例
  佐藤祐麻; 古田恵; 高島雄太; 庄司哲明; 北井秀典; 池澤靖元; 榊原純; 加藤達哉; 大野桜子; 松野吉宏; 今野哲, 日本肺癌学会学術集会号(CD-ROM), 64th, 2023
• 進展型小細胞肺癌における初回治療での免疫チェックポイント阻害薬併用による2次治療への影響に関する検討
  森永有美; 北井秀典; 森永大亮; 田上敬太; 石田有莉子; 佐藤祐麻; 佐藤峰嘉; 高橋宏典; 庄司哲明; 古田恵; 高島雄太; 池澤靖元; 朝比奈肇; 菊地順子; 菊地英毅; 品川尚文; 榊原純; 今野哲, 日本肺癌学会学術集会号(CD-ROM), 64th, 2023
• 当科におけるAYA世代胸部悪性腫瘍患者に関する検討
  塩泡 亜衣; 榊原 純; 佐藤 峰嘉; 高橋 宏典; 國崎 守; 庄司 哲明; 古田 恵; 高島 雄太; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 菊地 英毅; 品川 尚文; 今野 哲, 肺癌, 59, 7, 1197, 1197, Dec. 2019
  (NPO)日本肺癌学会, Japanese
• 当科における免疫チェックポイント阻害薬長期使用例の検討
  伊藤 祥太郎; 朝比奈 肇; 水柿 秀紀; 菊地 英毅; 菊地 順子; 榊原 純; 品川 尚文; 今野 哲, 肺癌, 59, 7, 1199, 1199, Dec. 2019
  (NPO)日本肺癌学会, Japanese
• ロルラチニブ治療後にクリゾチニブ再投与が著効したALK融合遺伝子陽性肺腺癌の1例
  辻 康介; 榊原 純; 北井 秀典; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 菊地 英毅; 品川 尚文; 今野 哲; 池澤 靖元; 畑中 豊; 佐々木 高明; 吉田 遼平; 千葉 伸一; 松本 慎吾; 後藤 功一, 肺癌, 59, 7, 1200, 1200, Dec. 2019
  (NPO)日本肺癌学会, Japanese
• 当科におけるAYA世代胸部悪性腫瘍患者に関する検討
  塩泡 亜衣; 榊原 純; 佐藤 峰嘉; 高橋 宏典; 國崎 守; 庄司 哲明; 古田 恵; 高島 雄太; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 菊地 英毅; 品川 尚文; 今野 哲, 肺癌, 59, 6, 749, 749, Nov. 2019
  (NPO)日本肺癌学会, Japanese
• 当科における免疫チェックポイント阻害薬長期使用例の検討
  伊藤 祥太郎; 朝比奈 肇; 水柿 秀紀; 菊地 英毅; 菊地 順子; 榊原 純; 品川 尚文; 今野 哲, 肺癌, 59, 6, 772, 772, Nov. 2019
  (NPO)日本肺癌学会, Japanese
• 当科におけるデュルバルマブ使用症例の後方視的検討
  辻 康介; 水柿 秀紀; 猪狩 智生; 佐藤 峰嘉; 國崎 守; 高島 雄太; 古田 恵; 朝比奈 肇; 菊地 順子; 菊地 英毅; 榊原 純; 品川 尚文; 今野 哲, 肺癌, 59, 6, 776, 776, Nov. 2019
  (NPO)日本肺癌学会, Japanese
• シスプラチン耐性肺癌の治療標的としての免疫プロテアソームの検討
  庄司 哲明; 菊地 英毅; 菊地 順子; 前田 真希枝; 高島 雄太; 古田 恵; 高橋 宏典; 木下 一郎; 秋田 弘俊; 榊原 純; 今野 哲, 肺癌, 59, 6, 908, 908, Nov. 2019
  (NPO)日本肺癌学会, Japanese
• 気管支鏡検査におけるFFPE組織検体および細胞検体を用いたROS1融合遺伝子の検査成功率の検証
  辻 康介; 榊原 純; 北井 秀典; 猪狩 智生; 佐藤 峰嘉; 高橋 宏典; 國崎 守; 庄司 哲明; 高島 雄太; 古田 恵; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 菊地 英毅; 品川 尚文; 樋田 泰浩; 加賀 基知三; 大井 優子; 中條 聖子; 畑中 佳奈子; 畑中 豊; 松野 吉宏; 今野 哲, 気管支学, 41, 6, 678, 678, Nov. 2019
  (NPO)日本呼吸器内視鏡学会, Japanese
• 当科におけるクライオバイオプシーの使用経験
  國崎 守; 品川 尚文; 辻 康介; 佐藤 理子; 猪狩 智生; 佐藤 峰嘉; 高橋 宏典; 高島 雄太; 古田 恵; 庄司 哲明; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 今野 哲; 松野 吉宏, 気管支学, 41, 6, 678, 678, Nov. 2019
  (NPO)日本呼吸器内視鏡学会, Japanese
• 当科における非小細胞肺癌化学放射線療法後のデュルバルマブ使用症例の後方視的検討
  辻 康介; 水柿 秀紀; 猪狩 智生; 佐藤 峰嘉; 國崎 守; 北井 秀典; 朝比奈 肇; 菊地 順子; 菊地 英毅; 榊原 純; 品川 尚文, 日本サルコイドーシス/肉芽腫性疾患学会雑誌, 39, 1-2, 116, 116, Oct. 2019
  日本サルコイドーシス, Japanese
• シスプラチン耐性肺癌の治療標的としての免疫プロテアソームの検討(Analysis of immunoproteasome as a therapeutic target in cisplatin-resistant small and non-small cell lung cancer)
  庄司 哲明; 菊地 英毅; 菊地 順子; 高島 雄太; 古田 恵; 木下 一郎; 秋田 弘俊; 榊原 純, 日本癌学会総会記事, 78回, P, 1001, Sep. 2019
  日本癌学会, English
• 当院におけるBRAF遺伝子変異の検査成功率の検討
  山本 岳; 品川 尚文; 辻 康介; 猪狩 智生; 佐藤 峰嘉; 國崎 守; 高橋 宏典; 庄司 哲明; 高島 雄太; 古田 恵; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 菊地 順子; 木下 一郎; 秋田 弘俊; 畑中 豊; 松野 吉宏; 榊原 純, 気管支学, 41, Suppl., S221, S221, 01 Jun. 2019
  (NPO)日本呼吸器内視鏡学会, Japanese
• 気管支鏡検査におけるFFPE検体,細胞診検体を用いたROS1融合遺伝子の検査成功率の検証
  辻 康介; 榊原 純; 北井 秀典; 猪狩 智生; 佐藤 峰嘉; 高橋 宏典; 國崎 守; 庄司 哲明; 高島 雄太; 古田 恵; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 菊地 英毅; 大井 優子; 中條 聖子; 畑中 佳奈子; 畑中 豊; 松野 吉宏; 品川 尚文, 気管支学, 41, Suppl., S222, S222, 01 Jun. 2019
  (NPO)日本呼吸器内視鏡学会, Japanese
• 当科におけるクライオバイオプシーの使用経験
  國崎 守; 品川 尚文; 山本 岳; 辻 康介; 瀧本 理子; 猪狩 智生; 佐藤 峰嘉; 高橋 宏典; 高島 雄太; 古田 恵; 庄司 哲明; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純, 気管支学, 41, Suppl., S351, S351, 01 Jun. 2019
  (NPO)日本呼吸器内視鏡学会, Japanese
• 当院におけるBRAF遺伝子変異の検査成功率の検討
  山本 岳; 品川 尚文; 辻 康介; 猪狩 智生; 佐藤 峰嘉; 國崎 守; 高橋 宏典; 庄司 哲明; 高島 雄太; 古田 恵; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 菊地 順子; 木下 一郎; 秋田 弘俊; 畑中 豊; 松野 吉宏; 榊原 純, 気管支学, 41, Suppl., S221, S221, Jun. 2019
  (NPO)日本呼吸器内視鏡学会, Japanese
• 気管支鏡検査におけるFFPE検体,細胞診検体を用いたROS1融合遺伝子の検査成功率の検証
  辻 康介; 榊原 純; 北井 秀典; 猪狩 智生; 佐藤 峰嘉; 高橋 宏典; 國崎 守; 庄司 哲明; 高島 雄太; 古田 恵; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 菊地 英毅; 大井 優子; 中條 聖子; 畑中 佳奈子; 畑中 豊; 松野 吉宏; 品川 尚文, 気管支学, 41, Suppl., S222, S222, Jun. 2019
  (NPO)日本呼吸器内視鏡学会, Japanese
• 当科におけるクライオバイオプシーの使用経験
  國崎 守; 品川 尚文; 山本 岳; 辻 康介; 瀧本 理子; 猪狩 智生; 佐藤 峰嘉; 高橋 宏典; 高島 雄太; 古田 恵; 庄司 哲明; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純, 気管支学, 41, Suppl., S351, S351, Jun. 2019
  (NPO)日本呼吸器内視鏡学会, Japanese
• The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan.
  Kiyotaka Yoh; Shingo Matsumoto; Kei Kunimasa; Masahiro Kodani; Koichi Nishi; Taku Nakagawa; Shunichi Sugawara; Tomohiro Kato; Jun Sakakibara-Konishi; Yuichiro Hayashi; Koji Tsuta; Noriko Motoi; Genichiro Ishii; Koichi Goto, JOURNAL OF CLINICAL ONCOLOGY, 37, 15, May 2019
  English, Summary international conference
• 小細胞肺癌切除検体におけるDLL3,ASCL1に関する検討(HOT1702)
  峯村 浩之; 古田 恵; 榊原 純; 菊池 創; 横内 浩; 西原 広史; 原田 眞雄; 山崎 成夫; 秋江 研志; 藤田 結花; 高村 圭; 小島 哲弥; 原田 敏之; 南 幸範; 渡部 直己; 大泉 聡史; 鈴木 弘行; 西村 正治; 秋田 弘俊; 磯部 宏, 日本呼吸器学会誌, 8, 増刊, 209, 209, 10 Mar. 2019
  (一社)日本呼吸器学会, Japanese
• 炎症性筋線維芽細胞性腫瘍に対しステロイド治療で長期の病勢コントロールが得られた1例
  國崎 守; 朝比奈 肇; 水柿 秀紀; 菊地 英毅; 榊原 純; 品川 尚文; 清水 亜衣; 松野 吉宏; 樋田 泰浩; 加賀 基知三; 中井 正人; 菅原 恵理; 西原 広史, 肺癌, 59, 1, 109, 109, Feb. 2019
  (NPO)日本肺癌学会, Japanese
• 非小細胞肺癌におけるHER2異常の前向き観察研究(HOT1303-A)
  合田 智宏; 木下 一郎; 秋田 弘俊; 大泉 聡史; 横内 浩; 中野 浩輔; 原田 敏之; 河井 康孝; 榊原 純; 森川 直人; 山田 範幸; 山崎 成夫; 菅原 俊一; 朝比奈 肇; 品川 尚文; 磯部 宏; 天野 虎次; 畑中 豊; 松野 吉宏; 西原 広史, 肺癌, 59, 1, 113, 113, Feb. 2019
  (NPO)日本肺癌学会, Japanese
• 手掌筋転移に対して放射線照射後に免疫チェックポイント阻害薬が著効した1例
  高橋 宏典; 水柿 秀紀; 國崎 守; 高島 雄太; 古田 恵; 庄司 哲明; 佐々木 真知子; 北井 秀典; 朝比奈 肇; 菊地 順子; 菊地 英毅; 榊原 純; 品川 尚文, 肺癌, 59, 1, 112, 112, Feb. 2019
  (NPO)日本肺癌学会, Japanese
• 脳転移を伴う非小細胞肺癌に対する免疫チェックポイント阻害剤投与例の後方視的検討
  佐藤 峰嘉; 朝比奈 肇; 高橋 宏典; 國崎 守; 古田 恵; 庄司 哲明; 高島 雄太; 佐々木 真知子; 北井 秀典; 水柿 秀紀; 菊地 英毅; 菊地 順子; 榊原 純; 品川 尚文, 肺癌, 59, 1, 112, 113, Feb. 2019
  (NPO)日本肺癌学会, Japanese
• 当院におけるFFPE検体、細胞診検体を用いたROS1融合遺伝子の検査成功率の検証
  北井 秀典; 榊原 純; 高橋 宏典; 國崎 守; 庄司 哲明; 高島 雄太; 古田 恵; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 品川 尚文; 畑中 佳奈子; 畑中 豊; 松野 吉宏; 大井 優子, 肺癌, 59, 1, 112, 112, Feb. 2019
  (NPO)日本肺癌学会, Japanese
• 脳転移を伴う非小細胞肺癌に対する免疫チェックポイント阻害剤投与例の後方視的検討
  佐藤 峰嘉; 朝比奈 肇; 高橋 宏典; 國崎 守; 古田 恵; 庄司 哲明; 高島 雄太; 佐々木 真知子; 北井 秀典; 水柿 秀紀; 菊地 英毅; 菊地 順子; 榊原 純; 品川 尚文, 肺癌, 59, 1, 112, 113, Feb. 2019
  (NPO)日本肺癌学会, Japanese
• DirectPath ver2.0における肺血管抽出機能の有用性の検討
  國崎 守; 品川 尚文; 高橋 宏典; 高島 雄太; 古田 恵; 庄司 哲明; 北井 秀典; 佐々木 真知子; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純, 気管支学, 41, 1, 90, 90, 25 Jan. 2019
  (NPO)日本呼吸器内視鏡学会, Japanese
• 気管支鏡下生検検体におけるPD-L1発現評価の後ろ向き検討
  高橋 宏典; 品川 尚文; 畑中 豊; 國崎 守; 古田 恵; 高島 雄太; 庄司 哲明; 北井 秀典; 菊池 創; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 菊地 英毅; 松野 吉宏; 榊原 純, 気管支学, 41, 1, 91, 91, 25 Jan. 2019
  (NPO)日本呼吸器内視鏡学会, Japanese
• Successful Treatment of Gefitinib Administration Through a Nasogastric Tube in a Patient with EGFR Mutation-positive Lung Adenocarcinoma Associated with Tracheoesophageal Fistula
  Furuta Megumi; Nishimura Masaharu; Sakakibara Jun; Ogi Takahiro; Abe Tomoe; Kitai Hidenori; Shimizu Kaoruko; Asahina Hajime; Shinagawa Naofumi; Oizumi Satoshi, The Journal of the Japan Society for Respiratory Endoscopy, 41, 1, 55, 60, 25 Jan. 2019
  <p><b><i>Background.</i></b> Gefitinib has been reported to be effective for patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (<i>EGFR</i>) mutations even with poor performance status (PS). Here, we report a case of successful treatment of gefitinib administration through a nasogastric tube in a patient with <i>EGFR</i> mutation-positive lung adenocarcinoma associated with bronchoesophageal fistula. <b><i>Case.</i></b> A 69-year-old woman complained of dyspnea and was admitted to an emergency hospital. Imaging tests revealed tracheal stenosis caused by mediastinal lymph node enlargement. She was transferred to our hospital under mechanical ventilation because of progressive severe hypoxia. Although tracheal stenosis improved by central necrosis of mediastinal lymph node metastasis on admission, tracheoesophageal fistula was observed. She was diagnosed with primary lung adenocarcinoma (cT4N2M1a, stage IV) and the <i>EGFR</i> mutation exon 19 deletion was detected. Because it was impossible to administer tracheoesophageal fistula orally, gefitinib was administered through a nasogastric tube. The fistula was closed three weeks after gefitinib administration and the tumor decreased in size, which resulted in improvement in PS. <b><i>Conclusion.</i></b> Gefitinib administration through a nasogastric tube is useful for patients that are positive for <i>EGFR</i> mutations with tracheoesophageal fistula and poor PS. </p>, 特定非営利活動法人 日本呼吸器内視鏡学会, Japanese
• ロルラチニブ治療後にクリゾチニブ再投与が著効したALK融合遺伝子陽性肺腺癌の1例
  辻康介; 榊原純; 北井秀典; 水柿秀紀; 朝比奈肇; 菊地順子; 菊地英毅; 品川尚文; 今野哲; 池澤靖元; 畑中豊; 佐々木高明; 吉田遼平; 千葉伸一; 松本慎吾; 後藤功一, 肺癌(Web), 59, 7, 2019
• 気管支鏡下生検検体におけるPD-L1発現評価の後ろ向き検討
  高橋 宏典; 品川 尚文; 畑中 豊; 國崎 守; 古田 恵; 高島 雄太; 庄司 哲明; 北井 秀典; 菊池 創; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 菊地 英毅; 松野 吉宏; 榊原 純, 気管支学, 41, 1, 91, 91, Jan. 2019
  (NPO)日本呼吸器内視鏡学会, Japanese
• 小細胞肺癌切除検体におけるDLL3,ASCL1に関する検討
  古田恵; 古田恵; 榊原純; 榊原純; 菊池創; 横内浩; 西原広史; 峯村浩之; 原田眞雄; 山崎成夫; 秋江研志; 藤田結花; 高村圭; 小島哲弥; 原田敏之; 南幸範; 渡部直己; 大泉聡史; 鈴木弘行; 西村正治, 日本肺癌学会総会号, 59th, 513, 25 Oct. 2018
  Japanese
• 脳転移を伴う非小細胞肺癌に対する免疫チェックポイント阻害剤投与例の後方視的検討
  佐藤峰嘉; 朝比奈肇; 高橋宏典; 國崎守; 古田恵; 庄司哲明; 高島雄太; 佐々木真知子; 北井秀典; 水柿秀紀; 菊地英毅; 菊地順子; 榊原純; 品川尚文, 日本肺癌学会総会号, 59th, 639, 25 Oct. 2018
  Japanese
• 当科における免疫チェックポイント阻害剤治療の現状
  高橋宏典; 水柿秀紀; 國崎守; 高島雄太; 古田恵; 庄司哲明; 佐々木真知子; 北井秀典; 朝比奈肇; 菊地順子; 菊地英毅; 榊原純; 品川尚文, 日本肺癌学会総会号, 59th, 644, 25 Oct. 2018
  Japanese
• 当院におけるFFPE検体,細胞診検体を用いたROS1融合遺伝子の検査成功率の検証
  北井秀典; 榊原純; 高橋宏典; 國崎守; 庄司哲明; 高島雄太; 古田恵; 水柿秀紀; 朝比奈肇; 菊地英毅; 大井優子; 畑中佳奈子; 畑中豊; 松野吉宏; 品川尚文, 日本肺癌学会総会号, 59th, 584, 25 Oct. 2018
  Japanese
• 非小細胞肺癌に対するBET阻害剤とWEE1阻害剤AZD1775の併用効果及びその機序に関する研究
  高島雄太; 菊地英毅; 菊地順子; 庄司哲明; 古田恵; 品川尚文; 木下一郎; 秋田弘俊; 榊原純, 日本肺癌学会総会号, 59th, 577, 25 Oct. 2018
  Japanese
• 炎症性筋線維芽細胞性腫瘍に対しステロイド治療で長期の病勢コントロールが得られた一例
  國崎守; 朝比奈肇; 朝比奈肇; 水柿秀紀; 菊地英毅; 榊原純; 清水亜衣; 松野吉宏; 樋田泰浩; 加賀基知三; 中井正人; 菅原恵理; 西原広史; 品川尚文, 日本肺癌学会総会号, 59th, 6, 733, 733, 25 Oct. 2018
  (NPO)日本肺癌学会, Japanese
• NSCLCにおけるHER2異常の前向き観察研究(HOT1303-A)
  横内 浩; 木下 一郎; 合田 智宏; 大泉 聡史; 中野 浩輔; 原田 敏之; 河井 康孝; 榊原 純; 森川 直人; 山田 範幸; 山崎 成夫; 菅原 俊一; 朝比奈 肇; 天野 虎次; 畑中 豊; 松野 吉宏; 西原 広史; 磯部 宏; 西村 正治; 秋田 弘俊; 北海道肺癌臨床研究会(HOT), 肺癌, 58, 6, 511, 511, Oct. 2018
  (NPO)日本肺癌学会, Japanese
• T790M検索を目的とした組織再生検及び血漿検査の後方視的検討
  猪狩 智生; 北井 秀典; 高橋 宏典; 國崎 守; 庄司 哲明; 古田 恵; 高島 雄太; 佐々木 真知子; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 畑中 豊; 松野 吉宏; 品川 尚文, 肺癌, 58, 6, 635, 635, Oct. 2018
  (NPO)日本肺癌学会, Japanese
• BET阻害剤は非小細胞肺癌に対して非相同末端結合機構を抑制しDNA損傷を増強することでWEE1阻害剤との相乗効果をもたらす(BET inhibitors synergize with WEE1 inhibitor by impairing nonhomologous end joining and enhancing DNA damages in NSCLC)
  高島 雄太; 菊地 英毅; 菊地 順子; 庄司 哲明; 古田 恵; 木下 一郎; 秋田 弘俊; 榊原 純, 日本癌学会総会記事, 77回, 1561, 1561, Sep. 2018
  日本癌学会, English
• 小細胞肺癌の遊走能・浸潤能におけるDLL3の機能解析(DLL3 regulates migration and invasion of small cell lung cancer)
  古田 恵; 榊原 純; 庄司 哲明; 高島 雄太; 菊池 創; 菊地 英毅; 菊地 順子; 木下 一郎; 秋田 弘俊, 日本癌学会総会記事, 77回, 2457, 2457, Sep. 2018
  日本癌学会, English
• 気管支鏡下生検検体におけるPD-L1発現評価の後ろ向き検討
  高橋 宏典; 品川 尚文; 畑中 豊; 國崎 守; 庄司 哲明; 高島 雄太; 古田 恵; 菊池 創; 北井 秀典; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 松野 吉宏; 西村 正治, 気管支学, 40, Suppl., S241, S241, May 2018
  (NPO)日本呼吸器内視鏡学会, Japanese
• 気管支鏡下生検検体におけるPD‐LI発現評価の後ろ向き検討
  高橋宏典; 品川尚文; 畑中豊; 畑中豊; 國崎守; 庄司哲明; 高島雄太; 古田恵; 菊池創; 北井秀典; 水柿秀紀; 朝比奈肇; 菊地英毅; 菊地順子; 榊原純; 松野吉宏; 西村正治, 気管支学, 40, S241, 01 May 2018
  Japanese
• DirectPath ver2.0における肺血管抽出機能の有用性の検討
  國崎守; 品川尚文; 高橋宏典; 高島雄太; 古田恵; 庄司哲明; 北井秀典; 佐々木真知子; 菊池創; 水柿秀紀; 朝比奈肇; 菊地英毅; 菊地順子; 榊原純; 西村正治, 気管支学, 40, Suppl., S252, S252, 01 May 2018
  (NPO)日本呼吸器内視鏡学会, Japanese
• A Clinical Analysis of 10 Cases with Oligometastases of Non-small Cell Carcinoma
  國崎守; 榊原純; 菊池創; 北井秀典; 水柿秀紀; 朝比奈肇; 菊地英毅; 品川尚文; 西村正治, 肺癌(Web), 58, 7, 959‐963(J‐STAGE), 2018
  Japanese
• DirectPathにおける肺血管抽出機能の有用性の検討
  國崎 守; 品川 尚文; 高島 雄太; 古田 恵; 庄司 哲明; 佐々木 真知子; 菊池 創; 池澤 靖元; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 西村 正治, 気管支学, 40, 1, 68, 68, Jan. 2018
  (NPO)日本呼吸器内視鏡学会, Japanese
• 当科におけるEGFR遺伝子変異陽性非小細胞肺癌の再生検の検討
  佐々木 真知子; 品川 尚文; 國崎 守; 庄司 哲明; 高島 雄太; 古田 恵; 菊池 創; 北井 秀典; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 西村 正治, 気管支学, 40, 1, 68, 68, Jan. 2018
  (NPO)日本呼吸器内視鏡学会, Japanese
• 超音波気管支鏡ガイド下針生検用の新しい吸引生検針の使用経験
  高橋 宏典; 品川 尚文; 阿部 結希; 小熊 昂; 國崎 守; 古田 恵; 高島 雄太; 庄司 哲明; 佐々木 真知子; 北井 秀典; 菊池 創; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 西村 正治, 気管支学, 40, 1, 69, 69, Jan. 2018
  (NPO)日本呼吸器内視鏡学会, Japanese
• 化学療法による腫瘍縮小後にエドキサバンが奏功した肺癌合併静脈血栓塞栓症の1例
  庄司 哲明; 水柿 秀紀; 池澤 靖元; 古田 恵; 高島 雄太; 菊池 創; Goudarzi Houman; 朝比奈 肇; 菊地 順子; 菊地 英毅; 榊原 純; 品川 尚文; 辻野 一三; 西村 正治, 肺癌, 57, 7, 914, 914, Dec. 2017
  (NPO)日本肺癌学会, Japanese
• 当科における非小細胞肺癌Oligometastases 10例についての後方視的検討
  國崎 守; 榊原 純; 佐々木 真知子; 池澤 靖元; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 菊地 順子; 品川 尚文; 西村 正治, 肺癌, 57, 7, 914, 915, Dec. 2017
  (NPO)日本肺癌学会, Japanese
• ニボルマブ投与後に間質性腎炎を発症した膜性腎症合併肺癌の1例
  佐々木 真知子; 水柿 秀紀; 高橋 宏典; 國崎 守; 庄司 哲明; 高島 雄太; 古田 恵; 菊池 創; 北井 秀典; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 品川 尚文; 西村 正治; 近藤 桂一; 深澤 雄一郎, 肺癌, 57, 7, 916, 916, Dec. 2017
  (NPO)日本肺癌学会, Japanese
• 血漿中にEGFR T790M遺伝子変異を認め、オシメルチニブ治療にmixed responseを示したEGFR遺伝子変異陽性非小細胞肺癌の1例
  小田 義崇; 國崎 守; 菊地 英毅; 阿部 結希; 小熊 昂; 高橋 宏典; 佐々木 真知子; 北井 秀典; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 榊原 純; 品川 尚文; 西村 正治, 肺癌, 57, 7, 916, 917, Dec. 2017
  (NPO)日本肺癌学会, Japanese
• 当科における非小細胞肺癌Oligometastases 10例についての後方視的検討
  國崎守; 榊原純; 佐々木真知子; 池澤靖元; 水柿秀紀; 朝比奈肇; 菊地英毅; 菊池順子; 品川尚文; 西村正治, 日本肺癌学会総会号, 58th, 5, 413, 413, 05 Sep. 2017
  (NPO)日本肺癌学会, Japanese
• 当科におけるNivolumab投与症例の後治療に関する検討
  澤岡亜衣; 朝比奈肇; 國崎守; 佐々木真知子; 池澤靖元; 水柿秀紀; 菊地英毅; 菊地順子; 榊原純; 品川尚文; 西村正治, 日本肺癌学会総会号, 58th, 5, 609, 609, 05 Sep. 2017
  (NPO)日本肺癌学会, Japanese
• 原発性肺扁平上皮癌におけるPD-L1とNT5E(CD73)の発現と予後に関する検討
  桑原 健; 畑中 豊; 畑中 佳奈子; 清水 知浩; 岡田 宏美; 加賀 基知三; 樋田 泰浩; 秋田 弘俊; 榊原 純; 外丸 詩野; 松野 吉宏, 日本癌学会総会記事, 76回, P, 3259, Sep. 2017
  日本癌学会, English
• EGFR-TKI初期耐性非小細胞肺癌の臨床病理学的特徴及び免疫微小環境に関する検討
  高島 雄太; 榊原 純; 畑中 豊; 畑中 佳奈子; 大原 克仁; 大泉 聡史; 樋田 泰浩; 加賀 基知三; 木下 一郎; 秋田 弘俊; 松野 吉宏; 西村 正治, 日本癌学会総会記事, 76回, P, 3264, Sep. 2017
  日本癌学会, English
• 原発性肺扁平上皮癌におけるPD-L1とNT5E(CD73)の発現と予後に関する検討
  桑原 健; 畑中 豊; 畑中 佳奈子; 清水 知浩; 岡田 宏美; 加賀 基知三; 樋田 泰浩; 秋田 弘俊; 榊原 純; 外丸 詩野; 松野 吉宏, 日本癌学会総会記事, 76回, P, 3259, Sep. 2017
  日本癌学会, English
• EGFR-TKI初期耐性非小細胞肺癌の臨床病理学的特徴及び免疫微小環境に関する検討
  高島 雄太; 榊原 純; 畑中 豊; 畑中 佳奈子; 大原 克仁; 大泉 聡史; 樋田 泰浩; 加賀 基知三; 木下 一郎; 秋田 弘俊; 松野 吉宏; 西村 正治, 日本癌学会総会記事, 76回, P, 3264, Sep. 2017
  日本癌学会, English
• 肺がん,頭頸部がん 非小細胞肺がんに対する複合免疫療法の可能性
  榊原純; 大泉聡史, 月刊腫瘍内科, 19, 5, 543‐548, 548, 28 May 2017
  (有)科学評論社, Japanese
• Strategy of combining conventional and targeted therapy with immunotherapy in non-small cell lung cancer
  榊原 純; 大泉 聡史, 腫瘍内科 = Clinical oncology, 19, 5, 543, 548, May 2017
  科学評論社, Japanese
• 全身麻酔下での中枢性気道病変に対する軟性気管支鏡によるインターベンションの検討
  池澤靖元; 品川尚文; 國崎守; 庄司哲明; 高島雄太; 古田恵; 佐々木真知子; 菊池創; 水柿秀紀; 朝比奈肇; 菊地英毅; 菊地順子; 榊原純; 西村正治, 気管支学, 39, Suppl., S269, S269, 01 May 2017
  (NPO)日本呼吸器内視鏡学会, Japanese
• 当科におけるEGFR遺伝子変異陽性非小細胞肺癌の再生検の検討
  佐々木真知子; 品川尚文; 池澤靖元; 國崎守; 庄司哲明; 古田恵; 高島雄太; 菊池創; 水柿秀紀; 朝比奈肇; 菊地順子; 菊地英毅; 榊原純; 西村正治, 気管支学, 39, Suppl., S237, S237, 01 May 2017
  (NPO)日本呼吸器内視鏡学会, Japanese
• DirectPathにおける肺血管抽出機能の有用性の検討
  國崎守; 品川尚文; 高島雄太; 古田恵; 庄司哲明; 佐々木真知子; 菊池創; 池澤靖元; 水柿秀紀; 朝比奈肇; 菊地英毅; 菊地順子; 榊原純; 西村正治, 気管支学, 39, Suppl., S414, S414, 01 May 2017
  (NPO)日本呼吸器内視鏡学会, Japanese
• 当科におけるカルボプラチンとアルブミン懸濁型パクリタキセル併用療法の後方視的検討
  庄司 哲明; 水柿 秀紀; 國崎 守; 佐々木 真知子; 菊池 創; 池澤 靖元; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 品川 尚文; 西村 正治, 肺癌, 57, 1, 46, 47, Feb. 2017
  (NPO)日本肺癌学会, Japanese
• 癌性胸膜炎に対するタルクによる胸膜癒着術の検討
  國崎 守; 池澤 靖元; 水柿 秀紀; 庄司 哲明; 佐々木 真知子; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 品川 尚文; 西村 正治, 肺癌, 57, 1, 48, 49, Feb. 2017
  (NPO)日本肺癌学会, Japanese
• 当科におけるアファチニブ使用症例の後方視的検討
  佐々木 真知子; 水柿 秀紀; 池澤 靖元; 國崎 守; 庄司 孝明; 高島 雄太; 古田 恵; 菊池 創; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 品川 尚文; 西村 正治, 肺癌, 57, 1, 49, 49, Feb. 2017
  (NPO)日本肺癌学会, Japanese
• 抗血小板薬・抗凝固薬内服患者における気管支鏡下生検の合併症の検討
  庄司哲明; 品川尚文; 高島雄太; 古田恵; 菊池創; 池澤靖元; 高階太一; 水柿秀紀; 朝比奈肇; 菊地英毅; 菊地順子; 榊原純; 大泉聡史; 西村正治, 気管支学, 39, 1, 88, 88, 25 Jan. 2017
  (NPO)日本呼吸器内視鏡学会, Japanese
• GGO病変に対するDirectPathの使用成績の検討
  池澤靖元; 品川尚文; 松本宗大; 國崎守; 庄司哲明; 高島雄太; 古田恵; 菊池創; 佐々木真知子; 水柿秀紀; 朝比奈肇; 菊地英毅; 菊地順子; 榊原純; 西村正治, 気管支学, 39, 1, 87, 87, 25 Jan. 2017
  (NPO)日本呼吸器内視鏡学会, Japanese
• 血漿中にEGFR T790M遺伝子変異を認め,オシメルチニブ治療にmixed rosponseを示したEGFR遺伝子変異陽性非小細胞肺癌の1例
  小田義崇; 國崎守; 菊地英毅; 阿部結希; 小熊昂; 高橋宏典; 佐々木真知子; 北井秀典; 水柿秀紀; 朝比奈肇; 菊地順子; 榊原純; 品川尚文; 西村正治, 肺癌(Web), 57, 7, 916‐917(J‐STAGE), 2017
  Japanese
• 当科におけるアファチニブ使用症例の後方視的検討
  佐々木真知子; 水柿秀紀; 池澤靖元; 國崎守; 庄司孝明; 高島雄太; 古田恵; 菊池創; 朝比奈肇; 菊地英毅; 菊地順子; 榊原純; 品川尚文; 西村正治, 肺癌(Web), 57, 1, 49(J‐STAGE), 2017
  Japanese
• 癌性胸膜炎に対するタルクによる胸膜癒着術の検討
  國崎守; 池澤靖元; 水柿秀紀; 庄司哲明; 佐々木真知子; 朝比奈肇; 菊地英毅; 菊地順子; 榊原純; 品川尚文; 西村正治, 肺癌(Web), 57, 1, 48‐49(J‐STAGE), 2017
  Japanese
• 当科における非小細胞肺癌Oligometastases 10例についての後方視的検尉
  國崎守; 榊原純; 佐々木真知子; 池澤靖元; 水柿秀紀; 朝比奈肇; 菊地英毅; 菊地順子; 品川尚文; 西村正治, 肺癌(Web), 57, 7, 914‐915(J‐STAGE), 2017
  Japanese
• 当科におけるカルボプラチンとアルブミン懸濁型パクリタキセル併用療法の後方視的検討
  庄司哲明; 水柿秀紀; 國崎守; 佐々木真知子; 菊池創; 池澤靖元; 朝比奈肇; 菊地英毅; 菊地順子; 榊原純; 品川尚文; 西村正治, 肺癌(Web), 57, 1, 46‐47(J‐STAGE), 2017
  Japanese
• 化学療法による腫瘍縮小後にエドキサバンが奏功した肺癌合併静脈血栓塞栓症の1例
  庄司哲明; 水柿秀紀; 池澤靖元; 古田恵; 高島雄太; 菊池創; GOUDARZI Houman; 朝比奈肇; 菊地順子; 菊地英毅; 榊原純; 品川尚文; 辻野一三; 西村正治, 肺癌(Web), 57, 7, 914(J‐STAGE), 2017
  Japanese
• ニボルマブ投与後に間質性腎炎を発症した膜性腎症合併肺癌の1例
  佐々木真知子; 水柿秀紀; 高橋宏典; 國崎守; 庄司哲明; 高島雄太; 古田恵; 菊池創; 北井秀典; 朝比奈肇; 菊地英毅; 菊地順子; 榊原純; 品川尚文; 西村正治; 近藤桂一; 深澤雄一郎, 肺癌(Web), 57, 7, 916(J‐STAGE), 2017
  Japanese
• 当科におけるアファチニブ使用症例の後方視的検討
  佐々木真知子; 水柿秀紀; 池澤靖元; 松本宗大; 國崎守; 庄司哲明; 高島雄太; 森本恵; 菊池創; 朝比奈肇; 菊地英毅; 菊地順子; 榊原純; 品川尚文; 西村正治, 日本肺癌学会総会号, 57th, 6, 659, 659, 05 Nov. 2016
  (NPO)日本肺癌学会, Japanese
• 当科におけるカルボプラチンとアルブミン懸濁型パクリタキセル併用療法の後方視的検討
  庄司哲明; 水柿秀紀; 國崎守; 佐々木真知子; 菊池創; 池澤靖元; 朝比奈肇; 菊地英毅; 菊地順子; 榊原純; 品川尚文; 西村正治, 日本肺癌学会総会号, 57th, 6, 699, 699, 05 Nov. 2016
  (NPO)日本肺癌学会, Japanese
• 癌性胸膜炎に対するタルクによる胸膜癒着術の検討
  國崎守; 池澤靖元; 水柿秀紀; 庄司哲明; 佐々木真知子; 朝比奈肇; 菊地英毅; 菊地順子; 榊原純; 品川尚文; 西村正治, 日本肺癌学会総会号, 57th, 6, 575, 575, 05 Nov. 2016
  (NPO)日本肺癌学会, Japanese
• 小細胞肺癌におけるNotch1,Numbに関する検討
  菊池創; 菊池創; 榊原純; 榊原純; 横内浩; 西原広史; 浦本秀隆; 原田眞雄; 山崎成夫; 秋江研志; 菅谷文子; 藤田結花; 荻喬博; 小島哲弥; 原田敏之; 樋口光徳; 本庄統; 南幸範; 渡部直己; 鈴木弘行; 棟方充; 西村正治; 西村正治, 日本肺癌学会総会号, 56, 6, 678, 678, Nov. 2016
  (NPO)日本肺癌学会, Japanese
• 非小細胞肺癌におけるNotch1、Numbの発現
  菊池 創; 榊原 純; 森本 恵; 池澤 靖元; 水柿 秀紀; 菊地 英毅; 菊地 順子; 大泉 聡史; 樋田 泰浩; 加賀 基知三; 木下 一郎; 秋田 弘俊; 西村 正治, 日本癌学会総会記事, 75回, J, 1062, Oct. 2016
  日本癌学会, English
• Expression of notch1, numb, and musashi1 in non-small cell lung cancer
  Hajime Kikuchi; Jun Sakakibara-Konishi; Yasuyuki Lkezawa; Taichi Takashina; Hidenori Mizugaki; Eiki Kikuchi; Junko Kikuchi; Naofumi Shinagawa; Satoshi Oizumi; Yasuhiro Hida; Kichizo Kaga; Lchiro Kinoshita; Hirotoshi Dosaka-Akita; Masaharu Nishimura, CANCER RESEARCH, 76, Jul. 2016
  English, Summary international conference
• 肺末梢GGO病変に対するDirectPathの使用成績の検討
  池澤靖元; 品川尚文; 庄司哲明; 高島雄太; 森本恵; 菊池創; 高階太一; 水柿秀紀; 菊地英毅; 榊原純; 大泉聡史; 西村正治, 気管支学, 38, Suppl., S236, S236, 01 May 2016
  (NPO)日本呼吸器内視鏡学会, Japanese
• 非小細胞肺癌術後補助化学療法(プラチナ+GEM)の無作為化II相試験:HOT0703
  榊原純; 榊原純; 福元伸一; 原田眞雄; 中野浩輔; 高村圭; 小島哲弥; 藤田結花; 原田敏之; 大泉聡史; 大泉聡史; 磯部宏; 西村正治; 西村正治, 日本呼吸器学会誌, 5, 増刊, 174, 174, 10 Mar. 2016
  (一社)日本呼吸器学会, Japanese
• 特発性気管狭窄症の1例
  菊池創; 品川尚文; 松本宗大; 庄司哲明; 高島雄太; 森本恵; 池澤靖元; 高階太一; 水柿秀紀; 菊地英毅; 菊地順子; 榊原純; 大泉聡史; 西村正治, 気管支学, 38, 1, 55, 55, 25 Jan. 2016
  (NPO)日本呼吸器内視鏡学会, Japanese
• 肺末梢病変に対するDirectPathの有用性の検討
  池澤靖元; 品川尚文; 庄司哲明; 高島雄太; 森本恵; 高階太一; 水柿秀紀; 菊地順子; 菊地英毅; 榊原純; 大泉聡史; 西村正治, 気管支学, 38, 1, 54, 54, 25 Jan. 2016
  (NPO)日本呼吸器内視鏡学会, Japanese
• Bf‐NAVIとDirectPathにおける気管支自動抽出能の比較
  高島雄太; 品川尚文; 森本恵; 菊池創; 池澤靖元; 高階太一; 水柿秀紀; 菊地順子; 菊地英毅; 榊原純; 大泉聡史; 西村正治, 気管支学, 38, 1, 54, 54, 25 Jan. 2016
  (NPO)日本呼吸器内視鏡学会, Japanese
• 静脈血栓塞栓症合併肺癌患者に対する経口FXa阻害剤エドキサバン使用に関する後方視的検討
  森本恵; 榊原純; 庄司哲明; 高島雄太; 菊池創; 池澤靖元; 高階太一; 水柿秀紀; 菊地英毅; 菊地順子; 品川尚文; 大泉聡史; 西村正治, 肺癌(Web), 55, 7, 1109(J‐STAGE), 1109, Dec. 2015
  (NPO)日本肺癌学会, Japanese
• 指尖転移を来たした肺扁平上皮癌の1例
  池澤靖元; 水柿秀紀; 庄司哲明; 高島雄太; 森本恵; 高階太一; 菊地英毅; 菊地順子; 榊原純; 品川尚文; 大泉聡史; 西村正治; 岡田宏美; 松野吉宏; 七戸龍司, 肺癌(Web), 55, 7, 1108(J‐STAGE), 1108, Dec. 2015
  (NPO)日本肺癌学会, Japanese
• 当科におけるcrizotinib既治療EML4‐ALK融合遺伝子陽性肺癌に対するalectinibの治療経験
  高島雄太; 庄司哲明; 森本恵; 菊池創; 池澤靖元; 高階太一; 水柿秀紀; 菊地英毅; 菊地順子; 榊原純; 品川尚文; 大泉聡史; 西村正治, 肺癌(Web), 55, 7, 1109(J‐STAGE), 1109, Dec. 2015
  (NPO)日本肺癌学会, Japanese
• An analysis of anticoagulation treatment for cancer patients with newly diagnosed VTE
  Yasuyuki Ikezawa; Jun Sakakibara; Tetsuaki Shoji; Yuta Takashima; Megumi Morimoto; Hajime Kikuchi; Taichi Takashina; Satoshi Oizumi; Ichizo Tsujino; Masaharu Nishimura, Japanese Journal of Lung Cancer, 55, 6, 1001, 1007, 20 Oct. 2015
  Japan Lung Cancer Society, Japanese, Book review
• 静脈血栓塞栓症合併肺癌患者に対する経口FXa阻害剤エドキサバン使用に関する検討
  森本恵; 榊原純; 庄司哲明; 高島雄太; 菊池創; 池澤靖元; 高階太一; 水柿秀紀; 菊地英毅; 菊地順子; 品川尚文; 大泉聡史; 西村正治, 日本肺癌学会総会号, 56th, 5, 530, 530, 05 Oct. 2015
  (NPO)日本肺癌学会, Japanese
• 非小細胞肺癌術後補助化学療法(platinum+GEM)の無作為化第II相試験:HOT0703
  藤田結花; 福元伸一; 原田眞雄; 藤内智; 藤兼俊明; 中野浩輔; 須甲憲明; 榊原純; 高村圭; 原田敏之; 小島哲弥; 秋江研志; 大泉聡史; 秋田弘俊; 磯部宏; 西村正治, 国立病院総合医学会抄録集(CD-ROM), 69th, ROMBUNNO.O-47-1, 47, Oct. 2015
  国立病院総合医学会, Japanese
• ヒト非小細胞肺癌(NSCLC)におけるNumbに関する研究
  菊池創; 榊原純; 池澤靖元; 高階太一; 水柿秀紀; 菊地英毅; 菊地順子; 品川尚文; 大泉聡史; 樋田泰浩; 加賀基知三; 木下一郎; 秋田弘俊; 西村正治, 日本肺癌学会総会号, 55, 5, 469, 469, Oct. 2015
  (NPO)日本肺癌学会, Japanese
• 肺 肺がん集学的治療の展望 非小細胞肺癌に対する術後補助化学療法(platinum+GEM)の無作為化第II相試験:HOT0703
  荻 喬博; 高村 圭; 福元 伸一; 原田 眞雄; 中野 浩輔; 須甲 憲明; 榊原 純; 伊藤 健一郎; 小島 哲弥; 藤田 結花; 原田 敏之; 秋江 研志; 大泉 聡; 磯部 宏; 西村 正治; 北海道肺癌臨床研究会; HOT, 日本癌治療学会誌, 50, 3, 1345, 1345, Sep. 2015
  (一社)日本癌治療学会, Japanese
• Bf‐NAVIとDirectPathにおける気管支自動抽出能の比較
  高島雄太; 品川尚文; 森本恵; 菊池創; 池澤靖元; 高階太一; 水柿秀紀; 菊地英毅; 菊地順子; 榊原純; 大泉聡史; 西村正治, 気管支学, 37, Suppl., S169, S169, 01 May 2015
  (NPO)日本呼吸器内視鏡学会, Japanese
• 肺末梢病変に対するDirectPathの有用性の検討
  池澤靖元; 品川尚文; 高島雄太; 森本恵; 菊池創; 高階太一; 水柿秀紀; 菊地順子; 菊地英毅; 榊原純; 大泉聡史; 西村正治, 気管支学, 37, Suppl., S170, S170, 01 May 2015
  (NPO)日本呼吸器内視鏡学会, Japanese
• Clinical analysis of 27 patients with malignant pleural mesothelioma treated at our institution
  Hajime Kikuchi; Hajime Asahina; Jun Sakakibara-Konishi; Naofumi Shinagawa; Satoshi Oizumi; Yasuhiro Hida; Kichizo Kaga; Tetsuya Inoue; Norio Katoh; Masaharu Nishimura, Japanese Journal of Lung Cancer, 55, 1, 2, 8, 20 Feb. 2015
  The Japan Lung Cancer Society, Japanese
• 肺小細胞癌治療後に発症した抗CV2抗体陽性脊髄症の1例
  佐藤智香; 長沼亮滋; 中野史人; 加納崇裕; 佐藤和則; 廣谷真; 矢部一郎; 榊原純; 大泉聡史; 佐々木秀直, 臨床神経学(Web), 55, 2, 132(J‐STAGE), 132, Feb. 2015
  (一社)日本神経学会, Japanese
• 非小細胞肺癌に対する術後補助化学療法(platinum+GEM)の無作為化第II相試験:HOT0703
  荻喬博; 高村圭; 福元伸一; 原田眞雄; 中野浩輔; 須甲憲明; 榊原純; 伊藤健一郎; 小島哲弥; 藤田結花; 原田敏之; 秋江研志; 大泉聡; 磯部宏; 西村正治; 荻喬博; 高村圭; 福元伸一; 原田眞雄; 中野浩輔; 須甲憲明; 榊原純; 伊藤健一郎; 小島哲弥; 藤田結花; 原田敏之; 秋江研志; 大泉聡; 磯部宏; 西村正治, 日本癌治療学会学術集会(Web), 53rd, WS66‐3 (WEB ONLY), 2015
  Japanese
• O1-2 Bf-NAVIとDirectPathにおける気管支自動抽出能の比較(末梢肺癌の診断1,Oralセッション1,第38回日本呼吸器内視鏡学会学術集会)
  高島 雄太; 品川 尚文; 森本 恵; 菊池 創; 池澤 靖元; 高階 太一; 水柿 秀紀; 菊地 英毅; 菊地 順子; 榊原 純; 大泉 聡史; 西村 正治, 気管支学, 37, 0, S169, 2015
  特定非営利活動法人 日本呼吸器内視鏡学会, Japanese
• O1-4 肺末梢病変に対するDirectPathの有用性の検討(末梢肺癌の診断1,Oralセッション1,第38回日本呼吸器内視鏡学会学術集会)
  池澤 靖元; 品川 尚文; 高島 雄太; 森本 恵; 菊池 創; 高階 太一; 水柿 秀紀; 菊地 順子; 菊地 英毅; 榊原 純; 大泉 聡史; 西村 正治, 気管支学, 37, 0, S170, 2015
  特定非営利活動法人 日本呼吸器内視鏡学会, Japanese
• 自然退縮を認めた,癌関連網膜症合併小細胞肺癌の1例
  中村順一; 北井秀典; 榊原純; 水柿秀紀; 大泉聡史; 西村正治; 廣橋良彦; 佐藤昇志; 齋藤航; 神田敦宏, 肺癌(Web), 54, 7, 990(J‐STAGE), 990, Dec. 2014
  (NPO)日本肺癌学会, Japanese
• 当院における血栓塞栓症合併胸部腫瘍症例の血栓治療に関する検討
  池澤靖元; 榊原純; 菊池創; 高階太一; 水柿秀紀; 菊地英毅; 菊地順子; 品川尚文; 大泉聡史; 西村正治, 肺癌(Web), 54, 7, 991(J‐STAGE), 991, Dec. 2014
  (NPO)日本肺癌学会, Japanese
• EGFR遺伝子変異陽性進行・再発肺癌に対する1次治療EGFR‐TKIのBeyond‐PDに関する検討
  菊池創; 菊地英毅; 高階太一; 池澤靖元; 水柿秀紀; 菊地順子; 品川尚文; 榊原純; 大泉聡史; 西村正治, 肺癌(Web), 54, 7, 991‐992(J‐STAGE), 992, Dec. 2014
  (NPO)日本肺癌学会, Japanese
• 肺末梢病変に対するDirectPathの有用性の検討
  池澤靖元; 品川尚文; 菊地創; 高階太一; 水柿秀紀; 菊地順子; 菊地英毅; 榊原純; 大泉聡史; 西村正治, 気管支学, 36, 6, 680, 680, 25 Nov. 2014
  (NPO)日本呼吸器内視鏡学会, Japanese
• 非小細胞肺癌術後補助化学療法(platinum+GEM)の無作為化第II相試験:HOT0703
  福元伸一; 原田眞雄; 中野浩輔; 須甲憲明; 榊原純; 高村圭; 伊藤健一郎; 小島哲弥; 藤田結花; 原田敏之; 秋江研志; 大泉聡史; 秋田弘俊; 磯部宏; 西村正治, 日本肺癌学会総会号, 55th, 5, 417, 417, 05 Oct. 2014
  (NPO)日本肺癌学会, Japanese
• 当院における血栓塞栓症合併胸部腫瘍症例の血栓治療に関する検討
  池澤靖元; 榊原純; 菊池創; 高階太一; 水柿秀紀; 菊地順子; 菊地英毅; 品川尚文; 大泉聡史; 西村正治, 日本肺癌学会総会号, 55th, 5, 684, 684, 05 Oct. 2014
  (NPO)日本肺癌学会, Japanese
• 自然退縮を示した,癌関連網膜症合併小細胞肺癌の1例
  中村順一; 北井秀典; 榊原純; 水柿秀紀; 大泉聡史; 廣橋良彦; 齋藤航; 神田敦宏; 佐藤昇志; 西村正治, 日本肺癌学会総会号, 55th, 5, 508, 508, 05 Oct. 2014
  (NPO)日本肺癌学会, Japanese
• EGFR遺伝子変異陽性進行・再発肺癌に対する1次治療EGFR‐TKIのBeyond‐PDに関する検討
  菊池創; 菊地英毅; 高階太一; 池澤靖元; 水柿秀紀; 菊地順子; 品川尚文; 榊原純; 大泉聡史; 西村正治, 日本肺癌学会総会号, 55th, 5, 460, 460, 05 Oct. 2014
  (NPO)日本肺癌学会, Japanese
• 肺癌におけるγsecretase inhibitorとBcl‐2 inhibitorの併用治療効果の検討
  榊原純; 池澤靖元; 水柿秀紀; 菊地順子; 菊地英毅; 品川尚文; 大泉聡史; 西村正治, 日本肺癌学会総会号, 55th, 5, 618, 618, 05 Oct. 2014
  (NPO)日本肺癌学会, Japanese
• EZH2阻害薬とHDAC阻害薬の併用療法の非小細胞肺癌細胞に対する抗腫瘍効果とEGFRシグナル変化
  高階太一; 木下一郎; 菊地順子; 榊原純; 大泉聡史; 西村正治; 秋田弘俊, 日本肺癌学会総会号, 55th, 5, 437, 437, 05 Oct. 2014
  (NPO)日本肺癌学会, Japanese
• Effects of combined epigenetic therapy with histone methyltransferase EZH2 inhibitor 3-deazaneplanocin and histone deacetylase inhibitor SAHA on non-small cell lung cancer cells
  Taichi Takashina; Ichiro Kinoshita; Junko Kikuchi; Yasushi Shimizu; Jun Sakakibara Konishi; Satoshi Oizumi; Masaharu Nishimura; Hirotoshi Dosaka Akita, CANCER RESEARCH, 74, 19, Oct. 2014
  English, Summary international conference
• Inhibition of Notch and HIF enhances the antitumor effect of radiation in Notch expressing lung cancer
  Yasuyuki Ikezawa; Jun Sakakibara-Konishi; Hidenori Mizugaki; Satoshi Oizumi; Masaharu Nishimura, CANCER RESEARCH, 74, 19, Oct. 2014
  English, Summary international conference
• Notch発現肺癌細胞におけるγセクレターゼインヒビターとABT-737併用治療効果の検討(Combination of γ-secretase inhibitor and ABT-737 shows synergistic antitumor effect in Notch expressing lung cancer)
  榊原 純; 大泉 聡史; 池澤 靖元; 水柿 秀紀; 菊池 順子; 菊池 英毅; 西村 正治, 日本癌学会総会記事, 73回, P, 1066, Sep. 2014
  日本癌学会, English
• EZH2阻害薬とHDAC阻害薬の併用療法の非小細胞肺癌細胞に対する抗腫瘍効果とEGFRシグナル変化(Effects of cotreatment with EZH2 inhibitor DZNep and HDAC inhibitor SAHA on NSCLC cells and EGFR signaling pathway)
  高階 太一; 木下 一郎; 菊地 順子; 清水 康; 榊原 純; 大泉 聡史; 西村 正治; 秋田 弘俊, 日本癌学会総会記事, 73回, P, 3128, Sep. 2014
  日本癌学会, English
• EZH2阻害薬とヒストン脱アセチル化酵素(HDAC)阻害薬の併用療法の非小細胞肺癌(NSCLC)細胞に対する抗腫瘍効果
  木下一郎; 高階太一; 菊地順子; 榊原純; 大泉聡史; 西村正治; 秋田弘俊, 日本がん分子標的治療学会学術集会プログラム・抄録集, 18th, 83, 29 May 2014
  Japanese
• 当院で経験した中枢性気道狭窄症例の検討
  菊池創; 品川尚文; 北井秀典; 高階太一; 池澤靖元; 朝比奈肇; 榊原純; 大泉聡史; 西村正治, 気管支学, 36, Suppl., S154, S154, 20 Mar. 2014
  (NPO)日本呼吸器内視鏡学会, Japanese
• 肺末梢病変に対する挿入部回転機能付き細径気管支鏡の有用性の検討
  北井秀典; 品川尚文; 菊池創; 庄司哲明; 高階太一; 池澤靖元; 朝比奈肇; 榊原純; 大泉聡史; 西村正治, 気管支学, 36, Suppl., S185, S185, 20 Mar. 2014
  (NPO)日本呼吸器内視鏡学会, Japanese
• O9-1 当院で経験した中枢性気道狭窄症例の検討(Interventional pulmonology,一般演題(口演),第37回日本呼吸器内視鏡学会学術集会)
  菊池 創; 品川 尚文; 北井 秀典; 高階 太一; 池澤 靖元; 朝比奈 肇; 榊原 純; 大泉 聡史; 西村 正治, 気管支学, 36, 0, S154, 2014
  特定非営利活動法人 日本呼吸器内視鏡学会, Japanese
• O22-6 肺末梢病変に対する挿入部回転機能付き細径気管支鏡の有用性の検討(気管支鏡 新技術,一般演題(口演),第37回日本呼吸器内視鏡学会学術集会)
  北井 秀典; 品川 尚文; 菊池 創; 庄司 哲明; 高階 太一; 池澤 靖元; 朝比奈 肇; 榊原 純; 大泉 聡史; 西村 正治, 気管支学, 36, 0, S185, 2014
  特定非営利活動法人 日本呼吸器内視鏡学会, Japanese
• 1.肺末梢病変に対するDirectPathの有用性の検討(第36回 日本呼吸器内視鏡学会北海道支部会)
  池澤 靖元; 品川 尚文; 菊地 創; 高階 太一; 水柿 秀紀; 菊地 順子; 菊地 英毅; 榊原 純; 大泉 聡史; 西村 正治, 気管支学, 36, 6, 680, 680, 2014
  特定非営利活動法人 日本呼吸器内視鏡学会, Japanese
• 当院における非小細胞肺癌に対するweekly nab‐PTX+CBDCA併用療法の検討
  庄司哲明; 朝比奈肇; 大橋洋介; 松本宗大; 北井秀典; 菊池創; 照井浩也; 榊原純; 品川尚文; 大泉聡史; 西村正治, 肺癌(Web), 53, 7, 918(J-STAGE), 918, Dec. 2013
  (NPO)日本肺癌学会, Japanese
• 当院における悪性胸膜中皮腫27例の検討
  菊池創; 朝比奈肇; 北井秀典; 池澤靖元; 高階太一; 品川尚文; 榊原純; 大泉聡史; 西村正治; 樋田泰浩; 加賀基知三; 井上哲也; 加藤徳雄, 肺癌(Web), 53, 7, 918(J-STAGE), 918, Dec. 2013
  (NPO)日本肺癌学会, Japanese
• 当院における皮膚筋炎・多発筋炎(DM/PM)合併肺癌の検討
  松本宗大; 朝比奈肇; 菊池創; 北井秀典; 品川尚文; 榊原純; 大泉聡史; 西村正治, 肺癌(Web), 53, 7, 917-918(J-STAGE), 918, Dec. 2013
  (NPO)日本肺癌学会, Japanese
• Bf‐NAVIにおける部位別自動抽出能の検討
  品川尚文; 北井秀典; 池澤靖元; 高階太一; 朝比奈肇; 榊原純; 大泉聡史; 西村正治, 気管支学, 35, 6, 682, 683, 25 Nov. 2013
  (NPO)日本呼吸器内視鏡学会, Japanese
• 気管支形成術後の縫合糸が原因と考えられた炎症性肉芽腫により気管支狭窄を繰り返した1例
  北井秀典; 品川尚文; 菊池創; 高階太一; 池澤靖元; 朝比奈肇; 榊原純; 大泉聡史; 西村正治, 気管支学, 35, 6, 683, 684, 25 Nov. 2013
  特定非営利活動法人 日本呼吸器内視鏡学会, Japanese
• 肺末梢病変に対する挿入部回転機能付き細径気管支鏡,極細径気管支鏡の有用性の検討
  北井秀典; 品川尚文; 菊池創; 高階太一; 池澤靖元; 朝比奈肇; 榊原純; 大泉聡史; 西村正治, 日本肺癌学会総会号, 54th, 5, 585, 585, 05 Oct. 2013
  (NPO)日本肺癌学会, Japanese
• 当院における非小細胞肺癌に対するweekly nab‐PTX+CBDCA併用療法の検討
  庄司哲明; 朝比奈肇; 大橋洋介; 松本宗大; 北井秀典; 照井浩也; 菊池創; 榊原純; 品川尚文; 大泉聡史; 西村正治, 日本肺癌学会総会号, 54th, 5, 608, 608, 05 Oct. 2013
  (NPO)日本肺癌学会, Japanese
• 放射線治療抵抗性とHIF及びNotch pathwayの関連性の検討
  池澤靖元; 榊原純; 水柿秀紀; 大泉聡史; 西村正治, 日本肺癌学会総会号, 54th, 5, 459, 459, 05 Oct. 2013
  (NPO)日本肺癌学会, Japanese
• 当院における皮膚筋炎・多発筋炎(DM/PM)合併肺癌の検討
  松本宗大; 朝比奈肇; 北井秀典; 菊地創; 池澤靖元; 高階太一; 品川尚文; 榊原純; 大泉聡史; 西村正治, 日本肺癌学会総会号, 54th, 5, 546, 546, 05 Oct. 2013
  (NPO)日本肺癌学会, Japanese
• EZH2阻害薬とヒストン脱アセチル化酵素阻害薬の併用療法の非小細胞肺癌細胞に対する抗腫瘍効果の検討
  高階太一; 木下一郎; 菊地順子; 池澤靖元; 榊原純; 大泉聡史; 西村正治; 秋田弘俊, 日本肺癌学会総会号, 54th, 5, 681, 681, 05 Oct. 2013
  (NPO)日本肺癌学会, Japanese
• 悪性胸膜中皮腫に対する病理診断と治療戦略 当院における悪性胸膜中皮腫27例の検討
  菊池 創; 朝比奈 肇; 北井 秀典; 池澤 靖元; 高階 太一; 品川 尚文; 榊原 純; 大泉 聡史; 樋田 泰浩; 加賀 基知三; 井上 哲也; 加藤 徳雄; 西村 正治, 肺癌, 53, 5, 382, 382, Oct. 2013
  (NPO)日本肺癌学会, Japanese
• 放射線治療抵抗性とHIF及びNotch pathwayの関連性の検討(The role of HIF-1 and Notch pathway in radioresistance of non small lung cancer cell lines)
  池澤 靖元; 榊原 純; 水柿 秀紀; 大泉 聡史; 西村 正治, 日本癌学会総会記事, 72回, 204, 204, Oct. 2013
  日本癌学会, English
• EZH2阻害剤とHDAC阻害剤を併用したエピジェネティック治療における非小細胞肺癌細胞に対する影響(Effects of combined epigenetic therapy with EZH2 and HDAC inhibitors on NSCLC cells)
  高階 太一; 木下 一郎; 菊池 順子; 菊池 英毅; 清水 康; 榊原 純; 大泉 聡史; 西村 正治; 秋田 弘俊, 日本癌学会総会記事, 72回, 295, 295, Oct. 2013
  日本癌学会, English
• 当院における悪性胸膜中皮腫27例の検討
  菊池創; 朝比奈肇; 北井秀典; 池澤靖元; 高階太一; 品川尚文; 榊原純; 大泉聡史; 樋田泰浩; 加賀基知三; 井上哲也; 加藤徳雄; 西村正治, 日本肺癌学会総会号, 53, 5, 382, 382, Oct. 2013
  (NPO)日本肺癌学会, Japanese
• 超音波気管支鏡ガイド下針生検における組織診の有用性の検討
  北井秀典; 品川尚文; 阿部智絵; 高階太一; 池澤靖元; 山田範幸; 朝比奈肇; 榊原純; 大泉聡史; 西村正治, 気管支学, 35, Suppl., S152, S152, 20 May 2013
  (NPO)日本呼吸器内視鏡学会, Japanese
• Bf‐NAVIにおける部位別自動抽出能の検討
  品川尚文; 北井秀典; 池澤靖元; 高階太一; 山田範幸; 朝比奈肇; 榊原純; 大泉聡史; 西村正治, 気管支学, 35, Suppl., S174, S174, 20 May 2013
  (NPO)日本呼吸器内視鏡学会, Japanese
• 原発性肺癌に対する動体追跡照射を用いた体幹部定位放射線治療
  井上哲也; 加藤徳雄; 鬼丸力也; 榊原純; 品川尚文; 大泉聡史; 鈴木隆介; 白土博樹, 日本医学放射線学会総会抄録集, 72nd, S271, S271, 28 Feb. 2013
  (公社)日本医学放射線学会, Japanese
• 4.Bf-NAVI^[○!R]における部位別自動抽出能の検討(第35回 日本呼吸器内視鏡学会北海道支部会)
  品川 尚文; 北井 秀典; 池澤 靖元; 高階 太一; 朝比奈 肇; 榊原 純; 大泉 聡史; 西村 正治, 気管支学, 35, 6, 682, 683, 2013
  特定非営利活動法人 日本呼吸器内視鏡学会, Japanese
• O5-5 超音波気管支鏡ガイド下針生検における組織診の有用性の検討(EBUS-1,一般演題口演,第36回日本呼吸器内視鏡学会学術集会)
  北井 秀典; 品川 尚文; 阿部 智絵; 高階 太一; 池澤 靖元; 山田 範幸; 朝比奈 肇; 榊原 純; 大泉 聡史; 西村 正治, 気管支学, 35, 0, S152, 2013
  特定非営利活動法人 日本呼吸器内視鏡学会, Japanese
• O15-5 Bf-NAVI(R)における部位別自動抽出能の検討(仮想気管支鏡-2,一般演題口演,第36回日本呼吸器内視鏡学会学術集会)
  品川 尚文; 北井 秀典; 池澤 靖元; 高階 太一; 山田 範幸; 朝比奈 肇; 榊原 純; 大泉 聡史; 西村 正治, 気管支学, 35, 0, S174, 2013
  特定非営利活動法人 日本呼吸器内視鏡学会, Japanese
• ガイドシース併用気管支腔内超音波断層法による経気管支生検で診断した末梢型肺カルチノイドの5病変の検討
  山田範幸; 品川尚文; 大泉聡史; 池澤靖元; 高階太一; 朝比奈肇; 榊原純; 松野吉宏; 西村正治, 気管支学, 34, 6, 643, 643, 25 Nov. 2012
  (NPO)日本呼吸器内視鏡学会, Japanese
• 超音波気管支鏡ガイド下針生検における組織診の有用性の検討
  阿部智絵; 品川尚文; 池澤靖元; 高階太一; 山田範幸; 朝比奈肇; 榊原純; 大泉聡史; 西村正治, 気管支学, 34, 6, 643, 644, 25 Nov. 2012
  特定非営利活動法人 日本呼吸器内視鏡学会, Japanese
• 超音波気管支鏡ガイド下針生検における組織診の有用性の検討
  阿部智絵; 品川尚文; 池澤靖元; 高階太一; 山田範幸; 朝比奈肇; 榊原純; 大泉聡史; 西村正治, 肺癌, 52, 5, 656, 656, 05 Oct. 2012
  (NPO)日本肺癌学会, Japanese
• 脳転移を有する非小細胞肺癌に対するPemetrexedを含む化学療法の有効性の検討
  北井秀典; 朝比奈肇; 大泉聡史; 高階太一; 池澤靖元; 山田範幸; 榊原純; 品川尚文; 西村正治, 肺癌, 52, 5, 601, 601, 05 Oct. 2012
  (NPO)日本肺癌学会, Japanese
• ヒストンメチル化酵素EZH2阻害剤3‐deazaneplanocin Aによる非小細胞肺癌細胞株に対する増殖抑制効果の検討
  高階太一; 木下一郎; 菊地順子; 菊地英毅; 清水康; 榊原純; 大泉聡史; 西村正治; 秋田弘俊, 肺癌, 52, 5, 748, 748, 05 Oct. 2012
  (NPO)日本肺癌学会, Japanese
• Minichromosome maintenance (MCM) protein 4 の非小細胞肺癌の細胞増殖における役割と臨床病理学的意義
  菊地 順子; 木下 一郎; 清水 康; 菊地 英毅; 武田 香陽子; 油谷 浩幸; 大泉 聡史; 小西 純; 加賀 基知三; 松野 吉宏; BIRRER Michael J.; 西村 正治; 秋田 弘俊, 北海道醫學雜誌 = Acta medica Hokkaidonensia, 87, 4, 195, 195, 01 Aug. 2012
  Japanese
• 非小細胞肺癌におけるBim、Noxa、Pumaの発現について(Expression of Bim, Noxa, and Puma in Non-small Cell Lung Cancer)
  榊原 純; 大泉 聡史; 菊地 順子; 菊地 英毅; 水柿 秀紀; 木下 一郎; 秋田 弘俊; 西村 正治, 日本癌学会総会記事, 71回, 565, 565, Aug. 2012
  日本癌学会, English
• 末梢肺におけるディスポーザブルゴールドマーカーによる金球留置の成績
  小倉粋; 品川尚文; 池澤靖元; 高階太一; 水柿秀紀; 山田範幸; 朝比奈肇; 榊原純; 井上哲也; 加藤徳雄; 鬼丸力也; 白戸博樹; 大泉聡史; 西村正治, 気管支学, 34, Suppl., S199, S199, 20 May 2012
  (NPO)日本呼吸器内視鏡学会, Japanese
• ガイドシース併用気管支腔内超音波断層法による経気管支生検で診断した末梢型肺カルチノイドの5病変の検討
  山田範幸; 大泉聡史; 池澤靖元; 高階太一; 小倉粋; 水柿秀紀; 朝比奈肇; 榊原純; 品川尚文; 松野吉宏; 西村正治, 気管支学, 34, Suppl., S217, S217, 20 May 2012
  (NPO)日本呼吸器内視鏡学会, Japanese
• GGO病変に対するナビゲーションシステム併用EBUS‐GS法の有用性の検討
  池澤靖元; 品川尚文; 高階太一; 小倉粋; 中野浩輔; 水柿秀紀; 山田範幸; 朝比奈肇; 榊原純; 大泉聡史; 須甲憲明; 西村正治, 気管支学, 34, Suppl., S185, S185, 20 May 2012
  (NPO)日本呼吸器内視鏡学会, Japanese
• Expression of Bim, Noxa, and Puma in non-small cell lung cancer
  Jun Sakakibara-Konishi; Satoshi Oizumi; Junko Kikuchi; Eiki Kikuchi; Hidenori Mizugaki; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Masaharu Nishimura, CANCER RESEARCH, 72, Apr. 2012
  English, Summary international conference
• ヒストンメチル化酵素EZH2阻害剤3‐deazaneplanocin Aによる非小細胞肺癌細胞株の増殖抑制効果の検討
  高階太一; 木下一郎; 菊地順子; 菊地英毅; 清水康; 榊原純; 大泉聡史; 西村正治; 秋田弘俊, 日本呼吸器学会誌, 1, 増刊, 324, 324, 10 Mar. 2012
  (一社)日本呼吸器学会, Japanese
• 気管支鏡検体による組織型診断の妥当性についての検討
  竹内裕; 品川尚文; 小倉粋; 水柿秀紀; 山田範幸; 朝比奈肇; 榊原純; 大泉聡史; 西村正治, 日本呼吸器学会誌, 1, 増刊, 224, 224, 10 Mar. 2012
  (一社)日本呼吸器学会, Japanese
• 肺末梢良性病変に対するガイドシース併用気管支腔内超音波断層法(EBUS‐GS)を用いた気管支鏡検査の有用性の検討
  品川尚文; 中野浩輔; 小倉粋; 水柿秀紀; 山田範幸; 朝比奈肇; 榊原純; 大泉聡史; 南須原康行; 西村正治, 日本呼吸器学会誌, 1, 増刊, 201, 201, 10 Mar. 2012
  (一社)日本呼吸器学会, Japanese
• 肺末梢病変に対するEBUS‐GS併用経気管支生検の合併症のまとめ
  池澤靖元; 品川尚文; 高階太一; 小倉粋; 竹内裕; 水柿秀紀; 山田範幸; 朝比奈肇; 榊原純; 大泉聡史; 西村正治, 気管支学, 34, 1, 86, 86, 25 Jan. 2012
  (NPO)日本呼吸器内視鏡学会, Japanese
• 空洞を有する肺末梢病変に対するEBUS‐GS併用経気管支鏡下生検の有用性と安全性の検討
  高階太一; 品川尚文; 朝比奈肇; 池澤靖元; 小倉粋; 竹内裕; 水柿秀紀; 山田範幸; 菊地英毅; 菊地順子; 榊原純; 大泉聡史; 西村正治, 気管支学, 34, 1, 86, 86, 25 Jan. 2012
  (NPO)日本呼吸器内視鏡学会, Japanese
• 4.空洞を有する肺末梢病変に対するEBUS-GS併用経気管支鏡下生検の有用性と安全性の検討(第33回 日本呼吸器内視鏡学会北海道支部会)
  高階 太一; 品川 尚文; 朝比奈 肇; 池澤 靖元; 小倉 粋; 竹内 裕; 水柿 秀紀; 山田 範幸; 菊地 英毅; 菊地 順子; 榊原 純; 大泉 聡史; 西村 正治, 気管支学 : 日本気管支研究会雑誌, 34, 1, 86, 86, 25 Jan. 2012
  日本呼吸器内視鏡学会, Japanese
• 5.肺末梢病変に対するEBUS-GS併用経気管支生検の合併症のまとめ(第33回 日本呼吸器内視鏡学会北海道支部会)
  池澤 靖元; 品川 尚文; 高階 太一; 小倉 粋; 竹内 裕; 水柿 秀紀; 山田 範幸; 朝比奈 肇; 榊原 純; 大泉 聡史; 西村 正治, 気管支学 : 日本気管支研究会雑誌, 34, 1, 86, 86, 25 Jan. 2012
  日本呼吸器内視鏡学会, Japanese
• ヒストンメチル化酵素EZH2阻害薬3‐deazaneplanocin Aによる非小細胞肺癌細胞株に対する増殖抑制効果の検討
  高階太一; 木下一郎; 菊地順子; 菊地英毅; 清水康; 榊原純; 大泉聡史; 西村正治; 秋田弘俊, 日本臨床腫瘍学会学術集会プログラム・抄録集, 10th, 196, 2012
  Japanese
• 7.ガイドシース併用気管支腔内超音波断層法による経気管支生検で診断した末梢型肺カルチノイドの5病変の検討(第34回 日本呼吸器内視鏡学会北海道支部会)
  山田 範幸; 品川 尚文; 大泉 聡史; 池澤 靖元; 高階 太一; 朝比奈 肇; 榊原 純; 松野 吉宏; 西村 正治, 気管支学, 34, 6, 2012
  特定非営利活動法人 日本呼吸器内視鏡学会, Japanese
• O24-3 GGO病変に対するナビゲーションシステム併用EBUS-GS法の有用性の検討(EBUS1,一般口演24,第35回日本呼吸器内視鏡学会学術集会)
  池澤 靖元; 品川 尚文; 高階 太一; 小倉 粋; 中野 浩輔; 水柿 秀紀; 山田 範幸; 朝比奈 肇; 榊原 純; 大泉 聡史; 須甲 憲明; 西村 正治, 気管支学, 34, 0, S185, 2012
  特定非営利活動法人 日本呼吸器内視鏡学会, Japanese
• P3-4 末梢肺におけるディスポーザブルゴールドマーカーによる金球留置の成績(解剖生理その他,ポスター3,第35回日本呼吸器内視鏡学会学術集会)
  小倉 粋; 品川 尚文; 池澤 靖元; 高階 太一; 水柿 秀紀; 山田 範幸; 朝比奈 肇; 榊原 純; 井上 哲也; 加藤 徳雄; 鬼丸 力也; 白戸 博樹; 大泉 聡史; 西村 正治, 気管支学, 34, 0, S199, 2012
  特定非営利活動法人 日本呼吸器内視鏡学会, Japanese
• P11-5 ガイドシース併用気管支腔内超音波断層法による経気管支生検で診断した末梢型肺カルチノイドの5病変の検討(EBUS2,ポスター11,第35回日本呼吸器内視鏡学会学術集会)
  山田 範幸; 大泉 聡史; 池澤 靖元; 高階 太一; 小倉 粋; 水柿 秀紀; 朝比奈 肇; 榊原 純; 品川 尚文; 松野 吉宏; 西村 正治, 気管支学, 34, 0, S217, 2012
  特定非営利活動法人 日本呼吸器内視鏡学会, Japanese
• EGFR遺伝子変異陽性進行非小細胞肺癌患者におけるゲフィチニブまたは全身化学療法後の再発形式の検討
  榊原純; 大泉聡史; 朝比奈肇; 山田範幸; 水柿秀紀; 小倉粋; 池澤靖元; 高階太一; 品川尚文; 西村正治, 肺癌, 51, 7, 844, 844, 20 Dec. 2011
  (NPO)日本肺癌学会, Japanese
• 小細胞肺癌の再発治療に関する後方視的研究
  朝比奈肇; 大泉聡史; 池澤靖元; 高階太一; 小倉粋; 水柿秀紀; 竹内裕; 山田範幸; 菊地英毅; 菊地順子; 榊原純; 品川尚文; 西村正治, 肺癌, 51, 7, 843, 844, 20 Dec. 2011
  (NPO)日本肺癌学会, Japanese
• 進行期非小細胞肺癌のPNA‐LNA PCR clamp法で解析したEGFR遺伝子変異の状況と予後との検討
  山田範幸; 朝比奈肇; 大泉聡史; 池澤靖元; 高階太一; 小倉粋; 水柿秀紀; 榊原純; 品川尚文; 小林国彦; 田中知明; 萩原弘一; 西村正治, 肺癌, 51, 5, 460, 460, 05 Oct. 2011
  (NPO)日本肺癌学会, Japanese
• EGFR遺伝子変異陽性進行非小細胞肺癌患者におけるゲフィチニブまたは全身化学療法後の再発形式の検討
  榊原純; 大泉聡史; 朝比奈肇; 山田範幸; 水柿秀紀; 小倉粋; 池澤靖元; 高階太一; 品川尚文; 西村正治, 肺癌, 51, 5, 566, 566, 05 Oct. 2011
  (NPO)日本肺癌学会, Japanese
• ヒストンメチルトランスフェラーゼEZH2阻害剤3-deazaneplanocin Aによる非小細胞肺癌細胞の増殖抑制(Growth inhibition of non-small cell lung cancer cells by the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin)
  木下 一郎; 菊地 順子; 高階 太一; 菊地 英毅; 清水 康; 榊原 純; 大泉 聡史; 西村 正治; 秋田 弘俊, 日本癌学会総会記事, 70回, 137, 138, Sep. 2011
  日本癌学会, English
• 肺末梢病変に対するEBUS‐GS併用経気管支生検の合併症のまとめ
  池澤靖元; 品川尚文; 高階太一; 小倉粋; 竹内裕; 水柿秀紀; 山田範幸; 朝比奈肇; 榊原純; 大泉聡史; 西村正治, 気管支学, 33, Suppl., S188, S188, 20 May 2011
  (NPO)日本呼吸器内視鏡学会, Japanese
• EBUS‐GS併用経気管支鏡下生検にて診断し動体追跡放射線照射にて治療した末梢小型肺癌の検討
  竹内裕; 品川尚文; 池澤靖元; 高階太一; 小倉粋; 水柿秀紀; 山田範幸; 朝比奈肇; 榊原純; 加藤徳雄; 鬼丸力也; 白土博樹; 大泉聡史; 西村正治, 気管支学, 33, Suppl., S174, S174, 20 May 2011
  (NPO)日本呼吸器内視鏡学会, Japanese
• 空洞を有する肺末梢病変に対するEBUS‐GS併用経気管支鏡下生検の有用性と安全性の検討
  高階太一; 品川尚文; 朝比奈肇; 池澤靖元; 小倉粋; 竹内裕; 水柿秀紀; 山田範幸; 菊地英毅; 菊地順子; 榊原純; 大泉聡史; 西村正治, 気管支学, 33, Suppl., S187, S187, 20 May 2011
  (NPO)日本呼吸器内視鏡学会, Japanese
• O3-4 EBUS-GS併用経気管支鏡下生検にて診断し動体追跡放射線照射にて治療した末梢小型肺癌の検討(インターベンション/動体追跡照射,一般口演3,第34回日本呼吸器内視鏡学会学術集会)
  竹内 裕; 品川 尚文; 池澤 靖元; 高階 太一; 小倉 粋; 水柿 秀紀; 山田 範幸; 朝比奈 肇; 榊原 純; 加藤 徳雄; 鬼丸 力也; 白土 博樹; 大泉 聡史; 西村 正治, 気管支学 : 日本気管支研究会雑誌, 33, 0, S174, 20 May 2011
  日本呼吸器内視鏡学会, Japanese
• O10-1 空洞を有する肺末梢病変に対するEBUS-GS併用経気管支鏡下生検の有用性と安全性の検討(EBUS-GS,一般口演10,第34回日本呼吸器内視鏡学会学術集会)
  高階 太一; 品川 尚文; 朝比奈 肇; 池澤 靖元; 小倉 粋; 竹内 裕; 水柿 秀紀; 山田 範幸; 菊地 英毅; 菊地 順子; 榊原 純; 大泉 聡史; 西村 正治, 気管支学 : 日本気管支研究会雑誌, 33, 0, S187, 20 May 2011
  日本呼吸器内視鏡学会, Japanese
• O10-4 肺末梢病変に対するEBUS-GS併用経気管支生検の合併症のまとめ(EBUS-GS,一般口演10,第34回日本呼吸器内視鏡学会学術集会)
  池澤 靖元; 品川 尚文; 高階 太一; 小倉 粋; 竹内 裕; 水柿 秀紀; 山田 範幸; 朝比奈 肇; 榊原 純; 大泉 聡史; 西村 正治, 気管支学 : 日本気管支研究会雑誌, 33, 0, S188, 20 May 2011
  日本呼吸器内視鏡学会, Japanese
• Expression of CD133 as a prognostic marker of non-small cell lung cancers
  Hidenori Mizugaki; Jun Sakakibara Konishi; Junko Kikuchi; Eiki Kikuchi; Jun Moriya; Kanako Kubota; Ichiro Kinoshita; Satoshi Oizumi; Hirotoshi Dosaka Akita; Yoshihiro Matsuno; Masaharu Nishimura, CANCER RESEARCH, 71, Apr. 2011
  English, Summary international conference
• Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A against non-small cell lung cancer cells
  Junko Kikuchi; Ichiro Kinoshita; Eiki Kikuchi; Yasushi Shimizu; Jun Sakakibara-Konishi; Satoshi Oizumi; Masaharu Nishimura; Hirotoshi Dosaka-Akita, CANCER RESEARCH, 71, Apr. 2011
  English, Summary international conference
• 当院における間質性肺疾患合併肺癌症例の検討
  朝比奈肇; 中野亮司; 池澤靖元; 高階太一; 小倉粋; 水柿秀紀; 竹内裕; 山田範幸; 菊地英毅; 菊地順子; 品川尚文; 榊原純; 大泉聡史; 西村正治, 日本呼吸器学会雑誌, 49, 増刊, 324, 324, 10 Mar. 2011
  (一社)日本呼吸器学会, Japanese
• 肺癌に伴う続発性気胸及び膿胸に対する治療に難渋した1例
  池澤靖元; 品川尚文; 榊原純; 高階太一; 小倉粋; 竹内裕; 水柿秀紀; 山田範幸; 朝比奈肇; 菊地順子; 菊地英毅; 大泉聡史; 西村正治; 中野亮司, 気管支学, 33, 1, 61, 61, 25 Jan. 2011
  (NPO)日本呼吸器内視鏡学会, Japanese
• 気管支鏡検体による組織型診断の妥当性と検査手技についての検討
  竹内裕; 菊地英毅; 品川尚文; 池澤靖元; 高階太一; 小倉粋; 伊藤健一郎; 水柿秀紀; 山田範幸; 朝比奈肇; 菊地順子; 榊原純; 大泉聡史; 西村正治; 松野吉宏, 気管支学, 33, 1, 58, 59, 25 Jan. 2011
  日本呼吸器内視鏡学会, Japanese
• 12.肺癌に伴う続発性気胸及び膿胸に対する治療に難渋した1例(第32回 日本呼吸器内視鏡学会北海道支部会)
  池澤 靖元; 品川 尚文; 榊原 純; 高階 太一; 小倉 粋; 竹内 裕; 水柿 秀紀; 山田 範幸; 朝比奈 肇; 菊地 順子; 菊地 英毅; 大泉 聡史; 西村 正治; 中野 亮司, 気管支学 : 日本気管支研究会雑誌, 33, 1, 61, 61, 25 Jan. 2011
  日本呼吸器内視鏡学会, Japanese
• 臨床病期I期の小細胞肺癌における切除症例の検討
  山田範幸; 朝比奈肇; 池澤靖元; 高階太一; 小倉粋; 水柿秀紀; 竹内裕; 榊原純; 品川尚文; 大泉聡史; 樋田泰浩; 加賀基知三; 西村正治, 日本臨床腫瘍学会学術集会プログラム・抄録集, 9th, 418, 2011
  Japanese
• 小細胞肺癌の再発治療に関する後方視的研究
  朝比奈肇; 大泉聡史; 池澤靖元; 高階太一; 小倉粋; 水柿秀紀; 竹内裕; 山田範幸; 菊地英毅; 菊地順子; 榊原純; 品川尚文; 西村正治, 日本臨床腫瘍学会学術集会プログラム・抄録集, 9th, 419, 2011
  Japanese
• 当院における間質性肺疾患合併肺癌症例の検討
  中野亮司; 朝比奈肇; 池澤靖元; 高階太一; 小倉粋; 水柿秀紀; 竹内裕; 山田範幸; 菊地英毅; 菊地順子; 品川尚文; 榊原純; 大泉聡史; 西村正治, 肺癌, 50, 7, 947, 948, 20 Dec. 2010
  (NPO)日本肺癌学会, Japanese
• 当院における悪性胸膜中皮腫14例の検討
  小倉粋; 朝比奈肇; 池澤靖元; 高階太一; 竹内裕; 水柿秀紀; 山田範幸; 菊地英毅; 菊地順子; 榊原純; 品川尚文; 大泉聡史; 西村正治; 中野亮司, 肺癌, 50, 7, 949, 949, 20 Dec. 2010
  (NPO)日本肺癌学会, Japanese
• 当科における非小細胞肺癌に対するペメトレキセド投与症例の検討
  池澤靖元; 菊地英毅; 高階太一; 小倉粋; 竹内裕; 朝比奈肇; 榊原純; 品川尚文; 大泉聡史; 西村正治, 肺癌, 50, 5, 611, 611, 05 Oct. 2010
  (NPO)日本肺癌学会, Japanese
• 当院における間質性肺疾患合併肺癌症例の検討
  中野亮司; 朝比奈肇; 池澤靖元; 高階太一; 小倉粋; 水柿秀紀; 竹内裕; 山田範幸; 菊地英毅; 菊地順子; 品川尚文; 榊原純; 大泉聡史; 西村正治, 肺癌, 50, 5, 656, 656, 05 Oct. 2010
  (NPO)日本肺癌学会, Japanese
• ポリコームタンパク質EZH2の非小細胞肺癌における役割
  菊地順子; 木下一郎; 菊地英毅; 榊原純; 清水康; 朝比奈肇; 品川尚文; 大泉聡史; 西村正治; 秋田弘俊, 肺癌, 50, 5, 625, 625, 05 Oct. 2010
  (NPO)日本肺癌学会, Japanese
• 肺門縦隔リンパ節腫大を伴う原発不明癌に対する経気管支針吸引リンパ節生検の有用性
  高階太一; 菊地英毅; 水柿秀紀; 池澤靖元; 小倉粋; 竹内裕; 山田範幸; 朝比奈肇; 菊地順子; 榊原純; 品川尚文; 大泉聡史; 樋田泰浩; 加賀基知三; 久保田加奈子; 松野吉宏; 西村正治, 肺癌, 50, 5, 629, 629, Oct. 2010
  (NPO)日本肺癌学会, Japanese
• Verification of antitumor effect of gamma-secretase-inhibitor and radiotherapy
  Hidenori Mizugaki; Jun Konishi; Junko Kikuchi; Eiki Kikuchi; Naofumi Shinagawa; Satoshi Oizumi; Masaharu Nishimura, CANCER RESEARCH, 70, Apr. 2010
  English, Summary international conference
• Distinctive expression of polycomb group proteins Bmi1 and EZH2 in non-small cell lung cancers and their clinical and clinicopathological significance
  Junko Kikuchi; Ichiro Kinoshita; Eiki Kikuchi; Jun Konishi; Yasushi Shimizu; Satoshi Oizumi; Masaharu Nishimura; Hirotoshi Dosaka-Akita, CANCER RESEARCH, 70, Apr. 2010
  English, Summary international conference
• Distinctive expression of polycomb group proteins Bmi1 and EZH2 in non-small cell lung cancers and their clinical and clinicopathological significance
  Junko Kikuchi; Ichiro Kinoshita; Eiki Kikuchi; Jun Konishi; Yasushi Shimizu; Satoshi Oizumi; Masaharu Nishimura; Hirotoshi Dosaka-Akita, CANCER RESEARCH, 70, Apr. 2010
  English, Summary international conference
• 気管支鏡下細胞診検体を用いたPNA-LNA PCR clamp法による上皮成長因子受容体(EGFR)遺伝子変異検出の検討
  山田 範幸; 大泉 聡史; 朝比奈 肇; 菊地 英毅; 菊地 順子; 小西 純; 品川 尚文; 西村 正治; 小林 国彦; 宮澤 仁志; 田中 知明; 萩原 弘一, 肺癌, 49, 7, 1055, 1055, Dec. 2009
  (NPO)日本肺癌学会, Japanese
• 気管支鏡下細胞診検体を用いたPNA-LNA PCR clamp法による上皮成長因子受容体(EGFR)遺伝子変異検出の検討
  山田 範幸; 大泉 聡史; 朝比奈 肇; 菊地 英毅; 菊地 順子; 小西 純; 品川 尚文; 小林 国彦; 宮澤 仁志; 田中 知明; 萩原 弘一; 西村 正治, 肺癌, 49, 5, 623, 623, Oct. 2009
  (NPO)日本肺癌学会, Japanese
• The role of minichromosome maintenance (MCM) protein 4 in proliferation and its clinicopathological significance in non-small cell lung cancers (NSCLCs)
  Ichiro Kinoshita; Junko Kikuchi; Yasushi Shimizu; Eiki Kikuchi; Jun Konishi; Hiroyuki Aburatani; Satoshi Oizumi; Masaharu Nishimura; Hirotoshi Akita, JOURNAL OF THORACIC ONCOLOGY, 4, 9, S884, S884, Sep. 2009
  English, Summary international conference
• The role of minichromosome maintenance (MCM) protein 4 in proliferation and its clinicopathological significance in non-small cell lung cancer
  Junko Kikuchi; Ichiro Kinoshita; Yasushi Shimizu; Eiki Kikuchi; Jun Konishi; Kayoko Takeda; Hiroyuki Aburatani; Satoshi Oizumi; Masaharu Nishimura; Hirotoshi Dosaka-Akita, CANCER RESEARCH, 69, May 2009
  English, Summary international conference
• P-491 CT透視下経気管支生検にて診断した末梢小型肺癌に対し,動体追跡放射線照射で治療した症例の検討(早期・小型肺癌,第49回日本肺癌学会総会号)
  竹内 裕; 品川 尚文; 伊藤 健一郎; 水柿 秀紀; 山田 範幸; 菊地 英毅; 菊地 順子; 小西 純; 田口 大志; 鬼丸 力也; 小野寺 祐也; 白土 博樹; 大泉 聡史; 西村 正治, 肺癌, 48, 5, 612, 612, 05 Oct. 2008
  日本肺癌学会, Japanese
• P-83 Gamma-Secretase Inhibitorによるヒト肺癌細胞におけるNotch3活性と細胞増殖の抑制(癌遺伝子・癌抑制遺伝子,第49回日本肺癌学会総会号)
  小西 純; 菊地 順子; 菊地 英毅; 品川 尚文; 大泉 聡史; 西村 正治, 肺癌, 48, 5, 510, 510, 05 Oct. 2008
  日本肺癌学会, Japanese
• Tetramer-blocking assay for defining antigen-specific cytotoxic T lymphocytes using peptide-MHC tetramer
  YOKOUCHI Hiroshi; CHAMOTO Kenji; WAKITA Daiko; NOGUCHI Daisuke; YAMAZAKI Koichi; DOSAKA AKITA Hirotoshi; NISHIMURA Masaharu; IKEDA Hiroaki; NISHIMURA Takashi, Cancer Sci, 97, 2, 148, 154, 2006
  English
• Gefitinib 投与によりPR判定となった非小細胞肺癌患者の検討(13 分子標的治療2, 第46回 日本肺癌学会総会)
  横内 浩; 山崎 浩一; 木下 一郎; 小西 純; 本村 文宏; 須甲 憲明; 原田 真雄; 秋江 研志; 小倉 滋明; 石田 卓; 棟方 充; 秋田 弘俊; 磯部 宏; 西村 正治, 肺癌, 45, 5, 559, 559, 05 Nov. 2005
  日本肺癌学会, Japanese
• Seven Cases of Benign Peripheral Pulmonary Diseases Diagnosed by Transbronchial Biopsy Using Endobronchial Ultrasonography With a Guide Sheath (EBUS-GS)
  ASAHINA Hajime; YAMAZAKI Koichi; KIKUCHI Eiki; IMURA Mikado; KIKUCHI Junko; SHINAGAWA Naofumi; KONISHI Jun; ONODERA Yuya; NISHIMURA Masaharu, 氣管支学 = The Journal of the Japan Society for Respiratory Endoscopy, 27, 2, 126, 130, 25 Mar. 2005
  Japanese
• 9. 当院ゲフィチニブ奏効肺非小細胞癌症例におけるEGF受容体(EGFR)突然変異(第30回日本肺癌学会北海道支部会)(支部活動)
  木下 一郎; 秋田 弘俊; 山崎 浩一; 小西 純; 西村 正治, 肺癌, 44, 6, 727, 727, 20 Oct. 2004
  日本肺癌学会, Japanese
• 10. 細胞株樹立に成功したアミラーゼ産生肺腺癌の1例(第30回日本肺癌学会北海道支部会)(支部活動)
  横内 浩; 山崎 浩一; 朝比奈 肇; 猪村 帝; 菊地 英毅; 菊地 順子; 品川 尚文; 小西 純; 西村 正治; 高岡 和夫; 泉 寛志; 森谷 純, 肺癌, 44, 6, 727, 727, 20 Oct. 2004
  日本肺癌学会, Japanese
• P11-8 非小細胞肺癌に対するゲフィチニブ使用症例の検討(ポスター総括11 : 基礎 ゲフィチニブ(臨床))
  小西 純; 山崎 浩一; 木下 一郎; 磯部 宏; 小倉 滋明; 関根 聡子; 石田 卓; 高島 理央; 中舘 恵; 西川 就; 服部 健史; 朝比奈 肇; 猪村 帝; 菊地 英毅; 菊地 順子; 品川 尚文; 横内 浩; 棟方 充; 秋田 弘俊; 西村 正治, 肺癌, 44, 5, 634, 634, 01 Oct. 2004
  日本肺癌学会, Japanese
• P10-27 非小細胞肺癌におけるB7-H1およびB7-DCの発現と腫瘍浸潤リンパ球の減少とPD-1発現の低下(ポスター総括10 : 病理2 免疫・血管新生)
  小西 純; 山崎 浩一; 横内 浩; 品川 尚文; 菊地 英毅; 菊地 順子; 朝比奈 肇; 猪村 帝; 西村 正治; 木下 一郎; 秋田 弘俊; 東 みゆき, 肺癌, 44, 5, 624, 624, 01 Oct. 2004
  日本肺癌学会, Japanese
• P2-48 気管支鏡挿入支援システムを用いたバーチャル気管支鏡によるナビゲーション併用CT透視下経気管支生検(ポスター総括2 : 診断2 生検)
  品川 尚文; 山崎 浩一; 浅野 文祐; 朝比奈 肇; 猪村 帝; 菊地 英毅; 菊地 順子; 小西 純; 横内 浩; 小野寺 裕也; 西村 正治, 肺癌, 44, 5, 425, 425, 01 Oct. 2004
  日本肺癌学会, Japanese
• P2-47 バーチャル気管支鏡とガイドシース併用気管支腔内超音波断層法を併用した経気管支生検の有用性の検討(ポスター総括2 : 診断2 生検)
  朝比奈 肇; 山崎 浩一; 猪村 帝; 菊地 英毅; 菊地 順子; 品川 尚文; 小西 純; 横内 浩; 西村 正治; 小野寺 裕也, 肺癌, 44, 5, 424, 424, 01 Oct. 2004
  日本肺癌学会, Japanese
• P8-4 動体追跡放射線照射法における金球標識(gold marker)保持についての検討(ポスター総括8 : 放治 放射線療法)
  猪村 帝; 山崎 浩一; 白土 博樹; 藤野 賢治; 鬼丸 力也; 朝比奈 肇; 菊地 順子; 菊地 英毅; 小西 純; 品川 尚文; 横内 浩; 木下 一郎; 原田 敏之; 秋田 弘俊; 宮坂 和男; 西村 正治, 肺癌, 44, 5, 558, 558, 01 Oct. 2004
  日本肺癌学会, Japanese
• 肺末梢病変に対するガイドシース併用気管支内腔超音波断層法(EBUS‐GS)におけるキュレット型誘導子の有用性について
  菊地英毅; 山崎浩一; 朝比奈肇; 猪村帝; 菊地順子; 小西純; 品川尚文; 白間信行; 木下一郎, 気管支学, 26, 4, 389, 389, 25 May 2004
  日本呼吸器内視鏡学会, Japanese
• EBUS‐GSにて診断した肺良性病変の7例
  朝比奈肇; 猪村帝; 菊地英毅; 菊地順子; 品川尚文; 小西純; 木下一郎; 山崎浩一; 小野寺祐也, 気管支学, 26, 4, 389, 389, 25 May 2004
  日本呼吸器内視鏡学会, Japanese
• 8.仮想気管支鏡によるナビゲーション下で極細径気管支鏡を使用して術前バリウムマーキングを行った肺癌の2症例(第25回日本呼吸器内視鏡学会北海道支部会)
  猪村 帝; 山崎 浩一; 木下 一郎; 横内 浩; 品川 尚文; 小西 純; 菊地 英毅; 菊地 順子; 朝比奈 肇; 西村 正治; 小野寺 祐也; 大竹 節之; 加地 苗人; 森川 利昭; 浅野 文祐, 気管支学 : 日本気管支研究会雑誌, 26, 4, 390, 390, 25 May 2004
  日本呼吸器内視鏡学会, Japanese
• 気管支内視鏡挿入支援システムの使用経験
  品川尚文; 山崎浩一; 朝比奈肇; 猪村帝; 菊地英毅; 菊地順子; 秋田弘俊; 小野寺祐也; 宮坂和男, 気管支学, 26, 4, 389, 389, 25 May 2004
  日本呼吸器内視鏡学会, Japanese
• 肺末梢病変に対するガイドシース併用気管支内腔超音波断層法(EBUS‐GS)の応用
  菊地英毅; 山崎浩一; 朝比奈肇; 猪村帝; 菊地順子; 小西純; 品川尚文; 横内浩; 木下一郎, 気管支学, 26, 3, 229, 229, 10 May 2004
  日本呼吸器内視鏡学会, Japanese
• W9-4 仮想気管支鏡によるナビゲーション下で極細径気管支鏡を用いて術前バリウムマーキングを行った肺癌の2症例(ワークショップ9 極細径気管支鏡)
  猪村 帝; 山崎 浩一; 小野寺 祐也; 浅野 文祐; 朝比奈 肇; 菊地 順子; 菊地 英毅; 小西 純; 品川 尚文; 横内 浩; 木下 一郎; 大竹 節之; 加地 苗人; 森川 利昭; 西村 正治, 気管支学 : 日本気管支研究会雑誌, 26, 3, 236, 236, 10 May 2004
  日本呼吸器内視鏡学会, Japanese
• OR2-4 肺末梢小型病変に対するバーチャル内視鏡と気管支内腔超音波断層法を併用した経気管支肺生検の有用性の検討(一般口演2 肺野小型病変の診断と治療2)
  朝比奈 肇; 山崎 浩一; 猪村 帝; 菊池 英毅; 菊池 順子; 品川 尚文; 小西 純; 横内 浩; 木下 一郎; 西村 正治; 秋田 弘俊; 小野寺 祐也, 気管支学 : 日本気管支研究会雑誌, 26, 3, 244, 244, 10 May 2004
  日本呼吸器内視鏡学会, Japanese
• バーチャル内視鏡による気管支内視鏡挿入支援システムの有用性の検討
  品川尚文; 山崎浩一; 朝比奈肇; 猪村帝; 菊地英毅; 菊地順子; 秋田弘俊; 小野寺祐也; 宮坂和男, 気管支学, 26, 3, 235, 235, 10 May 2004
  日本呼吸器内視鏡学会, Japanese
• A Case of Vagus Nerve Schwannoma in the Middle Mediastinum Presenting with Dyspnea
  SUGA Masayuki; OGURI Mituru; KONISHI Jyun; NISHIMURA Masaharu, 日本呼吸器学会雑誌 = The journal of the Japanese Respiratory Society, 42, 4, 342, 346, 10 Apr. 2004
  Japanese
• 1. 生前に脊髄内転移を診断し得た原発性肺癌についての検討(第29回日本肺癌学会北海道支部会)(支部活動)
  中舘 恵; 高島 理央; 小西 純; 原田 真雄; 磯部 宏, 肺癌, 43, 7, 1046, 1046, 30 Dec. 2003
  日本肺癌学会, Japanese
• 進行非小細胞肺癌に対するweekly Paclitaxel+Carboplatin併用第I相試験
  大室 順子; 菊地 英毅; 小西 純; 品川 尚文; 自間 信行; 木下 一郎; 山崎 浩一; 西村 正治; 秋田 弘俊, 肺癌, 43, 5, 573, 573, 20 Oct. 2003
  日本肺癌学会, Japanese
• 肺癌患者におけるNKT細胞の解析
  小西 純; 大室 順子; 菊地 英毅; 品川 尚文; 自間 信行; 木下 一郎; 山崎 浩一; 秋田 弘俊; 西村 正治, 肺癌, 43, 5, 503, 503, 20 Oct. 2003
  日本肺癌学会, Japanese
• 肺末梢病変に対するガイドシース併用気管支内腔超音波断層法(GS‐EBUS)の応用
  菊地英毅; 山崎浩一; 大室順子; 品川尚文; 小西純; 白間信行; 西村正治; 秋田弘俊; 須甲憲明, 気管支学, 25, 4, 197, 197, 25 May 2003
  日本呼吸器内視鏡学会, Japanese
• 気管支鏡検査中のSpO2の低下の頻度とhigh risk群の検討
  品川尚文; 山崎浩一; 菊地英毅; 大室順子; 小西純; 白間信行; 原田敏之; 西村正治; 秋田弘俊, 気管支学, 25, 3, 202, 202, 30 Apr. 2003
  特定非営利活動法人 日本呼吸器内視鏡学会, Japanese
• マイクロサンプリングプローベを用いた気道上皮被覆液中の薬物動態の検討
  大室順子; 山崎浩一; 小倉滋明; 石坂彰敏; 菊地英毅; 品川尚文; 小西純; 秋田弘俊; 西村正治, 気管支学, 25, 3, 191, 191, 30 Apr. 2003
  特定非営利活動法人 日本呼吸器内視鏡学会, Japanese
• 肺末梢病変に対するVirtual Bronchoscopyと極細径気管支鏡を併用したCTガイド下生検の有用性の検討(肺癌をめぐる画像および内視鏡診断のUp-to-Date)(ワークショップ3)
  品川 尚文; 山崎 浩一; 菊地 英毅; 大室 順子; 小西 純; 白間 信行; 若林 修; 原田 敏之; 木下 一郎; 西村 正治; 秋田 弘俊; 小野寺 祐也, 肺癌, 42, 5, 349, 349, 30 Oct. 2002
  日本肺癌学会, Japanese
• 非小細胞肺癌におけるFDG-PETの縦隔・肺門リンパ節転移に対する有用性の検討
  小西 純; 品川 尚文; 白間 信行; 原田 敏之; 若林 修; 木下 一郎; 山崎 浩一; 西村 正治; 塚本 江利子; 玉木 長良; 大竹 節之; 森川 利昭; 加藤 紘之; 秋田 弘俊, 肺癌, 42, 5, 392, 392, 30 Oct. 2002
  日本肺癌学会, Japanese
• 肺非小細胞癌における経気管支生検検体を用いたP53,Bcl-2,LRP発現による化学療法奏効性の予測
  原田 敏之; 小倉 滋明; 大室 順子; 菊地 英毅; 小西 純; 品川 尚文; 白間 信行; 若林 修; 木下 一郎; 山崎 浩一; 西村 正治; 磯部 宏; 山城 勝重; 伊藤 智雄; 秋田 弘俊, 肺癌, 42, 5, 429, 429, 30 Oct. 2002
  日本肺癌学会, Japanese
• E1AF発現および非発現肺癌細胞の遊走能・浸潤能におけるRho/ROCK系の関与
  白間 信行; 木下 一郎; 小西 純; 品川 尚文; 原田 敏之; 若林 修; 山崎 浩一; 吉田 幸一; 西村 正治; 秋田 弘俊, 肺癌, 42, 5, 510, 510, 30 Oct. 2002
  日本肺癌学会, Japanese
• 非小細胞肺癌における腫瘍組織浸潤リンパ球と臨床的因子の関連性の検討
  若林 修; 山崎 浩一; 大室 順子; 菊地 英毅; 小西 純; 品川 尚文; 白間 信行; 原田 敏之; 木下 一郎; 西村 正治; 森川 利昭; 加藤 紘之; 伊藤 智雄; 秋田 弘俊, 肺癌, 42, 5, 517, 517, 30 Oct. 2002
  日本肺癌学会, Japanese
• 1.Virtual Bronchoscopyによるナビゲーション後極細径気管支鏡(XP-40)を用いた肺生検にて診断し,定位放射線治療を施行した肺野小型結節影の2症例(第23回 日本気管支学会北海道支部会)
  品川 尚文; 山崎 浩一; 小西 純; 針生 寛之; 福元 伸一; 白間 信行; 横内 浩; 若林 修; 原田 敏之; 小島 哲弥; 大泉 聡史; 木下 一郎; 西村 正治; 秋田 弘俊; 小野 寺祐也, 気管支学 : 日本気管支研究会雑誌, 24, 4, 343, 343, 25 May 2002
  日本呼吸器内視鏡学会, Japanese
• 6.後縦隔脂肪肉腫による上部気管狭窄に対しT-tubeを挿入した1例(第23回 日本気管支学会北海道支部会)
  森岡 崇; 白井 真也; 今野 哲; 小西 純; 品川 尚文; 針生 寛之; 福元 伸一; 横内 浩; 白間 信行; 原田 敏之; 若林 修; 大泉 聡史; 小島 哲弥; 木下 一郎; 山崎 浩一; 西村 正治; 秋田 弘俊; 古田 康, 気管支学 : 日本気管支研究会雑誌, 24, 4, 343, 343, 25 May 2002
  日本呼吸器内視鏡学会, Japanese
• Virtual Bronchoscopy によるナビゲーション後、極細径気管支鏡を用いたCTガイド下生検の有用性の検討 : マルチメディアの臨床応用(第25回日本気管支学会総会)
  品川 尚文; 山崎 浩一; 小西 純; 福元 伸一; 白間 信行; 横内 浩; 若林 修; 原田 敏之; 小島 哲弥; 大泉 聡史; 木下 一郎; 西村 正治; 秋田 弘俊; 小野寺 祐也, 気管支学 : 日本気管支研究会雑誌, 24, 3, 170, 170, 15 Apr. 2002
  日本呼吸器内視鏡学会, Japanese
• B-29 分泌型gp96融合蛋白質(gp96-Ig)による癌拒絶と免疫遺伝子治療への応用
  山崎 浩一; 小西 純; 白間 信行; 横内 浩; 福元 伸一; 若林 修; 原田 敏之; 小島 哲弥; 大泉 聡史; 本村 文宏; 小倉 滋明; 秋田 弘俊; 川上 義和, 肺癌, 40, 5, 388, 388, 30 Sep. 2000
  日本肺癌学会, Japanese
• W1-4 気管支鏡によるマーカー挿入動体追跡放射線治療の有用性の検討
  原田 敏之; 小倉 滋明; 小西 純; 白間 信行; 福元 伸一; 横内 浩; 若林 修; 大泉 聡史; 小島 哲弥; 本村 文宏; 山崎 浩一; 秋田 弘俊; 清水 伸一; 白土 博樹; 宮坂 和男, 肺癌, 40, 5, 363, 363, 30 Sep. 2000
  日本肺癌学会, Japanese
• G-30 肺腺癌組織内のCD8^+リンパ球浸潤の定量的評価と術後予後との関係
  若林 修; 山崎 浩一; 小西 純; 白間 信行; 福元 伸一; 横内 浩; 原田 敏之; 大泉 聡史; 小島 哲弥; 本村 文宏; 三品 孝行; 小倉 滋明; 秋田 弘俊; 川上 義和, 肺癌, 40, 5, 493, 493, 30 Sep. 2000
  日本肺癌学会, Japanese

• 医学総論, 2024年, 博士後期課程, 医学研究科
• 基本医学研究, 2024年, 修士課程, 医学院
• 基本医学総論, 2024年, 修士課程, 医学院
• 医学総論, 2024年, 博士後期課程, 医学院
• 基盤医学研究, 2024年, 博士後期課程, 医学院
• 臨床医学研究, 2024年, 博士後期課程, 医学院

• 小細胞肺癌におけるmidkineを標的とした汎用性の高い治療開発の検討
  科学研究費助成事業
  01 Apr. 2025 - 31 Mar. 2028
  榊原 純
  日本学術振興会, 基盤研究(C), 北海道大学, 25K11446
• Analysis of Notch pathway regulation by Prox1 in Small cell lung cancer
  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
  Apr. 2021 - Mar. 2024
  榊原 純; 木下 一郎
  Prox1の小細胞肺癌（SCLC）における腫瘍原性に与える影響についての研究；SCLC細胞株のProx1の発現を最初に確認した。4つの(SCLC細胞株（MS-1、HCC827、SBC-3,SBC-5）を使用しProx1の発現をウエスタンブロットを用いてタンパク発現を確認したところMS-1、HCC827でProx1の発現を認め残りの2つのSBC-3とSBC-5のSCLC細胞株の発現は低かった。さらにPCRでもProx-1の発現を確認しタンパク発現とmRNAの発現が同様の結果であることを確認した。このため発現抑制のための実験にはMS-1とHCC827を使用することにした。Prox1の機能解析のために2つの細胞株でsiRNAを用いてProx1の発現が抑制されていることを確認した。増殖能についてMTT assayを行ったところProx1の抑制によりコントロールと比較して細胞増殖は増加した。clnogenic assayも行いMTT assayの結果と同様にProx1の抑制によりcolony数が増加した。さらにinvasion assayとmigration assayをtranswell chamberを用いて確認したところProx1の抑制によりコントロールと比較して細胞遊走能、浸潤能ともに増加した。
  Prox1とNotch pathwayの関連についての検討：Prox1の抑制時にNotch 関連タンパク(Notch1-4、HES-1、HEY-1）の発現をウエスタンブロットにて確認したがコントロールと比較してProx1抑制時にNotch関連タンパク発現に変化を認めなかった。さらにPCRでmRNAについても検討したがProx1の発現の抑制時に変化を認めなかった。
  CDDP耐性株におけるProx1の影響：当科でCDDP耐性株を当科で樹立しておりCDDP耐性株（MS-1）においてProx1の発現を確認したところProx1の発現が低下しており薬剤耐性との関与が考えられた。
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 21K08195
• A project intended for new diagnostic marker and therapy for mesothelioma based on ubiquitin-proteasome system
  Grants-in-Aid for Scientific Research
  01 Apr. 2018 - 31 Mar. 2022
  Tanino Mishie
  Malignant mesothelioma(MM) is an aggressive tumor which originates from the mesothelial cells of the serosal tissues. It has been reported to be associated with inhalation exposure to asbestos. MM caused by asbestos exposure, and it will become tumor after 30 to 40 years latency period. MM is treated by multidisciplinary treatment combined with surgical excision, chemotherapy and radiation, but it shows treatment resistance and poor prognosis. A novel treatment method has been desired. In this study, we focused on the role of OTUB1, one of the deubiquitinating enzyme. OTUB1 was highly expressed in MM tissue and cell lines. It regulated TGF-beta/SMAD pathway, followed by their motility and invasion. These findings suggest OTUB1 is one of the candidate protein for new therapy of MM.
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Asahikawa Medical College, 18K06980
• SCASH:進行非小細胞肺がん患者への症状クラスター高度サポート開発と評価
  科学研究費助成事業
  01 Apr. 2018 - 31 Mar. 2022
  濱田 珠美; 伊藤 俊弘; 石川 洋子; 榊原 純; 西村 直樹
  2020年度の本研究目的は、前半は、令和１年度の第２段階の「標準的治療を受ける進行NSCLC患者に感度高い効果的な問題解決戦略には、何が見出されているか？」また、優先的にSCASHが必要なサブグループが存在するのではないか?」の成果を洗練し、患者報告型成果指標を見出して、より細やかにニーズに対応でき効果を高く期待できるSCASH-Taylor Made(以下、SCASH-TM)案を考案する。後半は、効果を検証するため、リサーチパネルメンバーでRCTシェーマを検討し構築後、RCT本試験計画を立案し、予備試験へと進めることであった。「標準的治療を受ける進行NSCLC患者に感度高い効果的な問題解決戦略には、日常的に取り入れやすい行動療法（リラクゼーション）などが好感度で継続可能なものであり、症状の変化と効果に自覚のために、対話を中心とした高度実践者の介入が効果が期待できるものであるとわかった。COVID-19の感染拡大下のため、優先的にSCASHを適用するサブグループの解析ワークが遅れており継続して推進を図る。そこで、COVID-19 感染拡大予防も加味したできる限り非接触で介入内容の理解と感度高く効果を期待できるSCASH-Taylor Made案を考案し、関連するツールの整備を推進している。後半の目的は、治療期の進行NSCLC患者を対象としているためCOVID-19 感染拡大事情を注視して研究フィールドへの感染リスク回避と安全を担保できる状況を評価しており,2020年度は感染拡大中のため状況を注視している。
  日本学術振興会, 基盤研究(B), 旭川医科大学, 18H03080
• 肺癌組織系の違いによるNumbの肺癌増殖に対する機能について
  科学研究費補助金（基盤研究C）
  2018 - 2020
  榊原純
  文部科学省, Principal investigator, Competitive research funding
• Real-time tumor tracking radiotherapy for patients with hypoxic primary lung cancer
  Grants-in-Aid for Scientific Research
  01 Apr. 2016 - 31 Mar. 2019
  INOUE TETSUYA
  Hypoxic regions in tumors are known to be radio-resistant. Hypoxic imaging became possible by positron emission tomography (PET) using 18F-fluoromisonidazole (FMISO). Here we sought to determine whether FMISO-PET/CT can be used to predict the outcome for stage I non-small cell lung cancer (NSCLC) patients treated by stereotactic body radiotherapy (SBRT). From September 2013 to August 2017, 29 patients at Hokkaido university hospital with histopathologically confirmed stage I NSCLC were enrolled. FMISO-PET/CT was performed before SBRT for all patients. 18F-fluorodeoxy glucose (FDG)-PET/CT was also performed before SBRT. Four patients had a relapse. They were both FDG- and FMISO-positive. The proportion of recurrence in FMISO was 4/12 in positive and 0/17 in negative (p=0.01), whereas that in FDG was 4/19 in positive and 0/10 in negative (p=0.12). FMISO-PET/CT can be considered useful for predicting the outcome for stage I NSCLC patients treated by SBRT rather than FDG-PET/CT.
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 16K10378
• Life support program for symptom cluster reduction in patients with advanced non-small cell lung cancers (NSCLCs)
  Grants-in-Aid for Scientific Research
  01 Apr. 2014 - 31 Mar. 2018
  Hamada Tamami
  This study aimed to develop a symptom cluster reduction life support program focusing on two symptoms, Fatigue and Pain, included in symptoms clusters experienced by patients with advanced Non-Small Cell Lung Cancer (NSCLC) who have undergone standard therapies, and evaluate the efficacy of the program. Through the data analysis of 126 patients with advanced NSCLC and a literature review, we refined a model to reduce the accumulated burden. The result of a feasibility study of a program initiated by nurses based on the Cognitive Behavioral Intervention suggested the feasibility of implementing the model. Therefore, it is necessary to conduct further studies to promote the continuous use and evaluation of the program during the outpatient treatment period.
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), Asahikawa Medical College, 26293459
• Combined antitumor effec ot g-secretase inbitiro and ABT-737
  Grants-in-Aid for Scientific Research
  2012 - 2012
  SAKAKIBARA Jun; KINOSHITA Ichiro
  Inhibition of Notch by gamma-secretase inhibitor (GSI) has been shown to have an antitumor effect in Notch expressing non-small cell lung cancer (NSCLC) and induce apoptosis through modulation of Bcl-2 family proteins. ABT-737, a BH3-only mimetic, targets the prosurvival Bcl-2 family and also induces apoptosis. GSI XX or ABT-737 alone inhibited cell proliferation in a dose dependent manner and combination drug treatment showed a synergistic antitumor effect in Notch expressing NSCLC in vitro. In vivo, this drug combination significantly suppressed tumor proliferation compared to single drug treatment. Phospho-Bcl-2 was down-regulated and Bax was up-regulated by both the single and combination drug treatments. Bim was induced by single drug treatment and was enhanced by combination treatment. Combination treatment-induced apoptosis was decreased by Bim inhibition, suggesting that the antitumor effect of the drug combination was dependent on Bim.
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, Competitive research funding, 24591146
• γ-secretase Inhibitor Enhances Antitumor Effect of Radiation in Notch Expressing Lung Cancer
  Grants-in-Aid for Scientific Research
  2010 - 2011
  SAKAKIBARA Jun
  We discovered that the antitumor effect of combining GSI(-secretase inhibitor) and radiation was dependent on treatment schedule. GSI administration after radiation had the greatest growth inhibition of lung cancer in vitro and in vivo. We showed that the combination induced apoptosis of lung cancer cell lines through the regulation of MAPK and Bcl-2family proteins. Furthermore, activation of Notch after radiation was ameliorated by GSI administration, suggesting that treatment with GSI prevent Notch-induced radiation resistance.
  Japan Society for the Promotion of Science, Grant-in-Aid for Young Scientists (B), Hokkaido University, Competitive research funding, 22790742